<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.60, http://www.edgar-online.com -->
<TITLE> IMMUNOGEN INC (Form: 10-K, Received: 08/28/2009 09:35:21) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_BUSINESS_STOCK_REPORT **FIS_RISK_FACTORS **FIS_FACTORS_AFFECTING **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PART_I **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_VOTING_MATTERS **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_AUDITORS_OPINION_2 **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_EXHIBIT_INDEX **FIS_VALUATION_AND_QUALIFYING_ACCOUNTS FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="14">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="A2194303Z10-K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<BR>
<P>
<FONT SIZE=3>
	Use these links to rapidly review the document
<BR>
<A HREF="#A2194303Z10-K_HTM_BG49301_TABLE_OF_CONTENTS">
	TABLE OF CONTENTS
</A>
<BR>
<A HREF="#A2194303Z10-K_HTM_FA49301_FINANCIAL_STATEMENTS_AND_SUPPLEMENTARY_DATA_1ANK">
	INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</A>
<BR>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 3.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:3.0PT;">
</DIV>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 1.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:4.0PT;">
</DIV>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=5>
<B>
	UNITED STATES
<BR>
	SECURITIES AND EXCHANGE COMMISSION
<BR>
</B>
</FONT>
<FONT SIZE=2>
<B>
	Washington, D.C. 20549
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=5>
<B>
	Form&nbsp;10-K
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="55" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="428" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=3>
<FONT FACE="WINGDINGS">
	&#253;
</FONT>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=3>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=3>
<B>
	ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR&nbsp;15(d)&nbsp;OF&nbsp;THE SECURITIES&nbsp;EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
<B>
	For the fiscal year ended June&nbsp;30, 2009
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
<B>
	OR
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=3>
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=3>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=3>
<B>
	TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF&nbsp;THE SECURITIES&nbsp;EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
<B>
	For the transition period
	from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<BR>
</B>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Commission file number&nbsp;0-17999
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=5>
<B>
	ImmunoGen,&nbsp;Inc.
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Massachusetts
</B>
</FONT>
<FONT SIZE=2>
<BR>
	(State or other jurisdiction
<BR>
	of incorporation or organization)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	04-2726691
</B>
</FONT>
<FONT SIZE=2>
<BR>
	(I.R.S. Employer
<BR>
	Identification No.)
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
<B>
	830 Winter Street, Waltham, MA 02451
</B>
</FONT>
<FONT SIZE=2>
<BR>
	(Address of principal executive offices, including zip code)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
<B>
	(781)&nbsp;895-0600
</B>
</FONT>
<FONT SIZE=2>
<BR>
	(Registrant's telephone number, including area code)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	(Former address, if changed since last report)
<BR>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Securities registered pursuant to Section&nbsp;12(b) of the Act:
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="41%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Title of Each Class
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Name of Each Exchange on Which Registered
</B>
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Common Stock, $.01 par value
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	NASDAQ Global Market
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
	by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities
	Act.&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
	&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#253;
</FONT>
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
	Act.&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
	&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#253;
</FONT>
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of
	1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
	90&nbsp;days.&nbsp;
<FONT FACE="WINGDINGS">
	&#253;
</FONT>
	&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be
	submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T(&sect;229.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter
	period that the registrant was required to submit and post such
	files).&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
	&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K (&sect;229.405 of this chapter)
	is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this
	Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting
	company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act. (Check one):
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="95" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="38" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="74" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="38" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="90" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="38" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="112" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Large&nbsp;accelerated&nbsp;filer&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Accelerated&nbsp;filer&nbsp;
<FONT FACE="WINGDINGS">
	&#253;
</FONT>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Non-accelerated&nbsp;filer&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
<BR>
</FONT>
<FONT SIZE=1>
	(Do not check if a smaller
<BR>
	reporting company)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Smaller&nbsp;reporting&nbsp;company&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
	by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange
	Act).&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
	&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#253;
</FONT>
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate market value, based upon the closing sale price of the shares as reported by the NASDAQ Global Market, of voting stock held by non-affiliates
	at December&nbsp;31, 2008: $181,094,864 (excludes shares held by executive officers, directors, and beneficial owners of more than 10% of the Company's common stock). Exclusion of shares held by any
	person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person
	is controlled by or under common control with the registrant. Common Stock outstanding at August&nbsp;25, 2009: 57,057,596 shares.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Portions
	of the definitive Proxy Statement to be delivered to shareholders in connection with the Annual Meeting of Shareholders to be held on November&nbsp;11, 2009 are incorporated
	by reference into Part&nbsp;III.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 1.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:3.0PT;">
</DIV>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 3.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:4.0PT;">
</DIV>
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=1,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=710275,FOLIO='BLANK',FILE='DISK104:[09ZCX1.09ZCX49301]BA49301A.;13',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_BG49301_1_2">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
</A>
</FONT>
</P>
<A NAME="A2194303Z10-K_HTM_BG49301_TABLE_OF_CONTENTS">
</A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	ImmunoGen,&nbsp;Inc.
<BR>
	Form&nbsp;10-K
<BR>
	TABLE OF CONTENTS
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_BG49301_TOC">
</A>
</FONT>
</P>
<!-- COMMAND=ADD_START_LINKTABLE -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="22" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="385" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:17PT;">
<FONT SIZE=1>
<B>
	Item
<!-- COMMAND=ADD_SCROPPEDRULE,17PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Page
<BR>
	Number
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Part&nbsp;I
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DA49301_ITEM_1__BUSINESS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	1.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DA49301_ITEM_1__BUSINESS">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Business
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DA49301_ITEM_1__BUSINESS">
<FONT SIZE=2>
<BR>
	3
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_1A__RISK_FACTORS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	1A.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_1A__RISK_FACTORS">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Risk Factors
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_1A__RISK_FACTORS">
<FONT SIZE=2>
	23
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_1B__UNRESOLVED_STAFF_COMMENTS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	1B.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_1B__UNRESOLVED_STAFF_COMMENTS">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Unresolved Staff Comments
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_1B__UNRESOLVED_STAFF_COMMENTS">
<FONT SIZE=2>
	37
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_2__PROPERTIES">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_2__PROPERTIES">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Properties
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_2__PROPERTIES">
<FONT SIZE=2>
	38
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_3__LEGAL_PROCEEDINGS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	3.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_3__LEGAL_PROCEEDINGS">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Legal Proceedings
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_3__LEGAL_PROCEEDINGS">
<FONT SIZE=2>
	38
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_4__SUBMISSION_OF___DG402384">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	4.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_4__SUBMISSION_OF___DG402384">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Submission of Matters to a Vote of Security Holders
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_4__SUBMISSION_OF___DG402384">
<FONT SIZE=2>
	38
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_4_1__EXECUTIVE_OFFICERS_OF_THE_REGISTRANT">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	4.1
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_4_1__EXECUTIVE_OFFICERS_OF_THE_REGISTRANT">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Executive Officers of the Registrant
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DG49301_ITEM_4_1__EXECUTIVE_OFFICERS_OF_THE_REGISTRANT">
<FONT SIZE=2>
	38
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Part&nbsp;II
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_5__MARKET_FOR_REGISTRANT___ITE04666">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	5.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_5__MARKET_FOR_REGISTRANT___ITE04666">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_5__MARKET_FOR_REGISTRANT___ITE04666">
<FONT SIZE=2>
<BR>
	40
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_6__SELECTED_FINANCIAL_DATA">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	6.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_6__SELECTED_FINANCIAL_DATA">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Selected Financial Data
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_6__SELECTED_FINANCIAL_DATA">
<FONT SIZE=2>
	40
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_7__MANAGEMENT_S_DISCUSSIO__ITE03668">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	7.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_7__MANAGEMENT_S_DISCUSSIO__ITE03668">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Management's Discussion and Analysis of Financial Condition and Results of Operations
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DI49301_ITEM_7__MANAGEMENT_S_DISCUSSIO__ITE03668">
<FONT SIZE=2>
	41
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DM49301_ITEM_7A__QUANTITATIVE_AND_QUAL__ITE02619">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	7A.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DM49301_ITEM_7A__QUANTITATIVE_AND_QUAL__ITE02619">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Quantitative and Qualitative Disclosures About Market Risk
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_DM49301_ITEM_7A__QUANTITATIVE_AND_QUAL__ITE02619">
<FONT SIZE=2>
	57
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FA49301_ITEM_8__FINANCIAL_STATEMENTS_AND_SUPPLEMENTARY_DATA">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	8.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FA49301_ITEM_8__FINANCIAL_STATEMENTS_AND_SUPPLEMENTARY_DATA">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Financial Statements and Supplementary Data
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FA49301_ITEM_8__FINANCIAL_STATEMENTS_AND_SUPPLEMENTARY_DATA">
<FONT SIZE=2>
	59
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9__CHANGES_IN_AND_DISAGRE__ITE03576">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	9.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9__CHANGES_IN_AND_DISAGRE__ITE03576">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9__CHANGES_IN_AND_DISAGRE__ITE03576">
<FONT SIZE=2>
	93
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9A__CONTROLS_AND_PROCEDURES">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	9A.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9A__CONTROLS_AND_PROCEDURES">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Controls and Procedures
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9A__CONTROLS_AND_PROCEDURES">
<FONT SIZE=2>
	93
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9B__OTHER_INFORMATION">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	9B.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9B__OTHER_INFORMATION">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other Information
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FS49301_ITEM_9B__OTHER_INFORMATION">
<FONT SIZE=2>
	95
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Part&nbsp;III
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	10.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Directors, Executive Officers and Corporate Governance
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<FONT SIZE=2>
<BR>
	96
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	11.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Executive Compensation
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<FONT SIZE=2>
	96
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	12.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<FONT SIZE=2>
	96
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	13.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Certain Relationships and Related Transactions, and Director Independence
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<FONT SIZE=2>
	96
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	14.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Principal Accounting Fees and Services
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_PART3">
<FONT SIZE=2>
	96
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Part&nbsp;IV
<BR>
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FW49301_ITEM_15__EXHIBITS,_FINANCIAL_STATEMENT_SCHEDULES">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	15.
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FW49301_ITEM_15__EXHIBITS,_FINANCIAL_STATEMENT_SCHEDULES">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Exhibits, Financial Statement Schedules
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FW49301_ITEM_15__EXHIBITS,_FINANCIAL_STATEMENT_SCHEDULES">
<FONT SIZE=2>
<BR>
	97
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_SIGS">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Signatures
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_SIGS">
<FONT SIZE=2>
<BR>
	98
</FONT>
</A>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=2,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=121463,FOLIO='2',FILE='DISK104:[09ZCX1.09ZCX49301]BG49301A.;11',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_DA49301_1_3">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<A NAME="A2194303Z10-K_HTM_DA49301_BUSINESS">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DA49301_1">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DA49301_ITEM_1__BUSINESS">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DA49301_2">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Business
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this Annual Report on Form&nbsp;10-K, ImmunoGen,&nbsp;Inc. (ImmunoGen,&nbsp;Inc., together with its subsidiaries,
	is referred to in this document as "we", "us", "ImmunoGen", or the "Company"), incorporates by reference certain information from parts of other documents filed with the Securities and Exchange
	Commission. The Securities and Exchange Commission allows us to disclose important information by referring to it in that manner. Please refer to all such information when reading this Annual Report
	on Form&nbsp;10-K. All information is as of June&nbsp;30, 2009 unless otherwise indicated. For a description of the risk factors affecting or applicable to our business, see "Risk
	Factors," below.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	The Company
</B>
</FONT>
</P>
<EFX_BUSINESS_STOCK_REPORT>
<A NAME="FIS_BUSINESS_STOCK_REPORT"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We develop novel, targeted therapeutics for the treatment of cancer using our expertise in cancer biology, monoclonal antibodies,
	highly potent cytotoxic, or cell-killing, agents, and the design of linkers that enable these agents to be stably attached to the antibodies while in the blood stream and released in their
	fully active form after delivery to a cancer cell. An anticancer compound made using our Targeted Antibody Payload, or TAP, technology consists of a monoclonal antibody that binds specifically to an
	antigen target found on cancer cells with multiple copies of one of our proprietary cell-killing agents attached using one of our engineered linkers. Its antibody component enables a TAP
	compound to bind specifically to cancer cells that express a particular target antigen, the highly potent cytotoxic agent serves to kill the cancer cell, and the engineered linker controls the release
	and activation of the cytotoxic agent inside the cancer cell. Our TAP technology is designed to enable the creation of highly effective, well-tolerated anticancer products.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	believe that our TAP technology and our expertise in the development and humanization of monoclonal antibodies will enable us to become a leader in the application of antibody-based
	anticancer compounds. We plan to achieve this goal through the development of our own anticancer products and through collaborations with other companies. There are now six TAP compounds in clinical
	trials through our own programs and those of several of our collaborators. Our collaborators currently include: Amgen, Bayer HealthCare, Biogen Idec, Biotest, Genentech (a wholly-owned member of the
	Roche Group) and sanofi-aventis.
</FONT>
</P>
</EFX_BUSINESS_STOCK_REPORT>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	believe that the key initiatives central to our future success are:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Develop our own proprietary
	products.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We currently have two TAP compounds in clinical testing: IMGN901, a potential treatment for multiple myeloma,
	small-cell lung cancer or SCLC, Merkel cell carcinoma, ovarian cancer and other CD56-expressing cancers; and IMGN388, a potential treatment for solid tumors including
	melanomas, sarcomas and many carcinomas. We are advancing these compounds and also are using our scientific expertise to develop additional antibody-based anticancer compounds. Several of these
	additional compounds are in the research assessment phase from which we will determine their suitability to advance to preclinical development over the next six to 18&nbsp;months.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Support and expand our collaborative
	arrangements.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;Part of our business model is to establish collaborations with other companies in order to expand the application of our
	TAP technology and to provide us with additional sources of cash and revenue. For example, Genentech created trastuzumab-DM1, or T-DM1, under a collaborative arrangement with us that
	enabled it to use our maytansinoid cell-killing agents, including DM1, with antibodies that bind to HER2, such as its trastuzumab (Herceptin&reg;) antibody. In February 2009, we
	earned a $6.5&nbsp;million milestone payment with the start of T-DM1 Phase&nbsp;III clinical testing. Another compound is SAR3419, which was initially developed by us and was
	out-licensed to sanofi-aventis (then Aventis) from our preclinical pipeline as part of a broader collaboration between our companies. We have entered into other types of arrangements with
	collaborators around our technology, expertise, and product programs, and intend to continue to establish collaborations going forward.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=3,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=394823,FOLIO='3',FILE='DISK104:[09ZCX1.09ZCX49301]DA49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DA49301_1_4">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Support our TAP technology to maintain our strong position in our
	field.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We have developed highly potent cell-killing agents designed specifically for attachment to antibodies for targeted
	delivery to cancer cells, and have a portfolio of linkers to affix our cytotoxic agents to antibodies. These cell-killing agents and linkers provide us and our collaborators the
	flexibility to select the design that works best for each antibody and target. More antibody-cytotoxic agent compounds have advanced into clinical testing using our technology than that of any other
	company. We continue to conduct research to develop additional cell-killing agents and linkers to further strengthen our unique position in the field. We recently reported that we have
	developed a new family of engineered linkers that we believe will extend the utility of our technology for the treatment of multidrug-resistant cancers. We also recently filed a patent on a new family
	of cell-killing agents which can kill cancer cells through a different mechanism than used by our maytansinoid agents.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	were organized as a Massachusetts corporation in 1981. Our principal offices are located at 830 Winter Street, Waltham, Massachusetts (MA) 02451, and our telephone number is
	(781)&nbsp;895-0600. We maintain a website at
</FONT>
<FONT SIZE=2>
<I>
	www.immunogen.com
</I>
</FONT>
<FONT SIZE=2>
	, where certain information about us is available. Please note that
	information contained on the website is not a part of this document. Our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on
	Form&nbsp;8-K, and any amendments to those reports are available free of charge through the "Investor Information" section of our website as soon as reasonably practicable after those
	materials have been electronically filed with, or furnished to, the Securities and Exchange Commission. We have adopted a Code of Corporate Conduct that applies to all our directors, officers and
	employees and a Senior Officer and Financial Personnel Code of Ethics that applies to our senior officers and financial personnel. Our Code of Corporate Conduct and Senior
	Officer and Financial Personnel Code of Ethics are available free of charge through the "Investor Information" section of our website.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Our TAP Technology
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Traditional chemotherapeutic agents typically kill any rapidly-dividing cell, including healthy cells, which can result in significant
	adverse side effects and limit their ability to be dosed to full therapeutic potential. The invention of monoclonal antibodies enables scientists to create proteins that bind specifically to antigen
	targets found on cancer cells. This scientific advancement led to the development of a few highly successful anticancer antibody therapeutics (CD20-binding Rituxan&reg;,
	HER2-binding Herceptin, CD52-binding Campath&reg; and EGFR-binding Erbitux&reg; and Vectibix&reg;). For many of the targets that have been
	identified on cancer cells, however, the binding of a monoclonal antibody to the target lacks meaningful anticancer activity.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	created our TAP technology to significantly enhance the anticancer activity of monoclonal antibodies. We attach&#151;using our engineered linkers&#151;our highly potent
	cell-killing agents to such antibodies for targeted delivery to cancer cells. Our TAP technology can be used with antibodies that have anticancer activity of their own, such as
	trastuzumab, to achieve enhanced anticancer activity. The bigger opportunity, however, potentially may be use of our TAP technology with antibodies with little anticancer activity of their own,
	enabling effective antibody-based therapies to be developed for many more types of cancers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	developed our proprietary cell-killing agents specifically for attachment to antibodies for delivery to cancer cells. All TAP compounds currently in clinical or
	preclinical testing contain one of our maytansinoid cancer-cell killing agents (DM1 or DM4), which act by interfering with the activity of a substance, tubulin, that is essential for
	successful cell division. Cancer cells undergo frequent cell division, in contrast to most normal cells. Our maytansinoid agents are:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Potent.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;Our proprietary maytansinoid agents are 1,000- to
	10,000-fold more potent than traditional chemotherapy agents and are thus capable of killing cancer cells when the agents are present at low concentrations. This is important for an agent
	delivered to a cancer cell attached
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=4,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=910547,FOLIO='4',FILE='DISK104:[09ZCX1.09ZCX49301]DA49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DA49301_1_5">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	to
	an antibody, as generally only a small amount of antibody, and therefore, the attached cell-killing agent, will reach the cancer cells.
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Attachable.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;Our proprietary maytansinoid agents can be attached to an antibody using
	one of our engineered "linkers." Our linkers are designed to achieve a bond between the agent and the antibody that remains intact while the TAP compound is circulating in the bloodstream, rendering
	the cytotoxic agent inactive, but then enables the cytotoxic agent to exhibit its full potency once inside a cancer cell.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Producible.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;Our proprietary maytansinoid agents can be readily manufactured and our
	supplier produces these agents for us in a manner that can be scaled-up to commercial production quantities.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Protectable.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We hold issued US patents on our maytansinoid agents and related
	derivatives and also have intellectual property related to their methods of production.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have developed other types of cell-killing agents in addition to our maytansinoid agents. Most recently disclosed is our IGN family of highly potent
	cell-killing agents. Our IGNs kill cancer cells by attacking their DNA and thus offer potential to extend the utility of our technology to cancers that are insensitive to tubulin-acting
	agents. We have filed a patent on our IGN cell-killing agents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also have developed a portfolio of engineered linkers, which are used to attach our cell-killing agents to antibodies. Our linkers enable our cell-killing
	agents to remain securely attached to an antibody while a TAP compound is circulating in the blood stream, and then direct its release and activation inside a cancer cell. Our portfolio of linkers
	enables us to
	create highly-hindered disulfide bonds, less-hindered disulfide bonds and also a non-reducible or "non-cleavable" thioether bond. This provides us and our
	collaborators with flexibility in the construction of TAP compounds as the best design for each TAP compound varies depending upon the particular antibody and its target. We recently unveiled a new
	family of ImmunoGen linkers that have been shown in preclinical testing to provide enhanced activity against multi-drug resistant cancers. In recent years, we have gained increasing
	recognition by our collaborative partners for the depth of our expertise in the design, evaluation and development of antibody-cytotoxic agent compounds.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
	we have established capabilities and expertise with monoclonal antibodies. We have extensive experience in cancer biology and in the evaluation of potential targets for
	antibody-based anticancer treatments. We can create monoclonal antibodies for promising targets, and using our patented humanization technology we can modify these antibodies so that the human immune
	system is unable to detect them. We also have considerable expertise in functions critical to the advancement of an antibody-based product from the laboratory to the clinic, including
	cell-line development, preclinical evaluation and process development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Product Candidates
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the antigen target, cancer(s) expressing the target, and development stage for compounds in development
	by us and our collaborators. The results from preclinical testing and early clinical trials may not be predictive of results obtained in subsequent clinical trials and there can be no assurance that
	our or our collaborators' clinical trials will
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=5,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=578267,FOLIO='5',FILE='DISK104:[09ZCX1.09ZCX49301]DA49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DA49301_1_6">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	demonstrate
	the level of safety and efficacy of any product candidates necessary to obtain regulatory approval.
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="97" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="53" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="131" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="84" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="74" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:67PT;">
<FONT SIZE=1>
<B>
	Product Candidate
<!-- COMMAND=ADD_SCROPPEDRULE,67PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Antigen Target
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Cancer(s) expressing target
<SUP>
	(1)
</SUP>
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Development Stage
<SUP>
	(2)
</SUP>
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Collaborative
<BR>
	Partner, if any
</B>
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Trastuzumab-DM1 (T-DM1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	HER2
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Breast cancer
<BR>
	Gastric cancer
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	For HER2+ metastatic breast cancer:
<BR>
	&#149;&nbsp;&nbsp;3
<SUP>
	rd
</SUP>
	&nbsp;line use&#151;
<BR>
	&nbsp;&nbsp;&nbsp;&nbsp;Phase&nbsp;II
<BR>
	&nbsp;&nbsp;&nbsp;&nbsp;(potentially
<BR>
	&nbsp;&nbsp;&nbsp;&nbsp;pivotal trial)
<BR>
	&#149;&nbsp;&nbsp;2
<SUP>
	nd
</SUP>
	-line use&#151;
<BR>
	&nbsp;&nbsp;&nbsp;&nbsp;Phase&nbsp;III
<BR>
	&#149;&nbsp;&nbsp;1st-line use&#151;
<BR>
	&nbsp;&nbsp;&nbsp;&nbsp;Phase&nbsp;II
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Genentech/Roche
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	IMGN901
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	CD56
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Hematological malignancies including multiple myeloma; small-cell lung cancer; Merkel cell carcinoma; other
	cancers of neuroendocrine origin
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Phase&nbsp;I&#151;multiple myeloma
<BR>
	Phase&nbsp;I&#151;SCLC and other solid tumors
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proprietary to ImmunoGen
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	SAR3419
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	CD19
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	B-cell malignancies including non-Hodgkin's lymphoma
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Phase&nbsp;I&#151;non-Hodgkin's lymphoma
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	IMGN388
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	An integrin
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Solid tumors
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Phase&nbsp;I
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	ImmunoGen;
<BR>
	Centocor has opt-in rights
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	BIIB015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cripto
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Solid tumors
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Phase&nbsp;I
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Biogen Idec
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	BT-062
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	CD138
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Multiple myeloma, other
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Phase&nbsp;I&#151;multiple myeloma
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Biotest; ImmunoGen has opt-in rights
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	SAR566658
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	CA6
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Breast; ovarian; other solid tumors
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Preclinical
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	SAR650984
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	CD38
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Hematological malignancies
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Preclinical
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	TAP and other compounds
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Undisclosed
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Undisclosed
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research/preclinical
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	ImmunoGen/ collaborators
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</EFX_UNIDENTIFIED_TABLE>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
<SUP>
	(1)
</SUP>
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Types
	of cancers that express the target antigen. Not all tumors of any given type may express the antigen target and not all cancers that
	express the target may be listed.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
<SUP>
	(2)
</SUP>
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Compounds
	in clinical testing are being assessed in patients whose cancer expresses the target antigen. Compounds that are not in clinical
	testing and have an undisclosed status are listed as research/preclinical.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
<SUP>
	(3)
</SUP>
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Naked
	antibody.
</FONT>
</DD>
</DL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Trastuzumab-DM1 (T-DM1)
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T-DM1 consists of our DM1 cell-killing agent attached to the HER2-binding antibody, trastuzumab,
	using our thioether linker. Trastuzumab is the active component of the marketed
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=6,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=411432,FOLIO='6',FILE='DISK104:[09ZCX1.09ZCX49301]DA49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DA49301_1_7">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	anticancer
	compound, Herceptin. T-DM1 was created under a HER2-specific license agreement established between ImmunoGen and Genentech in 2000. Genentech and its corporate
	parent, Roche, are developing T-DM1 on a worldwide basis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
	date, we have earned $13.5&nbsp;million of a potential $44&nbsp;million in milestone payments with Genentech/Roche's advancement of T-DM1: $2&nbsp;million when its
	Investigational New Drug, or IND, became effective in January 2006, $5&nbsp;million when it entered Phase&nbsp;II clinical testing in July 2007, and $6.5&nbsp;million milestone when it began
	Phase&nbsp;III evaluation in February 2009. In May 2006, Genentech retained us to develop a commercial-scale manufacturing process for T-DM1. We have completed and transferred this
	process.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Multiple
	trials are being conducted by Genentech and/or Roche that evaluate T-DM1 for the treatment of HER2-positive metastatic breast cancer (HER2+ MBC). In
	March 2009, patient enrollment was completed in a Phase&nbsp;II trial evaluating T-DM1 as a third-line treatment for HER2+ MBC. Roche has disclosed that this trial could be
	used to gain approval of T-DM1 in the U.S. if the findings are compelling and that the
	findings from this trial are expected to be available in the fourth quarter of 2009, which would enable potential submission to the FDA in 2010. In February 2009, patient dosing began in a
	Phase&nbsp;III trial evaluating T-DM1 as a second-line treatment for HER2+ MBC. T-DM1 also is being evaluated as a first-line treatment for HER2+ MBC
	in a Phase&nbsp;II trial that began in July 2008. Clinical trials also are underway that evaluate T-DM1 used in combination with other agents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	IMGN901
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our IMGN901 TAP compound targets the antigen known as CD56. CD56-expressing (CD56+) cancers include multiple myeloma as
	well as other hematological malignancies. They also include small-cell lung cancer, or SCLC, Merkel cell carcinoma, ovarian tumors and other cancers of neuroendocrine origin. IMGN901
	consists of our CD56-binding antibody, huN901, with our DM1 cell-killing agent attached using one of our engineered linkers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are evaluating IMGN901 for the treatment of CD56+ solid tumors in our Study 002 and intend to use the expansion phase of this Phase&nbsp;I trial to gain additional information on
	the compound for specific types of CD56+ solid tumors. Almost 100% of SCLC and Merkel cell carcinomas express CD56, and we recently reported encouraging initial clinical data with IMGN901 for the
	treatment of these cancers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also are evaluating IMGN901 for the treatment of CD56+ multiple myeloma. Our Study 003 evaluates IMGN901 when used as a single agent for the treatment of this cancer, and our Study
	005 is designed to evaluate it when used in combination with lenalidomide (Revlimid&reg;) plus dexamethasone. We expect to start our Study 005 later this calendar year. Approximately 70% of
	multiple myeloma cases express CD56.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	SAR3419
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAR3419 consists of our DM4 cell-killing agent attached using one of our engineered linkers to a CD19-binding
	antibody that was created and humanized by us. We licensed this compound to sanofi-aventis in 2003 as part of a broader research collaboration. We earned a $1&nbsp;million milestone payment from
	sanofi-aventis in October 2007 with the start of SAR3419 clinical testing. SAR3419 is being evaluated for the treatment of non-Hodgkin's lymphoma in two Phase&nbsp;I clinical trials that
	have different dosing schedules. Data from the first clinical trial are expected to be reported in December 2009. Like
	Genentech, sanofi-aventis retained us to develop a commercial-scale manufacturing process for SAR3419. We have completed our process work for sanofi-aventis.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=7,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=801001,FOLIO='7',FILE='DISK104:[09ZCX1.09ZCX49301]DA49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_DC49301_1_8">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	BIIB015
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BIIB015 was created by Biogen Idec under a 2004 license that grants Biogen Idec the exclusive right to use our maytansinoid TAP
	technology with antibodies that target Cripto, an antigen found on solid tumors. BIIB015 consists of Biogen Idec's Cripto-binding antibody with our DM4 cell-killing agent attached using
	one of our engineered linkers. Biogen Idec submitted the IND for this compound to the FDA in February 2008, triggering a $1.5&nbsp;million milestone payment to us. BIIB015 advanced into
	Phase&nbsp;I testing in the summer of 2008.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	BT-062
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BT-062 was created by Biotest under a 2006 license that grants Biotest the exclusive right to use our maytansinoid TAP
	technology with antibodies that target CD138, an antigen found on multiple myeloma and certain other cancers. BT-062 consists of Biotest's anti-CD138 antibody with our DM4
	cell-killing agent attached using one of our engineered linkers. Biotest advanced BT-062 into Phase&nbsp;I
	evaluation in September 2008, triggering a $500,000 milestone payment to us. We have opt-in rights on BT-062 in the U.S.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Other Compounds
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A number of product candidates using our technology are in various stages of preclinical research and development internally and at our
	collaborators. Among these are the TAP compound, SAR566658, and the naked (non-TAP) antibody, SAR650984, both of which are in development through our collaboration with sanofi-aventis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Incidence of Relevant Cancers
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancer remains a leading cause of death worldwide, and is the second leading cause of death in the U.S. The American Cancer Society
	projects that 1.5&nbsp;million new cases of cancer will be diagnosed in the U.S. in 2009 and that approximately 562,000 people will die from various cancers. The total number of people living with
	cancer significantly exceeds the number of patients diagnosed with cancer in a given year as patients can live with cancer for a year or longer. Additionally, the potential market for anticancer drugs
	exceeds the number of patients treated as many types of cancer typically are treated with multiple compounds at the same time. Additionally, patients often receive multiple drug regimens sequentially,
	either to treat or help prevent recurrence of the disease.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are assessing our IMGN901 compound for the treatment of CD56+ solid tumors and multiple myeloma. According to the American Cancer Society, approximately 21,000 new cases of multiple
	myeloma will be diagnosed in the U.S. in 2009, and close to 11,000 people will die from the disease. Based on research conducted, we estimate that approximately 70% of multiple myeloma cases express
	the CD56 antigen targeted by IMGN901.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IMGN901
	has shown encouraging initial clinical findings for the treatment of SCLC and Merkel cell carcinoma. Close to 100% of these cancers express CD56. It is expected that
	approximately 29,000 new cases of SCLC will be diagnosed in the U.S. in 2009, as these cancers account for an estimated 13% of all U.S. lung cancer cases. Newly diagnosed patients generally respond to
	their first treatment regimen, but typically their SCLC then recurs. While many patients with recurrent disease could be eligible for additional treatment, survival at this stage is usually less than
	6&nbsp;months.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merkel
	cell carcinoma is an aggressive neuroendocrine cancer of the skin that typically occurs on the head/neck, most often in individuals of European ancestry. There are approximately
	800 to 1400 new cases of MCC diagnosed in the U.S. each year, with the incidence considered to be increasing. Medicinal therapy is generally used with patients whose cancer has recurred following
	surgery and with
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=8,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=497892,FOLIO='8',FILE='DISK104:[09ZCX1.09ZCX49301]DC49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DC49301_1_9">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	patients
	who have metastases at the time of diagnosis. Metastatic disease is associated with a poor outcome, with a median survival time of 6.8&nbsp;months
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are assessing our IMGN388 compound for the treatment of solid tumors. Cancers of particular interest include melanoma and lung, breast, and ovarian cancers. According to the American
	Cancer Society, approximately 504,000 new cases of these cancers are expected to be diagnosed in the U.S. in 2009.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	recent years, several antibody-based anticancer drugs&#151;such as Herceptin, Rituxan and Erbitux&#151;have enjoyed considerable commercial success, as have other
	targeted anticancer agents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Out-licenses and Collaborations
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of our business strategy to expand the use of and financial return from our TAP technology, we enter into license agreements
	with third parties where we grant the other party the exclusive right to use our TAP technology with their antibodies to specific antigen targets. We also had a research collaboration with
	sanofi-aventis that provided them access to compounds in our preclinical pipeline. As part of these agreements, we are entitled to receive upfront fees, potential milestone payments and royalties on
	the sales of any resulting products. Our principal out-licenses and collaborative agreements are described below.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	sanofi-aventis
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2003, we entered into a broad collaboration agreement with sanofi-aventis to discover, develop and commercialize antibody-based
	anticancer therapeutics.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	agreement provides sanofi-aventis with worldwide commercialization rights to new anticancer therapeutics developed to targets that were included in the collaboration, including the
	right to use our TAP technology and our humanization technology in the creation of therapeutics to these targets. The product candidates (targets) currently in the collaboration include SAR3419
	(CD19), SAR566658 (CA6), SAR650984 (CD38) and additional compounds at earlier stages of development that have yet to be disclosed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	collaboration agreement entitles us to receive milestone payments potentially totaling $21.5&nbsp;million per antigen target for each therapeutic developed under the collaboration
	agreement. We have earned a $500,000 payment in September 2004 for a preclinical milestone related to SAR3419, a $1&nbsp;million milestone payment in October 2007 with the start of clinical testing
	of SAR3419, a $500,000 payment in December 2007 for a preclinical milestone related to SAR650984 and a $500,000 payment in March 2008 for a preclinical milestone related to SAR566658. We also earned
	an aggregate of $8&nbsp;million of milestone payments related to two product candidates that previously had been in the collaboration, AVE9633 and AVE1642. Rights to these two product candidates and
	their respective targets have been returned to us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	agreement also entitles us to royalties on the commercial sales of any resulting products if and when such sales commence. Sanofi-aventis is responsible for the cost of the
	development, manufacturing and marketing of any products created through the collaboration. We are reimbursed for any preclinical and clinical materials that we make under the agreement. The
	collaboration agreement also provides us an option to certain co-promotion rights in the U.S. on a product-by-product basis. The terms of the collaboration
	agreement allow sanofi-aventis to terminate our co-promotion rights if there is a change of control of our company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	overall term of the agreement extends to the later of the latest patent to expire or twelve years after the latest launch of any product discovered, developed and/or commercialized
	under the agreement. Sanofi-aventis paid us an upfront fee of $12.0&nbsp;million in August 2003. Inclusive of its extensions, the agreement entitled us to receive committed research funding totaling
	$79.3&nbsp;million over
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=9,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=1024323,FOLIO='9',FILE='DISK104:[09ZCX1.09ZCX49301]DC49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DC49301_1_10">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the
	five years of the research collaboration. The two companies subsequently agreed to extend the date of research funding through October&nbsp;31, 2008 to enable completion of previously
	agreed-upon research. We earned $81.5&nbsp;million of committed research funding for activities performed under the completed research term of this agreement, and are now compensated for
	research performed for sanofi-aventis on a mutually agreed-upon basis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	October 2006, sanofi-aventis licensed non-exclusive rights to use our proprietary resurfacing technology to humanize antibodies to targets not included in the
	collaboration, including antibodies for non-cancer applications. This license provides sanofi-aventis with the
	non-exclusive right to use our proprietary humanization technology through August&nbsp;31, 2011 with the right to extend for one or more additional periods of three years each by
	providing us with written notice prior to expiration of the then-current license term. Under the terms of the license, we are entitled to a $1&nbsp;million license fee, half of which was
	paid upon contract signing and the second half was paid in August 2008, and in addition, we are entitled to receive milestone payments potentially totaling $4.5&nbsp;million for each antibody
	humanized under this agreement and also royalties on commercial sales, if any.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	August 2008, sanofi-aventis exercised its option under a 2006 agreement for expanded access to our TAP technology. The exercise of this option enables sanofi-aventis to evaluate, with
	certain restrictions, our maytansinoid TAP technology with antibodies to targets that were not included in the research collaboration between the companies and to license the exclusive right to use
	the technology to develop products to specific targets based on the terms in the 2006 agreement. We are entitled to earn upfront and milestone payments potentially totaling $32&nbsp;million per
	target for each compound developed under the 2006 agreement, as well as royalties on the commercial sales of any resulting products. We are also entitled to manufacturing payments for any materials
	made on behalf of sanofi-aventis. We received $3.5&nbsp;million with the exercise of this option in August 2008, in addition to the $500,000 we received in December 2006 with the signing of the
	option agreement. The agreement has a three-year term from the date of the exercise of the option and can be renewed by sanofi-aventis for one additional three-year term by
	payment of a $2&nbsp;million fee.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Genentech
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2000, we entered into two separate agreements with Genentech. The first agreement grants Genentech an exclusive license to our
	maytansinoid TAP technology for use with antibodies, such as trastuzumab, that target HER2. Under the terms of this agreement, Genentech has exclusive worldwide rights to develop and commercialize
	maytansinoid TAP compounds with antibodies that target HER2. Genentech is responsible for the manufacturing, product development and marketing of any products resulting from the agreement. We are
	reimbursed for any preclinical and clinical materials that we manufacture under the agreement. We received a $2&nbsp;million non-refundable payment from Genentech upon execution of the
	agreement. We also are entitled to up to $44&nbsp;million in milestone payments from Genentech under this agreement, as amended in May 2006, in addition to royalties on the net sales of any
	resulting products. Genentech and Roche began Phase&nbsp;III evaluation of T-DM1 in February 2009, which triggered a $6.5&nbsp;million milestone payment to us. Through June&nbsp;30,
	2009, we have received a total of $13.5&nbsp;million in milestone payments.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	May 2000 we also entered into a "right-to-test" agreement with Genentech. This agreement provided Genentech with the right to test our maytansinoid TAP
	technology with antibodies to a defined number of targets on an exclusive basis for specified option periods and to take exclusive licenses for individual targets on agreed-upon terms to
	use our maytansinoid TAP technology to develop products. We received non-refundable technology access fees totaling $5&nbsp;million for the eight-year term of the agreement.
	Genentech no longer has the right to designate new targets under this
	"right-to-test" agreement, although there are options with respect to previously designated targets that remain in effect for the remainder of the respective option periods,
	which will expire during 2009.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=10,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=205518,FOLIO='10',FILE='DISK104:[09ZCX1.09ZCX49301]DC49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DC49301_1_11">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	this agreement, in April 2005, July 2005, December 2005 and December 2008, Genentech licensed exclusive rights to use our maytansinoid TAP technology with antibodies to four
	undisclosed targets. Under the terms defined in the 2000 "right-to-test" agreement, for each license we received a $1&nbsp;million license fee and may receive up to
	$38&nbsp;million in milestone payments. We are also entitled to receive royalties on the sales of any resulting products. Genentech is responsible for the development, manufacturing, and marketing
	of any products resulting from these licenses.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Bayer HealthCare
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2008, we entered into a development and license agreement with Bayer HealthCare AG. The agreement grants Bayer HealthCare
	exclusive rights to use our maytansinoid TAP technology to develop and commercialize therapeutic compounds to a specific target. Bayer HealthCare is responsible for the research, development,
	manufacturing and marketing of any products resulting from the license. We received a $4&nbsp;million upfront payment upon execution of the agreement, and&#151;for each compound developed and
	marketed by Bayer HealthCare under this collaboration&#151;we could potentially receive up to $170.5&nbsp;million in milestone payments; additionally, we are entitled to receive royalties on
	the net sales of any resulting products. We also are entitled to receive payments for manufacturing any preclinical and clinical materials at the request of Bayer HealthCare as well as for any related
	process development activities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Biogen Idec
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2004, we entered into a development and license agreement with Biogen Idec MA&nbsp;Inc. The agreement grants Biogen Idec
	exclusive rights to use our maytansinoid TAP technology to develop and commercialize therapeutic compounds to the target Cripto. Biogen Idec is responsible for the research, development,
	manufacturing, and marketing of any products resulting from the license. We received a $1&nbsp;million upfront payment upon execution of the agreement. In January 2008, Biogen Idec submitted an IND
	to the FDA for BIIB015, which was created under this
	agreement. This event triggered a $1.5&nbsp;million milestone payment to us.. Assuming all benchmarks are met, we could receive up to $42&nbsp;million in milestone payments under this agreement.
	We are also entitled to receive royalties on net sales of resulting products. We also receive compensation from Biogen Idec for any product development research done on its behalf, as well as for the
	production of preclinical and clinical materials.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Biotest
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2006, we entered into a development and license agreement with Biotest AG. The agreement grants Biotest exclusive rights to use
	our maytansinoid TAP technology to develop and commercialize therapeutic compounds to the target CD138. We received a $1&nbsp;million upfront payment upon execution of the agreement. In September
	2008, Biotest began Phase&nbsp;I evaluation of BT-062, which was created under this agreement. This event triggered a $500,000 milestone payment to us. Assuming all benchmarks are met
	under this agreement, we could receive up to $35.5&nbsp;million in milestone payments. We are also entitled to receive royalties on net sales of any resulting products. We receive payments for
	manufacturing any preclinical and clinical materials made at the request of Biotest.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	agreement also provides us with the right to elect, at specific stages during the clinical evaluation of any compound created under this agreement, to participate in the U.S.
	development and commercialization of that compound in lieu of receiving royalties on U.S. sales and the milestone payments not yet earned. We can exercise this right by making a payment to Biotest of
	an agreed-upon fee of $5&nbsp;million or $15&nbsp;million, depending on the stage of development. Upon exercise of this right, we would share equally with Biotest the associated costs
	of product development and commercialization in the U.S. along with the profit, if any, from U.S. product sales.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=11,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=553730,FOLIO='11',FILE='DISK104:[09ZCX1.09ZCX49301]DC49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DC49301_1_12">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Amgen
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2000, we entered into a ten-year "right-to-test" agreement with Abgenix,&nbsp;Inc.,
	which was later acquired by Amgen,&nbsp;Inc. The agreement provides Amgen with the right to test our maytansinoid TAP technology with antibodies to a defined number of targets on an exclusive and
	non-exclusive basis for specified option periods and to take exclusive or non-exclusive licenses for individual
	targets on agreed-upon terms to use our maytansinoid TAP technology to develop products. We received a $5&nbsp;million technology access fee in September 2000 and, with respect to each
	exclusive license taken, we are entitled to an upfront payment of $1&nbsp;million and milestone payments potentially totaling $34&nbsp;million and royalties on net sales of resulting products, if
	and when such sales commence. In April 2007 and July 2008, we granted Amgen a non-exclusive option and exclusive option, respectively, to test our TAP technology with antibodies to
	specific targets. For each option taken, Amgen paid us a nominal fee. Under this "right-to-test" agreement, there can be option periods in effect that extend beyond the
	expiration of the agreement in September 2010. As of the date of this Annual Report on Form&nbsp;10-K, Amgen has not taken any licenses under this agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	In-Licenses
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time we may in-license certain rights to targets or technologies for use in conjunction with our internal
	efforts to develop both TAP and naked-antibody products and related technologies. In exchange, we may be obligated to pay upfront fees, potential milestone payments and royalties on any product sales.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Centocor,&nbsp;Inc.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2004, we entered into a development and license agreement with Centocor,&nbsp;Inc., a wholly-owned subsidiary of
	Johnson&nbsp;&amp; Johnson. Under the terms of this agreement, Centocor was granted exclusive worldwide rights to develop and commercialize anticancer therapeutics that comprise an antibody developed by
	Centocor that binds to an integrin cancer target and a maytansinoid cell-killing agent developed by us. Under the terms of the agreement, we received an upfront payment of
	$1&nbsp;million upon execution of the agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	December 2007, we licensed from Centocor the exclusive, worldwide right to develop and commercialize a TAP compound, IMGN388, that consists of an integrin-binding antibody developed
	by them and one of our maytansinoid cell-killing agents. This license reallocates the parties' respective responsibilities and financial obligations from the license referenced above.
	Centocor has the right to opt-in on future development and commercialization of IMGN388 at an agreed-upon stage in early clinical testing. Should Centocor not exercise this
	right, Centocor would be entitled to receive milestone payments potentially totaling $30&nbsp;million, with the first payment due upon the completion of a successful Phase&nbsp;III trial, and also
	royalties on IMGN388 sales, if any. In this event, ImmunoGen has the right to obtain a new partner for IMGN388, with certain restrictions. Should Centocor exercise its opt-in right,
	ImmunoGen would receive an opt-in fee and be released from its obligation to pay Centocor any milestone payments or royalties on sales. Both companies would contribute to the costs of
	developing the compound. The two companies would share equally any profits on the sales of the compound in the U.S. and
	ImmunoGen would receive royalties on any international sales. The companies have agreed to share certain third-party expenses. In June 2008, the FDA approved the IND application for IMGN388. This
	event triggered a $1&nbsp;million milestone payment to a third party, half of which was paid by ImmunoGen.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Other Licenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also have licenses with third parties, including other companies and academic institutions, to gain access to techniques and
	materials for drug discovery and product development and the rights to
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=12,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=827426,FOLIO='12',FILE='DISK104:[09ZCX1.09ZCX49301]DC49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DC49301_1_13">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	use
	those techniques and materials to make our product candidates. These licenses include rights to certain antibodies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Patents, Trademarks and Trade Secrets
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have a strategy of obtaining patent protection for our proprietary technologies and product candidates. As of June&nbsp;30, 2009,
	our patent portfolio had a total of 268 worldwide issued patents and 473 patent applications worldwide that we own or license from third parties.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have issued and pending patents related to monoclonal antibodies. These antibodies may be a component of a TAP compound or may be developed as a "naked" antibody anticancer
	therapeutic. Among these patents is an issued U.S. patent claiming a method of humanizing murine antibodies to avoid their detection by the human immune system. This patent covers certain technology
	that we have licensed to sanofi-aventis on a non-exclusive basis, as described elsewhere in this Annual Report on Form&nbsp;10-K under the heading "Outlicenses and
	Collaboration&#151;
</FONT>
<FONT SIZE=2>
<I>
	sanofi-aventis
</I>
</FONT>
<FONT SIZE=2>
	." We have received comparable patents in other jurisdictions, primarily in the major countries of Europe and in
	Japan. These patents will expire between 2013 and 2014.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
	the eight product candidates named in the table on page&nbsp;6 of this Annual Report on Form&nbsp;10-K that are being developed by us or by our collaboration partners,
	one is a naked antibody and seven are TAP compounds that contain our proprietary maytansinoid cell-killing agents. We seek to protect our maytansinoids and TAP compounds through a
	multi-pronged approach. As of June&nbsp;30, 2009, we owned 20 issued U.S. patents related to our maytansinoid technology, as follows: claiming composition and use of certain maytansinoids; claiming
	conjugates composed of maytansinoids and cell-binding agents; claiming a process for the preparation of certain maytansinoids; and claiming methods of preparation of conjugates composed of
	maytansinoids and cell-binding agents. In all cases we have received or are applying for comparable patents in other jurisdictions, primarily in the major countries of Europe and in Japan.
	We also have submitted patent applications in the U.S., Europe, Japan and elsewhere covering other aspects of our TAP technology, including methods of attachment of cell-killing molecules
	to antibodies and the antibody component of TAP compounds as discussed above, as well as the use of some of these product candidates and inventions for certain diseases. We expect our work will lead
	to other patent applications. In all such cases, we will either be the assignee or owner of such patents or have an exclusive license to the technology covered by the patents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Typically,
	multiple issued and pending patents can apply for each TAP compound, and the patents that apply can vary among the TAP compounds and over time. For example, we have issued
	patents that extend beyond 2020 that cover aspects of the manufacturing of the maytansinoid cell-killing agents used to make T-DM1, IMGN901 and other TAP compounds. We have
	issued patents covering our DM1 and DM4 maytansinoid cell-killing agents that expire in 2010 and 2024, respectively, and a pending patent application covering conjugates using our SMCC
	thioether linker which, if issued as filed, would cover antibody-maytansinoid conjugates using this linker, such as T-DM1.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of June&nbsp;30, 2009, we also owned issued patents covering proprietary derivatives of non-maytansinoid cell-killing molecules. These additional patent
	families are currently not material to our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	described elsewhere in this annual report on Form&nbsp;10-K under the heading
	"In-Licenses&#151;
</FONT>
<FONT SIZE=2>
<I>
	Centocor,&nbsp;Inc.
</I>
</FONT>
<FONT SIZE=2>
	," we have in-licensed certain technology from Centocor in connection with the
	development of our IMGN388 product candidate. In addition, we have in-licensed intellectual property relating to our IMGN901 product candidate from Dana-Farber Cancer
	Institute. We do not believe that the terms of this license are material to our business or prospects.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=13,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=608805,FOLIO='13',FILE='DISK104:[09ZCX1.09ZCX49301]DC49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DC49301_1_14">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	cannot provide assurance that the patent applications will issue as patents or that any patents, if issued, will provide us with adequate protection against competitors with respect
	to the covered products, technologies or processes.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, many of the processes and much of the know-how that are important to us depend upon the skills, knowledge and experience of our key scientific and technical
	personnel, which skills, knowledge and experience are not patentable. To protect our rights in these areas, we require that all employees, consultants, advisors and collaborators enter into
	confidentiality agreements with us. Further, we require that all employees enter into assignment of invention agreements as a condition of employment. We cannot provide assurance, however, that these
	agreements will provide adequate or any meaningful protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure of such
	trade secrets, know-how or proprietary information. Further, in the absence of patent protection, we may be exposed to competitors who independently develop substantially equivalent
	technology or otherwise gain access to our trade secrets, know-how or other proprietary information.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Competition
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We focus on highly competitive areas of product development. Our competitors include major pharmaceutical companies and other
	biotechnology firms. For example, Wyeth, Seattle Genetics,&nbsp;Inc., and Medarex,&nbsp;Inc. have programs to attach a proprietary cell-killing small molecule to an antibody for
	targeted delivery to cancer cells. Pharmaceutical and biotechnology companies, as well as other institutions, also compete with us for promising targets for antibody-based therapeutics and in
	recruiting highly qualified scientific personnel. Many competitors and potential competitors have substantially greater scientific, research and product development capabilities, as well as greater
	financial, marketing and human resources than we do. In addition, many specialized biotechnology firms have formed collaborations with large, established companies to support the research, development
	and commercialization of products that may be competitive with ours.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	particular, competitive factors within the antibody and cancer therapeutic market include:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the safety and efficacy of products;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the timing of regulatory approval and commercial introduction;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	special regulatory designation of products, such as Orphan Drug designation; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the effectiveness of marketing, sales, and reimbursement efforts.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	competitive position depends on our ability to develop effective proprietary products, implement clinical development programs, production plans and marketing plans, including
	collaborations with other companies with greater marketing resources than ours, and to obtain patent protection and secure sufficient capital resources.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuing
	development of conventional and targeted chemotherapeutics by large pharmaceutical companies and biotechnology companies may result in new compounds that may compete with our
	product candidates. In addition, antibodies developed by certain of these companies have been approved for use as cancer therapeutics. In the future, additional antibodies may compete with our product
	candidates. In addition, other companies have created or have programs to create potent cell-killing agents for attachment to antibodies. These companies may compete with us for technology
	out-license arrangements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
	of the acceptance of combination therapy for the treatment of cancer and the variety of genes and targets implicated in cancer incidence and progression, we believe that products
	resulting from applications of new technologies may be complementary to our own.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=14,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=270017,FOLIO='14',FILE='DISK104:[09ZCX1.09ZCX49301]DC49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DC49301_1_15">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
	new technologies include, but are not limited to:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the use of genomics technology to identify new gene-based targets for the development of anticancer drugs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the use of high-throughput screening to identify and optimize lead compounds;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the use of gene therapy to deliver genes to regulate gene function; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the use of therapeutic vaccines.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Regulatory Matters
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Government Regulation and Product Approval
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other
	things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import
	of products such as those we are developing. A new drug must be approved by the FDA through the new drug application, or NDA, process and a new biologic must be approved by the FDA through the
	biologics license application, or BLA, process before it may be legally marketed in the U.S.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	U.S. Drug Development Process
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S., the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and in the case of biologics, also under
	the Public Health Service Act, and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes
	and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process,
	approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA's refusal to approve pending applications, withdrawal of an
	approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts,
	restitution, disgorgement, or civil or criminal
	penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a drug or biologic may be marketed in the U.S. generally
	involves the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices
	or other applicable regulations;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	submission to the FDA of an IND which must become effective before human clinical trials may begin;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	performance of adequate and well-controlled human clinical trials according to Good Clinical Practices to
	establish the safety and efficacy of the proposed drug for its intended use;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	submission to the FDA of an NDA or BLA;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to
	assess compliance with current good manufacturing practice, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	FDA review and approval of the NDA or BLA.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=15,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=418779,FOLIO='15',FILE='DISK104:[09ZCX1.09ZCX49301]DC49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_DE49301_1_16">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates
	will be granted on a timely basis, if at all.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
	a pharmaceutical candidate is identified for development it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and
	formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. The
	sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness
	criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective
	30&nbsp;days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must
	resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during studies due to safety concerns or
	non-compliance.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
	clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with good clinical practice regulations. These regulations include the
	requirement that all research subjects provide informed consent. Further, an institutional review board, or IRB, must review and approve the plan for any clinical trial before it commences at any
	institution. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are
	reasonable in relation to anticipated benefits. The IRB also approves the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal
	representative and must monitor the study until completed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
	new clinical protocol must be submitted to the IND for FDA review, and to the IRBs for approval. Protocols detail, among other things, the objectives of the study, dosing
	procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human
	clinical trials are typically conducted in three sequential phases that may overlap or be combined:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Phase&nbsp;I:
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;The drug is initially introduced into healthy human subjects and
	tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially
	when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Phase&nbsp;II:
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;Involves studies in a limited patient population to identify
	possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Phase&nbsp;III:
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical
	efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the
	product and provide, if appropriate, an adequate basis for product labeling.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progress
	reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for
	serious and unexpected adverse events. Phase&nbsp;I, Phase&nbsp;II, and Phase&nbsp;III testing may not be completed successfully within any specified period, if at all. The FDA or the sponsor
	may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend
	or terminate approval of a clinical trial at its
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=16,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=332120,FOLIO='16',FILE='DISK104:[09ZCX1.09ZCX49301]DE49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DE49301_1_17">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	institution
	if the clinical trial is not being conducted in accordance with the IRB's requirements or if the drug has been associated with unexpected serious harm to patients.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
	with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the
	drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
	batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate
	packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	U.S. Review and Approval Processes
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process,
	analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product.
	The submission of an NDA or BLA is subject to the payment of user fees; a waiver of such fees may be obtained under certain limited circumstances.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, under the Pediatric Research Equity Act of 2007, or PREA, an NDA, BLA and certain types of supplements to an NDA or BLA must contain data to assess the safety and
	effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and
	effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan
	designation has been granted. PREA sunsets on October&nbsp;1, 2012.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDA reviews all NDAs and BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional
	information rather than accept a NDA or BLA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA
	accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. FDA may refer the NDA or BLA to an advisory committee for review,
	evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows
	such recommendations. The approval process is lengthy and difficult and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional
	clinical or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from
	clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA may issue a complete response letter, which may require additional
	clinical or other data or impose other conditions that must be met in order to secure final approval of the NDA or BLA, or an approved letter following satisfactory completion of all aspects of the
	review process. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to
	assure and preserve the product's identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things whether the product is safe, pure and potent and the facility in which
	it is manufactured, processed, packed or held meets standards designed to assure the product's continued safety, purity and potency. Before approving an NDA, the FDA will inspect the facility or
	facilities where the product is manufactured.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NDAs
	or BLAs receive either standard or priority review. A drug representing a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. In
	addition,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=17,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=875339,FOLIO='17',FILE='DISK104:[09ZCX1.09ZCX49301]DE49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DE49301_1_18">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	products
	studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive
	accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is
	reasonably likely to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a
	sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. Priority review and accelerated approval do not change the
	standards for approval, but may expedite the approval process.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could
	restrict the commercial value of the product. In addition, the FDA may require us to conduct Phase&nbsp;IV testing which involves clinical trials designed to further assess a drug's safety and
	effectiveness after NDA or BLA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Patent Term Restoration and Marketing Exclusivity
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and specifics of FDA approval of the use of our drugs, some of our U.S. patents may be eligible for
	limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent
	restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining
	term of a patent beyond a total of 14&nbsp;years from the product's approval date. The patent term restoration period is generally one-half the time between the effective date of an IND,
	and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the
	extension and the extension must be applied for prior to expiration of the patent. The United States Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for
	any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current
	expiration date, depending on the expected length of clinical trials and other factors involved in the filing of the relevant NDA.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market
	exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of
	non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously
	approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for
	review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of
	reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA
	also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or
	sponsored by the applicant are deemed by FDA to be essential to the approval of the application, for example, for new indications, dosages, or strengths of an existing drug. This
	three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original
	active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to
	conduct or obtain a right of
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=18,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=285354,FOLIO='18',FILE='DISK104:[09ZCX1.09ZCX49301]DE49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DE49301_1_19">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reference
	to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
	exclusivity is another type of exclusivity in the U.S. Pediatric exclusivity, if granted, provides an additional six months to an existing exclusivity or statutory delay in
	approval resulting from a patent certification. This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary
	completion of a pediatric study in accordance with an FDA-issued "Written Request" for such a study. The current pediatric exclusivity provision will sunset on October&nbsp;1, 2012.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Orphan Drug Designation
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is
	generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of
	developing and making available in the U.S. a drug for this type of disease or condition will be recovered from sales in the U.S. for that drug. Orphan drug designation must be requested before
	submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not
	convey any advantage in or shorten the duration of the regulatory review and approval process.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product
	exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for seven years. Orphan drug
	exclusivity, however, also could block the approval of one of our products for seven years if a competitor obtains approval of the same drug as defined by the FDA or if our product candidate is
	determined to be contained within the competitor's product for the same indication or disease.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDA also administers a clinical research grants program, whereby researchers may compete for funding to conduct clinical trials to support the approval of drugs, biologics, medical
	devices, and medical foods for rare diseases and conditions. A product does not have to be designated as an orphan drug to be eligible for the grant program. An application for an orphan grant should
	propose one discrete clinical study to facilitate FDA approval of the product for a rare disease or condition. The study may address an unapproved new product or an unapproved new use for a product
	already on the market.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	may pursue this designation with respect to product candidates intended for qualifying patient populations. A drug that receives Orphan Drug designation and is the first product of
	its kind to receive FDA marketing approval for its product claim is entitled to a seven-year exclusive marketing period in the U.S. for that product claim.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	New Drugs for Serious or Life Threatening Illnesses
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA Modernization Act allows the designation of "Fast Track" status to expedite development of new drugs, including review and
	approvals, and is intended to speed the availability of new therapies to desperately ill patients. "Fast Track" procedures permit early consultation and commitment from the FDA regarding preclinical
	studies and clinical trials necessary to gain marketing approval. We may seek "Fast Track" status for some, or all, of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Fast
	Track" status also incorporates initiatives announced by the President of the U.S. and the FDA Commissioner in March 1996 intended to provide cancer patients with faster access to
	new cancer therapies. One of these initiatives states that the initial basis for approval of anticancer agents to treat
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	19
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=19,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=40249,FOLIO='19',FILE='DISK104:[09ZCX1.09ZCX49301]DE49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DE49301_1_20">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	refractory,
	hard-to-treat cancer may be objective evidence of response, rather than statistically improved disease-free and/or overall survival, as had been common
	practice. The sponsor of a product approved under this accelerated mechanism is required to follow up with further studies on clinical safety and effectiveness in larger groups of patients.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Post-Approval Requirements
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems
	occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the
	market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and
	approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies,
	and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. We rely, and expect to continue to rely, on third parties for the
	production of clinical and commercial quantities of our products. Future FDA and state inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt
	production or distribution, or require substantial resources to correct.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	drug products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,
	reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records
	and signature requirements, and complying with FDA promotion and advertising requirements. FDA strictly regulates labeling, advertising, promotion and other types of information on products that are
	placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
	time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing
	of products regulated by the FDA. For example, on September&nbsp;27, 2007, the Food and Drug Administration Amendments Act of 2007, or FDAAA, gave the FDA enhanced postmarket authority, including
	the authority to require postmarket studies and clinical trials, labeling changes based on new safety information, and compliance with a risk evaluation and mitigation strategy approved by the FDA.
	Failure to comply with any requirements under the new law may result in significant penalties. The new law also authorizes significant civil money penalties for the dissemination of false or
	misleading direct-to-consumer advertisements. Additionally, the new law expands the clinical trial registry so that sponsors of all clinical trials, except for Phase&nbsp;I
	trials, are required to submit certain clinical trial information for inclusion in the clinical trial registry data bank, including summary adverse effect information. In addition, FDA regulations and
	guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be
	enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Foreign Regulation
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to regulations in the U.S., we will be subject to a variety of foreign regulations governing clinical trials and commercial
	sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before
	we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and the time may be
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	20
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=20,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=94252,FOLIO='20',FILE='DISK104:[09ZCX1.09ZCX49301]DE49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DE49301_1_21">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	longer
	or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	European Union regulatory systems, we may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which is
	compulsory for medicines produced by certain biotechnological processes and optional for those which are highly innovative, provides for the grant of a single marketing authorization that is valid for
	all European Union member states. For drugs without approval in any Member State, the decentralized procedure
	provides for approval by one or more other, or concerned, Member States of an assessment of an application performed by one Member State, known as the reference Member State. Under this procedure, an
	applicant submits an application, or dossier, and related materials (draft summary of product characteristics, draft labeling and package leaflet) to the reference Member State and concerned Member
	States. The reference Member State prepares a draft assessment and drafts of the related materials within 120&nbsp;days after receipt of a valid application. Within 90&nbsp;days of receiving the
	reference Member State's assessment report, each concerned Member State must decide whether to approve the assessment report and related materials. If a Member State cannot approve the assessment
	report and related materials on the grounds of potential serious risk to public health, the disputed points may eventually be referred to the European Commission, whose decision is binding on all
	Member States.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Reimbursement
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of pharmaceutical products depend in significant part on the availability of third-party reimbursement. Third-party payors
	include government healthcare programs, managed care providers, private health insurers and other organizations. We anticipate third-party payors will provide reimbursement for our products. However,
	these third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the
	reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. Our
	product candidates may not be considered cost-effective. It is time consuming and expensive for us to seek reimbursement from third-party payors. Reimbursement may not be available or
	sufficient to allow us to sell our products on a competitive and profitable basis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription drugs for Medicare
	beneficiaries, and included a major expansion of the prescription drug benefit under Medicare Part&nbsp;D. Under Part&nbsp;D, Medicare beneficiaries may enroll in prescription drug plans offered
	by private entities which provide coverage of outpatient prescription drugs. Part&nbsp;D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement
	to Medicare Advantage plans. Unlike Medicare Part&nbsp;A and B, Part&nbsp;D coverage is not standardized. Part&nbsp;D prescription drug plan sponsors are not required to pay for all covered
	Part&nbsp;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&nbsp;D prescription drug formularies
	must include drugs within each therapeutic category and class of covered Part&nbsp;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&nbsp;D
	prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
	is not clear what effect the MMA will have on the prices paid for currently approved drugs and the pricing options for future approved drugs. Government payment for some of the costs
	of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&nbsp;D prescription drug plan will
	likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and
	payment
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	21
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=21,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=563003,FOLIO='21',FILE='DISK104:[09ZCX1.09ZCX49301]DE49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DE49301_1_22">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	limitations
	in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost
	of prescription drugs. At the present time, Medicare is prohibited from negotiating directly with pharmaceutical companies for drugs. However, the administration of President Obama is supporting and
	Congress is currently considering major changes to the way that healthcare is provided to U.S. citizens. While we cannot predict whether any legislative or regulatory proposals will be adopted, the
	adoption of such proposals could have an effect on the payments for our approved products, if any, and could have a material adverse effect on our business, financial condition and profitability.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from
	country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide
	reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or
	indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for
	pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Research and Development Spending
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During each of the three years ended June&nbsp;30, 2009, 2008 and 2007, we spent approximately $45.9&nbsp;million,
	$60.0&nbsp;million and $49.4&nbsp;million, respectively, on research and development activities. During the year ended June&nbsp;30, 2009, approximately 14% of our full-time
	equivalent research and development personnel were dedicated to our sanofi-aventis collaboration compared to 36% and 55% during the years ended June&nbsp;30, 2008 and 2007, respectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Raw Materials and Manufacturing
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We procure certain raw material components of finished conjugate, including antibodies, ansamitocin P3, DM1, DM4, and linker, for
	ourselves and on behalf of our collaborators. In order to meet our commitments to our collaborators as well as our own needs, we are required to enter into agreements with third parties to produce
	these components well in advance of our production needs. Our principal suppliers for these components include Cytovance Biologics&nbsp;LLC, SAFC,&nbsp;Inc. and Societ&agrave; Italiana
	Corticosteroidi&nbsp;S.r.l.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, we operate a conjugate manufacturing facility. A portion of the cost of operating this facility, including the cost of manufacturing personnel, is reimbursed by our
	collaborators based on the number of batches of preclinical and clinical materials produced on their behalf. Over the past few years, we have expanded and upgraded the capabilities of our
	manufacturing facility.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Employees
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2009, we had 210 full-time employees, of whom 174 were engaged in research and development
	activities. Seventy-four research and development employees hold post-graduate degrees, of which 39 hold Ph.D. degrees and five hold M.D. degrees. We consider our relations
	with our employees to be good. None of our employees are covered by a collective bargaining agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have entered into confidentiality agreements with all of our employees, members of our board of directors and consultants. Further, we have entered into assignment of invention
	agreements with all of our employees.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=22,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=986171,FOLIO='22',FILE='DISK104:[09ZCX1.09ZCX49301]DE49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_23">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Third-Party Trademarks
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Herceptin is a registered trademark of Genentech. Rituxan is a registered trademark of Biogen Idec. Erbitux is a registered trademark
	of ImClone Systems.
</FONT>
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DG49301_ITEM_1A__RISK_FACTORS">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DG49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;1A.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Risk Factors
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	THE RISKS AND UNCERTAINTIES DESCRIBED BELOW ARE THOSE THAT WE CURRENTLY BELIEVE MAY MATERIALLY AFFECT OUR COMPANY. ADDITIONAL RISKS AND UNCERTAINTIES
	THAT WE ARE UNAWARE OF OR THAT WE CURRENTLY DEEM IMMATERIAL ALSO MAY BECOME IMPORTANT FACTORS THAT AFFECT OUR COMPANY.
</I>
</FONT>
</P>
<EFX_FACTORS_AFFECTING>
<A NAME="FIS_FACTORS_AFFECTING"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We have a history of operating losses and expect to incur significant additional operating losses.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have generated operating losses since our inception. As of June&nbsp;30, 2009, we had an accumulated deficit of
	$321.5&nbsp;million. For the years ended June&nbsp;30, 2009, 2008, and 2007, we generated losses of $31.9&nbsp;million, $32.0&nbsp;million and $19.0&nbsp;million, respectively. We may never
	be profitable. We expect to incur substantial additional operating expenses over the next several years as our research, development, preclinical testing, clinical trials and collaborator support
	activities continue. We intend to continue to invest significantly in our product candidates. Further, we expect to invest significant resources supporting our existing collaborators as they work to
	develop, test and commercialize TAP and other antibody compounds. We or our collaborators may encounter technological or regulatory difficulties as part of this development and commercialization
	process that we cannot overcome or remedy. We may also incur substantial marketing and other costs in the future if we decide to establish marketing and sales capabilities to commercialize our product
	candidates. None of our or our collaborators' product candidates has generated any commercial revenue and our only revenues to date have been primarily from upfront and milestone payments, research
	and development support and clinical materials reimbursement from our collaborative partners. We do not expect to generate revenues from the commercial sale of our product candidates or royalties on
	revenues from the commercial sale of our collaborators' product candidates in the near future, and we may never generate revenues from the commercial sale of products. Even if we do successfully
	develop products that can be marketed and sold commercially, we will need to generate significant revenues from those products to achieve and maintain profitability. Even if we do become profitable,
	we may not be able to sustain or increase profitability on a quarterly or annual basis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	If we are unable to obtain additional funding when needed, we may have to delay or scale back some of our programs or grant rights to third parties
	to develop and market our product candidates.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will continue to expend substantial resources developing new and existing product candidates, including costs associated with
	research and development, acquiring new technologies, conducting preclinical studies and clinical trials, obtaining regulatory approvals and manufacturing products as well as providing certain support
	to our collaborators in the development of their products. We believe that our current working capital and future payments, if any, from our collaboration arrangements will be sufficient to meet our
	current and projected operating and capital
	requirements for fiscal year 2010 and at least a portion of the following fiscal year. However, we may need additional financing sooner due to a number of factors including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	if either we or any of our collaborators incur higher than expected costs or experience slower than expected progress in
	developing product candidates and obtaining regulatory approvals;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	lower revenues than expected under our collaboration agreements; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	acquisition of technologies and other business opportunities that require financial commitments.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	23
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=23,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=395216,FOLIO='23',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_24">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
</UL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
	funding may not be available to us on favorable terms, or at all. We may raise additional funds through public or private financings, collaborative arrangements or other
	arrangements. Debt financing, if available, may involve covenants that could restrict our business activities. If we are unable to raise additional funds through equity or debt financing when needed,
	we may be required to delay, scale back or eliminate expenditures for some of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to
	internally develop and market. If we are required to grant such rights, the ultimate value of these product candidates to us may be reduced.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	If our TAP technology does not produce safe, effective and commercially viable products, our business will be severely harmed.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our TAP technology yields novel product candidates for the treatment of cancer. To date, no TAP product candidate has obtained
	regulatory approval and the most advanced TAP product candidate is in Phase&nbsp;III clinical testing. Our TAP product candidates and/or our collaborators' TAP product candidates may not prove to be
	safe, effective or commercially viable treatments for cancer and our TAP technology may not result in any future meaningful benefits to us or for our current or potential collaborative partners.
	Furthermore, we are aware of only one
	compound that is a conjugate of an antibody and a cytotoxic small molecule that has obtained approval by the FDA and is based on technology similar to our TAP technology. If our TAP technology fails
	to generate product candidates that are safe, effective and commercially viable treatments for cancer, or fails to obtain FDA approval, our business will be severely harmed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Clinical trials for our and our collaborative partners' product candidates will be lengthy and expensive and their outcome is uncertain.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before obtaining regulatory approval for the commercial sale of any product candidates, we and our collaborative partners must
	demonstrate through clinical testing that our product candidates are safe and effective for use in humans. Conducting clinical trials is a time-consuming, expensive and uncertain process
	and typically requires years to complete. Our, as well as our collaborative partners', most advanced TAP product candidate is in Phase&nbsp;III clinical testing. In our industry, the results from
	preclinical studies and early clinical trials often are not predictive of results obtained in later-stage clinical trials. Some compounds that have shown promising results in preclinical studies or
	early clinical trials subsequently fail to establish sufficient safety and efficacy data necessary to obtain regulatory approval. At any time during the clinical trials, we, our collaborative
	partners, or the FDA might delay or halt any clinical trials of our product candidates for various reasons, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	occurrence of unacceptable toxicities or side effects;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	ineffectiveness of the product candidate;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	insufficient drug supply;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	negative or inconclusive results from the clinical trials, or results that necessitate additional studies or clinical
	trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	delays in obtaining or maintaining required approvals from institutions, review boards or other reviewing entities at
	clinical sites;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	delays in patient enrollment;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	insufficient funding or a reprioritization of financial or other resources; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	other reasons that are internal to the businesses of our collaborative partners, which they may not share with us.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=24,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=76133,FOLIO='24',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_25">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
</UL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	failure or substantial delay in successfully completing clinical trials and obtaining regulatory approval for our product candidates or our collaborative partners' product candidates
	could severely harm our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We and our collaborative partners are subject to extensive government regulations and we and our collaborative partners may not be able to obtain
	necessary regulatory approvals.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and our collaborative partners may not receive the regulatory approvals necessary to commercialize our product candidates, which
	would cause our business to be severely harmed. Pharmaceutical product candidates, including those in development by us and our collaborative partners, are subject to extensive and rigorous government
	regulation. The FDA regulates, among other things, the development, testing, manufacture, safety, record-keeping, labeling, storage, approval, advertising, promotion, sale and distribution of
	pharmaceutical products. If our potential products or our collaborators' potential products are marketed abroad, they will also be subject to extensive regulation by foreign governments. None of our
	product candidates has been approved for sale in the U.S. or any foreign market. The regulatory review and approval process, which includes preclinical studies and clinical trials of each product
	candidate, is lengthy, complex, expensive and uncertain. Securing FDA approval requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each
	indication to establish the product candidate's safety and efficacy. Data obtained from preclinical studies and clinical trials are susceptible to varying interpretation, which may delay, limit or
	prevent regulatory approval. The approval process may take
	many years to complete and may involve ongoing requirements for post-marketing studies. In light of the limited regulatory history of monoclonal antibody-based therapeutics, regulatory
	approvals for our or our collaborative partners' product candidates may not be obtained without lengthy delays, if at all. Any FDA or other regulatory approvals of our or our collaborative partners'
	product candidates, once obtained, may be withdrawn. The effect of government regulation may be to:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	delay marketing of potential products for a considerable period of time;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	limit the indicated uses for which potential products may be marketed;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	impose costly requirements on our activities; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	place us at a competitive disadvantage to other pharmaceutical and biotechnology companies.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	may encounter delays or rejections in the regulatory approval process because of additional government regulation from future legislation or administrative action or changes in FDA
	policy during the period of product development, clinical trials and FDA regulatory review. Failure to comply with FDA or other applicable regulatory requirements may result in criminal prosecution,
	civil penalties, recall or seizure of products, total or partial suspension of production or injunction, as well as other regulatory action against our product candidates or us. Outside the U.S., our
	ability to market a product is contingent upon receiving clearances from the appropriate regulatory authorities. The foreign regulatory approval process includes similar risks to those associated with
	the FDA approval process. In addition, we are, or may become, subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and
	manufacturing practices, the experimental use of animals and the use and disposal of hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our
	research work. If we fail to comply with the laws and regulations pertaining to our business, we may be subject to sanctions, including the temporary or permanent suspension of operations, product
	recalls, marketing restrictions and civil and criminal penalties.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=25,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=291851,FOLIO='25',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_26">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Our and our collaborative partners' product candidates will remain subject to ongoing regulatory review even if they receive marketing approval. If
	we or our collaborative partners fail to comply with continuing regulations, we could lose these approvals and the sale of our products could be suspended.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we or our collaborative partners receive regulatory approval to market a particular product candidate, the approval could be
	conditioned on us or our collaborative partners conducting costly post-approval studies or could limit the indicated uses included in product labeling. Moreover, the product may later
	cause adverse effects that limit or prevent its widespread use, force us or our collaborative partners to withdraw it from the market or impede or delay our or our collaborative partners' ability to
	obtain regulatory approvals in additional countries. In addition, the manufacturer of the product and its facilities will continue to be subject to FDA review and periodic inspections to ensure
	adherence to applicable regulations. After receiving marketing approval, the manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping related to
	the product remain subject to extensive regulatory requirements. We or our collaborative partners may be slow to adapt, or we or our collaborative partners may never adapt, to changes in existing
	regulatory requirements or adoption of new regulatory requirements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	we or our collaborative partners fail to comply with the regulatory requirements of the FDA and other applicable U.S. and foreign regulatory authorities, or if previously unknown
	problems with our or our partners' products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions,
	including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	restrictions on the products, manufacturers or manufacturing processes;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	warning letters;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	civil or criminal penalties;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	fines;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	injunctions;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	product seizures or detentions;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	import bans;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	voluntary or mandatory product recalls and publicity requirements;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	suspension or withdrawal of regulatory approvals;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	total or partial suspension of production; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	refusal to approve pending applications for marketing approval of new drugs or supplements to approved applications.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	one of these could have a material adverse effect on our business or financial condition.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	If our collaborative partners fail to perform their obligations under our agreements with them, or determine not to continue with clinical trials for
	particular product candidates, our business could be severely impacted.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our strategy for the development and commercialization of our product candidates depends, in large part, upon the formation and
	maintenance of collaborative arrangements. Collaborations provide an opportunity for us to:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	generate cash flow and revenue;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	fund some of the costs associated with our internal research and development, preclinical testing, clinical trials and
	manufacturing;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=26,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=744229,FOLIO='26',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_27">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	seek and obtain regulatory approvals faster than we could on our own;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successfully commercialize existing and future product candidates; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	secure access to targets which, due to intellectual property restrictions, would otherwise be unavailable to our
	technology.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	we fail to secure or maintain successful collaborative arrangements, the development and marketing of compounds that use our technology may be delayed, scaled back or otherwise may
	not occur. In addition, we may be unable to negotiate other collaborative arrangements or, if necessary, modify our existing arrangements on acceptable terms. We cannot control the amount and timing
	of resources our collaborative partners may devote to our product candidates. Our collaborative partners may separately pursue competing product candidates, therapeutic approaches or technologies to
	develop treatments for the diseases targeted by us or our collaborative efforts, or may decide, for reasons not known to us, to discontinue development of product candidates under our agreements with
	them. Any of our collaborative partners may slow or discontinue the development of a product candidate covered by a collaborative arrangement for reasons that can include, but are not limited
	to:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a change in the collaborative partner's strategic focus as a result of merger, management changes, adverse business
	events, or other causes;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a change in the priority of the product candidate relative to other programs in the collaborator's pipeline;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a reassessment of the patent situation related to the compound or its target;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a change in the anticipated competition for the product candidate;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	preclinical studies and clinical trial results; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a reduction in the financial resources the collaborator can or is willing to apply to the development of new compounds.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
	if our collaborative partners continue their collaborative arrangements with us, they may nevertheless determine not to actively pursue the development or commercialization of any
	resulting products. Also, our collaborative partners may fail to perform their obligations under the collaborative agreements or may be slow in performing their obligations. Our collaborative partners
	can terminate our collaborative agreements under certain conditions. The decision to advance a product that is covered by a collaborative agreement through clinical trials and ultimately to
	commercialization is in the discretion of our collaborative partners. If any collaborative partner were to terminate or breach our agreements, fail to complete its obligations to us in a timely
	manner, or decide to discontinue its development of a product candidate, our anticipated revenue from the agreement and from the development and commercialization of the products would be severely
	limited. If we are not able to establish additional collaborations or any or all of our existing collaborations are terminated and we are not able to enter into alternative collaborations on
	acceptable terms, or at all, our continued development, manufacture and commercialization of our product candidates could be delayed or scaled back as we may not have the funds or capability to
	continue these activities. If our collaborators fail to successfully develop and commercialize TAP compounds, our business would be severely harmed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We depend on a small number of collaborators for a substantial portion of our revenue. The loss of, or a material reduction in activity by, any one
	of these collaborators could result in a substantial decline in our revenue.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have and will continue to have collaborations with a limited number of companies. As a result, our financial performance depends on
	the efforts and overall success of these companies. Also, the failure of any one of our collaborative partners to perform its obligations under its agreement with us,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=27,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=578112,FOLIO='27',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_28">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	including
	making any royalty, milestone or other payments to us, could have an adverse effect on our financial condition. Further, any material reduction by any one of our collaborative partners in
	its level of commitment of resources, funding, personnel, and interest in continued development under its agreement with us could have an adverse effect on our financial condition. In July 2003, we
	entered into a discovery, development and commercialization collaboration with sanofi-aventis that entitled us to receive committed research funding. We recorded $81.5&nbsp;million of committed
	research and development support revenue under this agreement. The committed funding portion of this agreement ended in October 2008 and there are no other agreements in place at this time that
	entitle us to committed research funding. As a result, we expect a reduction in our research and development revenue. To date, we have recorded $13.5&nbsp;million in milestone payments with the
	advancement of T-DM1. Our agreement with Genentech entitles us to receive up to $44&nbsp;million in milestone payments and also royalties on commercial sales, if any. Failure of
	Genentech to continue to advance T-DM1 would have an adverse effect on our financial outlook. Also, if consolidation trends in the healthcare industry continue, the number of our potential
	collaborators
	could decrease, which could have an adverse impact on our development efforts. If a present or future collaborator of ours were to be involved in a business combination, its continued pursuit and
	emphasis on our product development program could be delayed, diminished or terminated.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	If our collaborative partners' requirements for clinical materials to be manufactured by us are significantly lower than we have estimated, our
	financial results and condition could be adversely affected.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We procure certain components of finished conjugate, including ansamitocin P3, DM1, DM4, and linker, on behalf of our collaborators. In
	order to meet our commitments to our collaborative partners, we are required to enter into agreements with third parties to produce these components well in advance of our production of clinical
	materials on behalf of our collaborative partners. If our collaborative partners do not require as much clinical material as we have contracted to produce, we may not be able to recover our investment
	in these components and we may suffer significant losses. Collaborators have discontinued development of product candidates in the past and in the periods subsequent to these discontinuations, we had
	significantly reduced demand for conjugated material which adversely impacted our financial results.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, we operate a conjugate manufacturing facility. A portion of the cost of operating this facility, including the cost of manufacturing personnel, is reimbursed by our
	collaborators based on the number of batches of preclinical and clinical materials produced on their behalf. If we produce fewer batches of clinical materials for our collaborators, a smaller amount
	of the cost of operating the conjugate manufacturing facility will be charged to our collaborative partners and our financial condition could be adversely affected.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	If our antibody requirements for clinical materials to be manufactured are significantly higher than we estimated, the inability to procure
	additional antibody in a timely manner could impair our ability to initiate or advance our clinical trials.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third-party suppliers to manufacture antibodies used in our own proprietary product candidates. Due to the specific nature
	of the antibody and availability of production capacity, there is significant lead time required by these suppliers to provide us with the needed materials. If our antibody requirements for clinical
	materials to be manufactured are significantly higher than we estimated, we may not be able to readily procure additional antibody which would impair our ability to advance our clinical trials
	currently in process or initiate additional trials. For example, enrollment of new patients into all clinical trials of IMGN901 was suspended in late 2006 due to insufficient supply of IMGN901. We
	believe we have resolved these supply issues and that we have sufficient supply of IMGN901 to complete these trials on a timely basis. There can be no assurance that we will not have
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	28
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=28,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=731611,FOLIO='28',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_29">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	future
	supply problems that could delay or stop our clinical trials or otherwise could have a material adverse effect on our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We currently rely on one third-party manufacturer with commercial production experience to produce our cell-killing agents, DM1 and DM4.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third-party suppliers to manufacture materials used to make TAP compounds. Our cell-killing agents DM1 and
	DM4&#151;collectively DMx&#151;are manufactured from a precursor, ansamitocin P3. As part of preparing to produce TAP compounds for later-stage clinical trials and commercialization, we
	have transitioned from our original supplier of ansamitocin P3, as well as our single supplier that converts ansamitocin P3 to DMx, to one larger company with more commercial production experience.
	Any delay or interruption in our supply of DMx could lead to a delay or interruption in our manufacturing operations, preclinical studies and clinical trials of our product candidates and our
	collaborators' product candidates, which could negatively affect our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We may be unable to establish the manufacturing capabilities necessary to develop and commercialize our and our collaborative partners' potential
	products.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently, we have only one conjugate manufacturing facility that we use to manufacture conjugated compounds for us and our
	collaborative partners for preclinical studies and early-stage clinical testing. Two of our partners have contracted for separate large, scale manufacturing
	capacity to make materials to support potential future commercialization of their compounds. We do not currently have the manufacturing capacity needed to make our product candidates for commercial
	sale. In addition, our manufacturing capacity may be insufficient to complete all clinical trials contemplated by us and our collaborative partners over time. We intend to rely in part on third-party
	contract manufacturers to produce sufficiently large quantities of drug materials that are and will be needed for later-stage clinical trials and commercialization of our potential products. We are
	currently in the process of developing relationships with third-party manufacturers that we believe will be necessary to continue the development of our product candidates. Third-party manufacturers
	may not be able to meet our needs with respect to timing, quantity or quality of materials. If we are unable to contract for a sufficient supply of needed materials on acceptable terms, or if we
	should encounter delays or difficulties in our relationships with manufacturers, our clinical trials may be delayed, thereby delaying the submission of product candidates for regulatory approval and
	the market introduction and subsequent commercialization of our potential products. Any such delays may lower our revenues and potential profitability.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition to the outsourcing of manufacturing, we may develop our manufacturing capacity in part by expanding our current facilities. This activity would require substantial additional
	funds and we would need to hire and train significant numbers of employees to staff these facilities. We may not be able to develop manufacturing facilities that are sufficient to produce drug
	materials for later-stage clinical trials or commercial use. We and any third-party manufacturers that we may use must continually adhere to cGMP regulations enforced by the FDA through its facilities
	inspection program. If our facilities or the facilities of third-party manufacturers cannot pass a pre-approval plant inspection, the FDA will not grant approval to our product candidates.
	In complying with these cGMP regulations and foreign regulatory requirements, we and any of our third-party manufacturers will be obligated to expend time, money and effort on production,
	record-keeping and quality control to assure that our potential products meet applicable specifications and other requirements. If we or any third-party manufacturer with whom we may contract fail to
	maintain regulatory compliance, we or the third party may be subject to fines and/or manufacturing operations may be suspended.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	29
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=29,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=92825,FOLIO='29',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_30">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We have only one conjugate manufacturing facility and any prolonged and significant disruption at that facility could impair our ability to
	manufacture our and our collaborative partners' product candidates for clinical testing.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently, we are contractually obligated to manufacture Phase&nbsp;I and non-pivotal Phase&nbsp;II clinical products
	for companies licensing our TAP technology. We manufacture this material, as well as material for our own product candidates, in our conjugate manufacturing facility. We have only one such
	manufacturing facility in which we can manufacture clinical products. Our current manufacturing facility contains highly specialized equipment and utilizes complicated production processes developed
	over a number of years that would be difficult, time-consuming and costly to duplicate. Any prolonged disruption in the operations of our manufacturing facility would have a significant
	negative impact on our ability to manufacture products for clinical testing on our own and would cause us to seek additional third-party
	manufacturing contracts, thereby increasing our development costs. Even though we carry business interruption insurance policies, we may suffer losses as a result of business interruptions that exceed
	the coverage available or any losses may be excluded under our insurance policies. Certain events, such as natural disasters, fire, political disturbances, sabotage or business accidents, which could
	impact our current or future facilities, could have a significant negative impact on our operations by disrupting our product development efforts until such time as we are able to repair our facility
	or put in place third-party contract manufacturers to assume this manufacturing role.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives applicable to our product candidates could
	limit our potential product revenue.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Antibody-based anticancer products are often much more costly to produce than traditional chemotherapeutics and tend to have
	significantly higher prices. Factors that help justify the price include the high mortality associated with many types of cancer and the need for more and better treatment options.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulations
	governing drug pricing and reimbursement vary widely from country to country. Some countries require approval of the sales price of a drug before it can be marketed. Some
	countries restrict the physicians that can authorize the use of more expensive medications. Some countries establish treatment guidelines to help limit the use of more expensive therapeutics and the
	pool of patients that receive them. In some countries, including the U.S., third-party payers frequently seek discounts from list prices and are increasingly challenging the prices charged for medical
	products. Because our product candidates are in the development stage, we do not know the level of reimbursement, if any, we will receive for any products that we are able to successfully develop. If
	the reimbursement for any of our product candidates is inadequate in light of our development and other costs, our ability to achieve profitability would be affected.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare will continue to affect the business and financial condition of
	pharmaceutical and biopharmaceutical companies. A number of legislative and regulatory proposals to change the healthcare system in the U.S. and other major healthcare markets have been proposed and
	adopted in recent years. For example, the U.S. Congress enacted a limited prescription drug benefit for Medicare recipients as part of the Medicare Prescription Drug, Improvement and Modernization Act
	of 2003. While the program established by this statute may increase demand for any products that we are able to successfully develop, if we participate in this program, our prices will be negotiated
	with drug procurement organizations for Medicare beneficiaries and are likely to be lower than prices we might otherwise obtain. Non-Medicare third-party drug procurement organizations may
	also base the price they are willing to pay on the rate paid by drug procurement organizations for Medicare beneficiaries. In addition, ongoing initiatives in the U.S. have increased and will continue
	to increase pressure on drug pricing. The announcement or adoption of any such initiative could have an adverse effect on potential revenues from any product candidate that we may successfully
	develop.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=30,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=867612,FOLIO='30',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_31">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We may be unable to establish sales and marketing capabilities necessary to successfully commercialize our potential products.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have no direct sales or marketing capabilities. We anticipate relying on third parties to market and sell most of our
	primary product candidates or we may outlicense these products prior to the time when these capabilities are needed. If we decide to market our potential products through a direct sales force, we
	would need either to hire a sales force with expertise in pharmaceutical sales or to contract with a third party to provide a sales force which meets our needs. We may be unable to establish
	marketing, sales and distribution capabilities necessary to commercialize and gain market acceptance for our potential products and be competitive. In addition, co-promotion or other
	marketing arrangements with third parties to commercialize potential products could significantly limit the revenues we derive from these potential products, and these third parties may fail to
	commercialize our compounds successfully.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	If our product candidates or those of our collaborative partners do not gain market acceptance, our business will suffer.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if clinical trials demonstrate the safety and efficacy of our and our collaborative partners' product candidates and the necessary
	regulatory approvals are obtained, our and our collaborative partners' product candidates may not gain market acceptance among physicians, patients, healthcare payors and other members of the medical
	community. The degree of market acceptance of any product candidates that we or our collaborative partners develop will depend on a number of factors, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	their degree of clinical efficacy and safety;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	their advantage over alternative treatment methods;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our/the marketer's and our collaborative partners' ability to gain acceptable reimbursement and the reimbursement policies
	of government and third-party payors; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the quality of the distribution capabilities for product candidates, both ours and our collaborative partners.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Physicians
	may not prescribe any of our future products until such time as clinical data or other factors demonstrate the safety and efficacy of those products as compared to
	conventional drug and other treatments. Even if the clinical safety and efficacy of therapies using our products is established, physicians may elect not to recommend the therapies for any number of
	other reasons, including whether the mode of administration of our products is effective for certain conditions, and whether the physicians are already using competing products that satisfy their
	treatment objectives. Physicians, patients, third-party payors and the medical community may not accept and use any product candidates that we, or our collaborative partners, develop. If our products
	do not achieve significant market acceptance and use, we will not be able to recover the significant investment we have made in developing such products and our business will be severely harmed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We may be unable to compete successfully.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The markets in which we compete are well established and intensely competitive. We may be unable to compete successfully against our
	current and future competitors. Our failure to compete successfully may result in pricing reductions, reduced gross margins and failure to achieve market acceptance for our potential products. Our
	competitors include research institutions, pharmaceutical companies and biotechnology companies, such as Wyeth, Seattle Genetics,&nbsp;Inc. and Medarex,&nbsp;Inc. Many of these organizations have
	substantially more experience and more capital, research and development, regulatory, manufacturing, human and other resources than we do. As a result, they may:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	develop products that are safer or more effective than our product candidates;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=31,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=183062,FOLIO='31',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_32">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	obtain FDA and other regulatory approvals or reach the market with their products more rapidly than we can, reducing the
	potential sales of our product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	devote greater resources to market or sell their products;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	adapt more quickly to new technologies and scientific advances;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	initiate or withstand substantial price competition more successfully than we can;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	have greater success in recruiting skilled scientific workers from the limited pool of available talent;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	more effectively negotiate third-party licensing and collaboration arrangements; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	take advantage of acquisition or other opportunities more readily than we can.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	number of pharmaceutical and biotechnology companies are currently developing products targeting the same types of cancer that we target, and some of our competitors' products have
	entered clinical trials or already are commercially available.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	product candidates, if approved and commercialized, will also compete against well-established, existing, therapeutic products that are currently reimbursed by government
	healthcare programs, private health insurers and health maintenance organizations. In addition, if our product candidates are approved and commercialized, we may face competition from generic products
	if the product candidate is a small molecule drug, or biosimilars if the product candidate is a biologic. The route to market for generic versions of small molecule drugs was established with the
	passage of the Hatch-Waxman Amendments in 1984, but there currently is no process in the U.S. for the submission or approval of a biosimilar product. The U.S. Congress has been considering the issue
	and legislation has been proposed. It is not currently evident, however, whether any of the pending legislative proposals will be enacted. In Europe, however, the European Agency for the Evaluation of
	Medical Products has issued guidelines for approving products through an abbreviated pathway, and biosimilars have been approved in Europe. If a biosimilar version of one of our potential products
	were approved in the U.S. or Europe, it could have a negative effect on sales of the potential product and our financial condition.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	face and will continue to face intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for relationships with academic
	and research institutions and for licenses to proprietary technology. In addition, we anticipate that we will face increased competition in the future as new companies enter our markets and as
	scientific developments surrounding antibody-based therapeutics for cancer continue to accelerate. While we will seek to expand our technological capabilities to remain competitive, research and
	development by others may render our technology or product candidates obsolete or noncompetitive or result in treatments or cures superior to any therapy developed by us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	If we are unable to protect our intellectual property rights adequately, the value of our technology and our product candidates could be diminished.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in part on obtaining, maintaining and enforcing our patents and other proprietary rights and our ability to avoid
	infringing the proprietary rights of others. Patent law relating to the scope of claims in the biotechnology field in which we operate is still evolving, is surrounded by a great deal of uncertainty
	and involves complex legal, scientific and factual questions. To date, no consistent policy has emerged regarding the breadth of claims allowed in biotechnology patents. Accordingly, our pending
	patent applications may not result in issued patents. Although we own numerous patents, the issuance of a patent is not conclusive as to its validity or
	enforceability. Through litigation, a third party may challenge the validity or enforceability of a patent after its issuance.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	32
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=32,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=480088,FOLIO='32',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_33">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Also,
	patents and applications owned or licensed by us may become the subject of interference proceedings before the U.S. Patent and Trademark Office or a patent office in a foreign
	jurisdiction to determine priority of invention that could result in substantial cost to us. An adverse decision in an interference proceeding may result in our loss of rights under a patent or patent
	application. It is unclear how much protection, if any, will be given to our patents if we attempt to enforce them or if they are challenged in court or in other proceedings. A competitor may
	successfully challenge our patents or a challenge could result in limitations of the patents' coverage. In addition, the cost of litigation or interference proceedings to uphold the validity of
	patents can be substantial. If we are unsuccessful in these proceedings, third parties may be able to use our patented technology without paying us licensing fees or royalties. Moreover, competitors
	may infringe our patents or successfully avoid them through design innovation. To prevent infringement or unauthorized use, we may need to file infringement claims, which are expensive and
	time-consuming. In an infringement proceeding, a court may decide that a patent of ours is not valid. Even if the validity of our patents were upheld, a court may refuse to stop the other
	party from using the technology at issue on the ground that its activities are not covered by our patents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	recent years, policymakers have also proposed reforming U.S. patent laws and regulations. For example, patent reform legislation was introduced in both houses of the U.S. Congress in
	2009, and the Senate Judiciary Committee approved a patent reform bill in April 2009. In general, the proposed legislation attempts to address issues surrounding the enforceability of patents and the
	increase in patent litigation by, among other things, changing the way damages for patent infringement are calculated, establishing new procedures for challenging patents and establishing different
	methods for invalidating patents. While we cannot predict what form any new patent reform laws or regulations ultimately may take, final legislation could introduce new substantive rules and
	procedures for challenging patents, and certain reforms that make it easier for competitors to challenge our patents could have a material adverse effect on our business and prospects.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Policing
	unauthorized use of our intellectual property is difficult, and we may not be able to prevent misappropriation of our proprietary rights, particularly in countries where the
	laws may not protect such rights as fully as in the U.S.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition to our patent rights, we also rely on unpatented technology, trade secrets, know-how and confidential information. Third parties may independently develop
	substantially equivalent information and techniques or otherwise gain access to or disclose our technology. We may not be able to effectively protect our rights in unpatented technology, trade
	secrets, know-how and confidential information. We require each of our employees,
	consultants and corporate partners to execute a confidentiality agreement at the commencement of an employment, consulting or collaborative relationship with us. Further, we require that all employees
	enter into assignment of invention agreements as a condition of employment. However, these agreements may not provide effective protection of our information or, in the event of unauthorized use or
	disclosure, they may not provide adequate remedies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Any inability to license from third parties their proprietary technologies or processes which we use in connection with the development and
	manufacture of our product candidates may impair our business.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other companies, universities and research institutions have or may obtain patents that could limit our ability to use, manufacture,
	market or sell our product candidates or impair our competitive position. As a result, we would have to obtain licenses from other parties before we could continue using, manufacturing, marketing or
	selling our potential products. Any necessary licenses may not be available on commercially acceptable terms, if at all. If we do not obtain required licenses, we may not be able to market our
	potential products at all or we may encounter significant delays in product development while we redesign products or methods that are found to infringe on the patents held by others.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	33
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=33,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=528236,FOLIO='33',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_34">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights held by third
	parties and we may be unable to protect our rights to, or to commercialize, our product candidates.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent litigation is very common in the biotechnology and pharmaceutical industries. Third parties may assert patent or other
	intellectual property infringement claims against us with respect to our technologies, products or other matters. From time to time, we have received correspondence from third parties alleging that we
	infringe their intellectual property rights. Any claims that might be brought against us alleging infringement of patents may cause us to incur significant expenses and, if successfully asserted
	against us, may cause us to pay substantial damages and limit our ability to use the intellectual property subject to these claims. Even if we were to prevail, any litigation would be costly and
	time-consuming and could divert the attention of our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit, we may be forced to
	stop or delay developing, manufacturing or selling potential products that incorporate the challenged intellectual property unless we enter into royalty or license agreements. There may be third-party
	patents, patent applications and other intellectual property relevant to our potential products that may block or compete with our products or processes. In addition, we sometimes undertake research
	and development with respect to potential products even when we are aware of third-party patents that may be relevant to our potential products, on the basis that such patents may be challenged or
	licensed by us. If our subsequent challenge to such patents were not to
	prevail, we may not be able to commercialize our potential products after having already incurred significant expenditures unless we are able to license the intellectual property on commercially
	reasonable terms. We may not be able to obtain royalty or license agreements on terms acceptable to us, if at all. Even if we were able to obtain licenses to such technology, some licenses may be
	non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Ultimately, we may be unable to commercialize some of our potential products or may have to
	cease some of our business operations, which could severely harm our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We use hazardous materials in our business, and any claims relating to improper handling, storage or disposal of these materials could harm our
	business.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development and manufacturing activities involve the controlled use of hazardous materials, chemicals, biological
	materials and radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and certain waste
	products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by applicable laws and regulations, we cannot completely
	eliminate the risk of accidental contamination or injury from these materials. In the event of such an accident, we could be held liable for any resulting damages, and any liability could exceed our
	resources. We may be required to incur significant costs to comply with these laws in the future. Failure to comply with these laws could result in fines and the revocation of permits, which could
	prevent us from conducting our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We face product liability risks and may not be able to obtain adequate insurance.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we secure waivers from all participants in our clinical trials, the use of our product candidates during testing or after
	approval entails an inherent risk of adverse effects, which could expose us to product liability claims. Regardless of their merit or eventual outcome, product liability claims may result
	in:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	decreased demand for our product;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	injury to our reputation and significant negative media attention;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	withdrawal of clinical trial volunteers;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	34
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=12,SEQ=34,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=151367,FOLIO='34',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_35">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	costs of litigation;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	distraction of management; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	substantial monetary awards to plaintiffs.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	may not have sufficient resources to satisfy any liability resulting from these claims. We currently have $5&nbsp;million of product liability insurance for products which are in
	clinical testing. This coverage may not be adequate in scope to protect us in the event of a successful product liability claim. Further, we may not be able to maintain our current insurance or obtain
	general product liability insurance on reasonable terms and at an acceptable cost if we or our collaborative partners begin commercial production of our proposed product candidates. This insurance,
	even if we can obtain and maintain it, may not be sufficient to provide us with adequate coverage against potential liabilities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We depend on our key personnel and we must continue to attract and retain key employees and consultants.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We depend on our key scientific and management personnel. Our ability to pursue the development of our current and future product
	candidates depends largely on retaining the services of our existing personnel and hiring additional qualified scientific personnel to perform research and development. We will also need to hire
	personnel with expertise in clinical testing, government regulation, manufacturing, marketing and finance. Attracting and retaining qualified personnel will be critical to our success. We may not be
	able to attract and retain personnel on acceptable terms given the competition for such personnel among biotechnology, pharmaceutical and healthcare companies, universities and non-profit
	research institutions. Failure to retain
	our existing key management and scientific personnel or to attract additional highly qualified personnel could delay the development of our product candidates and harm our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Our stock price can fluctuate significantly and results announced by us and our collaborators can cause our stock price to decline.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stock price can fluctuate significantly due to business developments announced by us and by our collaborators, as a result of
	market trends and as a result of our low stock price and daily trading volume. The business developments that could impact our stock price include disclosures related to clinical findings with
	compounds that make use of our TAP technology, new collaborations and clinical advancement or discontinuation of product candidates that make use of our TAP technology. Our stock price can also
	fluctuate significantly with the level of overall investment interest in small-cap biotechnology stocks.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	operating results have fluctuated in the past and are likely to continue to do so in the future. Our revenue is unpredictable and may fluctuate due to the timing of
	non-recurring licensing fees, decisions of our collaborative partners with respect to our agreements with them, reimbursement for manufacturing services, the achievement of milestones and
	our receipt of the related milestone payments under new and existing licensing and collaboration agreements. Revenue historically recognized under our prior collaboration agreements may not be an
	indicator of revenue from any future collaborations. In addition, our expenses are unpredictable and may fluctuate from quarter to quarter due to the timing of expenses, which may include obligations
	to manufacture or supply product or payments owed by us under licensing or collaboration agreements. It is possible that our quarterly and/or annual operating results will not meet the expectations of
	securities analysts or investors, causing the market price of our common stock to decline. We believe that quarter-to-quarter and year-to-year
	comparisons of our operating results are not good indicators of our future performance and should not be relied upon to predict the future performance of our stock price.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=13,SEQ=35,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=898061,FOLIO='35',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_36">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	The potential sale of additional shares of our common stock may cause our stock price to decline.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;11, 2007, we filed a Registration Statement on Form&nbsp;S-3 with the Securities and Exchange Commission.
	The Securities and Exchange Commission declared the Registration Statement effective on August&nbsp;13, 2007. Subject to our ongoing obligations under the Securities Act of 1933, as amended, and the
	Securities Exchange Act of 1934, as amended, the Registration Statement permits us to offer and sell up to an aggregate of $75&nbsp;million of
	our common stock. Pursuant to the shelf registration statement, on June&nbsp;20, 2008, a private investor purchased 7,812,500 shares of our common stock at $3.20 per share resulting in gross
	proceeds of $25&nbsp;million. Additionally, on June&nbsp;23, 2009, we sold 5,750,000 shares of our common stock at $7.00 per share in a public offering resulting in gross proceeds of
	$40.3&nbsp;million. The potential sale of additional shares of our common stock may be dilutive to our shares outstanding and may cause our stock price to decrease.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	We do not intend to pay cash dividends on our common stock.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not paid cash dividends since our inception and do not intend to pay cash dividends in the foreseeable future. Therefore,
	shareholders will have to rely on appreciation in our stock price, if any, in order to achieve a gain on an investment.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	36
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=14,SEQ=36,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=740641,FOLIO='36',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_37">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DG49301_A_WARNING_ABOUT_FORWARD-LOOKING_STATEMENTS">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DG49301_2">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	A WARNING ABOUT FORWARD-LOOKING STATEMENTS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This report includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These
	statements relate to analyses and other information which are based on forecasts of future results and estimates of amounts that are not yet determinable. These statements also relate to our future
	prospects, developments and business strategies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
	forward-looking statements are identified by their use of terms and phrases, such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict,"
	"project," "will" and other similar terms and phrases, including references to assumptions. These statements are contained in the "Business," "Risk Factors" and "Management's Discussion and Analysis
	of Financial Condition and Results of Operations" sections, as well as other sections of this Annual Report on Form&nbsp;10-K.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-looking
	statements in this report include, but are not limited to:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successfully finding and managing the relationships with collaborative partners;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the uncertainty as to whether our TAP compounds or those of our collaborators will succeed in entering human clinical
	trials and uncertainty as to the results of such trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the risk that we and/or our collaborators may not be able to obtain regulatory approvals necessary to commercialize
	product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the potential development by competitors of competing products and technologies; uncertainty whether our TAP technology
	will produce safe, effective and commercially viable products;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our ability to successfully protect our intellectual property;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our reliance on third-party manufacturers to achieve supplies of our maytansinoid cell-killing agents, DM1 and
	DM4;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the risk that we may be unable to establish the manufacturing capabilities necessary to develop and commercialize our
	potential products;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the adequacy of our liquidity and capital resources;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	government regulation of our activities, facilities, products and personnel; the dependence on key personnel;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	uncertainties as to the extent of reimbursement for the costs of our potential products and related treatments by
	government and private health insurers and other organizations; the potential adverse impact of government-directed health care reform; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the risk of product liability claims; and economic conditions, both generally and those specifically related to the
	biotechnology industry.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
	forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those contemplated by our
	forward-looking statements. These known and unknown risks, uncertainties and other factors are described in detail in the "Risk Factors" section and in other sections of this Annual Report on
	Form&nbsp;10-K. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
</FONT>
</P>
</EFX_FACTORS_AFFECTING>
</EFX_RISK_FACTORS>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DG49301_ITEM_1B__UNRESOLVED_STAFF_COMMENTS">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DG49301_3">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;1B.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Unresolved Staff Comments
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	37
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=15,SEQ=37,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=839566,FOLIO='37',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_38">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<BR>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DG49301_ITEM_2__PROPERTIES">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DG49301_4">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Properties
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We lease approximately 89,000 square feet of laboratory and office space in a building located at 830 Winter Street, Waltham, MA. The
	initial term of the 830 Winter Street lease expires on March&nbsp;31, 2020, with an option for us to extend the lease for two additional five-year terms. We currently are attempting to
	sublease approximately 14,000 square feet of laboratory and office space at this location. We also lease approximately 43,850 square feet of space in Norwood, MA, which serves as our conjugate
	manufacturing facility and office space. The Norwood lease expires on June&nbsp;30, 2011, with an option for us to extend the lease for an additional five-year term.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also lease approximately 15,000 square feet of laboratory and office space in a building located at 148 Sidney Street, Cambridge, MA, which we vacated in March 2008 when we relocated
	all our Cambridge operations to Waltham, MA. The 148 Sidney Street lease expires on October&nbsp;30, 2010. In May 2008, we entered into a sub-sublease for this entire space for the
	remainder of the lease term.
</FONT>
</P>
</EFX_PROPERTIES>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DG49301_ITEM_3__LEGAL_PROCEEDINGS">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DG49301_5">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Legal Proceedings
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time we may be a party to various legal proceedings arising in the ordinary course of our business. We are not currently
	subject to any material legal proceedings.
</FONT>
</P>
</EFX_LEGAL_PROCEEDINGS>
<EFX_VOTING_MATTERS>
<A NAME="FIS_VOTING_MATTERS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DG49301_ITEM_4__SUBMISSION_OF___DG402384">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DG49301_6">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Submission of Matters to a Vote of Security Holders
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No matters were submitted to a vote of our security holders through solicitation of proxies or otherwise during the fourth quarter of
	the fiscal year ended June&nbsp;30, 2009.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DG49301_ITEM_4_1__EXECUTIVE_OFFICERS_OF_THE_REGISTRANT">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DG49301_7">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;4.1.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Executive Officers of the Registrant
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ImmunoGen's executive officers are appointed by the Board of Directors at the first meeting of the Board following the annual meeting
	of shareholders or at other Board
	meetings as appropriate, and hold office until the first Board meeting following the next annual meeting of shareholders and until a successor is chosen, subject to prior death, resignation or
	removal. Information regarding our executive officers is presented below.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Daniel
	M. Junius, age 57, joined ImmunoGen in 2005, and has served as our President and Chief Executive Officer since January 2009. Prior to that he served as our President and Chief
	Operating Officer and Acting Chief Financial Officer since July 2008 to December 2008, as our Executive Vice President and Chief Financial Officer from 2006 to July 2008, and as our Senior Vice
	President and Chief Financial Officer from 2005 to 2006. Prior to joining ImmunoGen, he served as Executive Vice President and Chief Financial Officer of New England Business Service,&nbsp;Inc.
	(NEBS), a supplier of business products and services to small businesses, from 2002 to 2004, and as Senior Vice President and Chief Financial Officer of NEBS from 1998 to 2002. Mr.&nbsp;Junius is
	also a director of ImmunoGen.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John
	M. Lambert, Ph.D., age 58, joined ImmunoGen in 1987, and has served as our Executive Vice President, Research and Development and Chief Scientific Officer since July 2008. Prior to
	that he served as our Senior Vice President, Research and Development and Chief Scientific Officer from early 2008 to July 2008, as our Senior Vice President, Pharmaceutical Development, from 2000 to
	early 2008, as our Vice President, Research and Development, from 1994 to 2000, and as our Senior Director of Research from 1987 to 1994. Prior to joining ImmunoGen, Dr.&nbsp;Lambert was an
	assistant professor at Harvard Medical School working at the Dana-Farber Cancer Institute. Dr.&nbsp;Lambert holds a Ph.D. in Biochemistry from University of Cambridge in England, and
	completed his postdoctoral work at the University of California at Davis and at Glasgow University in Scotland.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;James
	J. O'Leary, MD, age 45, joined ImmunoGen in 2008, and has served as our Vice President and Chief Medical Officer since that date. Prior to joining ImmunoGen, Dr.&nbsp;O'Leary
	served as Senior Medical Director Clinical Oncology of Bayer Corporation, a pharmaceutical company from 2006 to
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=16,SEQ=38,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=962668,FOLIO='38',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DG49301_1_39">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2008.
	Prior to that, he served as Medical Director Clinical Oncology of Pfizer Global Research and Development, a pharmaceutical company, from 2003 to 2006, and as Assistant Medical Director Clinical
	Oncology of Pfizer from 2000 to 2003. Prior to that, he served as a Medical Reviewer, Division of Oncology Drug Products at the U.S. Food and Drug Administration from 1998 to 2000. Dr.&nbsp;O'Leary
	has a Doctor of Medicine degree from the State University of New York&#151;Health Science Center at Brooklyn.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gregory
	D. Perry, age 49, joined ImmunoGen in January 2009, and has served as our Senior Vice President and Chief Financial Officer since that date. Prior to joining ImmunoGen, he served
	as Chief Financial Officer of Elixir Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, from 2007 to 2008. Prior to that, he served as Chief Financial Officer for Domantis&nbsp;Ltd., a
	biopharmaceutical company, in 2006, and as Senior Vice President, Finance and Chief Financial Officer of Transkaryotic Therapies,&nbsp;Inc., a biopharmaceutical company, from 2003 to 2005.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peter
	Williams, age 55, joined ImmunoGen in August 2009, and has served as our Vice President, Business Development since that date. Prior to joining ImmunoGen, he served as a Senior
	Director of Business Development at Alnylam Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company, from 2006 to August 2009. Prior to that, he served as Vice President of Business Development of
	Link Medicine Corporation, a drug development company, from 2005 to 2006. Prior to that he, acted as an independent business development consultant from 2003 to 2006. Prior to that, he served as a
	Senior Director of Business Development at Millennium Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company, from 1998 to 2003.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	39
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=17,SEQ=39,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=437837,FOLIO='39',FILE='DISK104:[09ZCX1.09ZCX49301]DG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_DI49301_1_40">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_VOTING_MATTERS>
</EFX_PART_I>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	PART II
</B>
</FONT>
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DI49301_ITEM_5__MARKET_FOR_REGISTRANT___ITE04666">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DI49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
<BR>
</I>
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Market Price of Our Common Stock and Related Stockholder Matters
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is quoted on the NASDAQ Global Market under the symbol "IMGN." The table below sets forth the high and low closing
	price per share of our common stock as reported by&nbsp;NASDAQ:
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="255" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Fiscal Year 2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Fiscal Year 2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	High
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Low
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	High
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Low
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	First Quarter
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.80
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.95
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.72
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.29
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Second Quarter
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.89
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.47
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.43
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.97
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Third Quarter
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.19
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.85
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.73
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Fourth Quarter
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.83
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.49
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.73
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.01
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of August&nbsp;12, 2009, the closing price per share of our common stock was $7.36, as reported by NASDAQ, and we had approximately 530 holders of record of our common stock and,
	according to our estimates, approximately 9,331 beneficial owners of our common stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have not paid any cash dividends on our common stock since our inception and do not intend to pay any cash dividends in the foreseeable future.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Equity Compensation Plan Information (in thousands)
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="144" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="79" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="97" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="90" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	(c)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	(a)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=4 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number of securities
<BR>
	remaining available for
<BR>
	future issuance under
<BR>
	equity compensation plans
<BR>
	(excluding securities
<BR>
	reflected in column (a))
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	(b)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number of securities to
<BR>
	be issued upon exercise
<BR>
	of outstanding options,
<BR>
	warrants and rights
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:48PT;">
<FONT SIZE=1>
<B>
	Plan category
<!-- COMMAND=ADD_SCROPPEDRULE,48PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Weighted-average exercise
<BR>
	price of outstanding options,
<BR>
	warrants and rights
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Equity compensation plans approved by security holders
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,529
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.36
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,734
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Equity compensation plans not approved by security holders
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,529
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.36
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,734
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
<SUP>
	(1)
</SUP>
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	These
	plans consist of the Restated Stock Option Plan and the 2006 Employee, Director and Consultant Equity Incentive Plan.
</FONT>
</DD>
</DL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Recent Sales of Unregistered Securities; Uses of Proceeds from Registered Securities; Issuer Repurchases of Equity Securities
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.
</FONT>
</P>
</EFX_MARKET>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DI49301_ITEM_6__SELECTED_FINANCIAL_DATA">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DI49301_2">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Selected Financial Data
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table (in thousands, except per share data) sets forth our consolidated financial data for each of our five fiscal years
	through our fiscal year ended June&nbsp;30, 2009. The information set forth below should be read in conjunction with "Management's Discussion and Analysis of Financial
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	40
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=40,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=766950,FOLIO='40',FILE='DISK104:[09ZCX1.09ZCX49301]DI49301A.;14',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DI49301_1_41">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Condition
	and Results of Operations" and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form&nbsp;10-K.
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="173" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=14 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2006
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2005
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Consolidated Statement of Operations Data:
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total revenues
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27,988
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	40,249
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38,212
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	32,088
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35,718
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total operating expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	59,804
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74,361
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,438
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	53,474
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48,395
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other (expense) income, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(221
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,119
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,274
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,569
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,755
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	(Benefit) provision for income taxes
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(100
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	29
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(31,937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(32,020
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(18,987
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(17,834
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,951
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Basic and diluted net loss per common share
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	(0.63
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	(0.75
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	(0.45
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	(0.43
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	(0.27
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Basic and diluted weighted average common shares outstanding
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	51,068
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	42,969
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	41,759
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	41,184
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	40,868
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Consolidated Balance Sheet Data:
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash, cash equivalents and marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	71,125
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	47,871
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	59,700
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	75,023
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	90,565
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100,704
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	83,338
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	80,421
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	94,128
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	110,132
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stockholders' equity
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	66,857
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	55,299
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	58,401
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	72,350
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	86,842
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
</EFX_FINANCIAL_DATA>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DI49301_ITEM_7__MANAGEMENT_S_DISCUSSIO__ITE03668">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DI49301_3">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Management's Discussion and Analysis of Financial Condition and Results of Operations
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	OVERVIEW
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since our inception, we have been principally engaged in the development of novel, targeted therapeutics for the treatment of cancer
	using our expertise in cancer biology, monoclonal antibodies, and small molecule cytotoxic, or cell-killing, agents. Our Targeted Antibody Payload, or TAP, technology uses antibodies to
	deliver a potent cytotoxic agent specifically to cancer cells, and consists of a tumor-targeting monoclonal antibody with one of our proprietary cell-killing agents attached using one of
	our engineered linkers. The antibody component enables a TAP compound to bind specifically to cancer cells that express a particular target antigen, the highly potent cytotoxic agent serves to kill
	the cancer cell, and the engineered linker controls the release of the cytotoxic agent inside the cancer cell. Our TAP technology is designed to enable the creation of highly effective,
	well-tolerated anticancer products. All of our and our collaborative partners' TAP compounds currently in preclinical and clinical testing contain either DM1 or DM4 as the cytotoxic agent.
	Both DM1 and DM4 are our proprietary derivatives of a naturally occurring substance called maytansine. We also use our expertise in antibodies and cancer biology to develop "naked," or
	non-conjugated, antibody anticancer product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have entered into collaborative agreements that enable companies to use our TAP technology to develop commercial product candidates to specified targets. We have also used our
	proprietary TAP technology in conjunction with our in-house antibody expertise to develop our own anticancer product candidates. Under the terms of our collaborative agreements, we are
	generally entitled to upfront fees, milestone payments, and royalties on any commercial product sales. In addition, under certain agreements we are entitled to research and development funding based
	on activities performed at our collaborative partner's request. We are reimbursed for our direct and a portion of overhead costs to manufacture preclinical and clinical materials and, under certain
	collaborative agreements, the reimbursement includes a profit margin. Currently, our collaborative partners include Amgen, Bayer HealthCare, Biogen Idec, Biotest , Genentech (a wholly-owned member of
	the Roche Group) and
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	41
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=41,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=484852,FOLIO='41',FILE='DISK104:[09ZCX1.09ZCX49301]DI49301A.;14',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DI49301_1_42">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	sanofi-aventis.
	We expect that substantially all of our revenue for the foreseeable future will result from payments under our collaborative arrangements. Details for some of our major and recent
	collaborative agreements follow.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sanofi-aventis
</I>
</FONT>
<FONT SIZE=2>
	&#151;In July 2003, we entered into a discovery, development and commercialization collaboration with sanofi-aventis. Under the terms of this
	agreement, in consideration of an upfront payment of $12&nbsp;million, sanofi-aventis gained worldwide commercialization rights to new anticancer therapeutics developed to targets included in the
	collaboration, including the right to use our TAP technology and our humanization technology in the creation of therapeutics to these targets. The agreement included a research support funding
	commitment by sanofi-aventis for $50.7&nbsp;million over the first three years of the agreement, and then for an additional $18.2&nbsp;million when
	the agreement was extended for a fourth year, and then for an additional $10.4&nbsp;million when the agreement was extended for a fifth year. We earned $81.5&nbsp;million of committed research
	funding for activities performed under the completed research term of this agreement, of which $2.7&nbsp;million, $10.8&nbsp;million, and $18.9&nbsp;million was recognized during fiscal years
	2009, 2008 and 2007, respectively, and are now compensated for research performed for sanofi-aventis on a mutually agreed-upon basis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	collaboration agreement also provides for certain other payments based on the achievement of product candidate milestones and royalties on sales of any resulting products, if and
	when such sales commence. For the targets included in the collaboration at this time, we are entitled to milestone payments potentially totaling $21.5&nbsp;million for each product candidate
	developed under this agreement. Through the end of fiscal 2009, we have earned an aggregate of $10.5&nbsp;million in milestone payments under this agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
	in October 2006, sanofi-aventis licensed non-exclusive rights to use our proprietary humanization technology, which enables antibodies of murine origin to avoid
	detection by the human immune system. This license provides sanofi-aventis with the non-exclusive right to use our proprietary humanization technology through August&nbsp;31, 2011 with
	the right to extend for one or more additional periods of three years each by providing us with written notice prior to expiration of the then-current license term. Under the terms of the
	license, we received a $1&nbsp;million license fee, half of which was paid upon contract signing and the second half was paid in August 2008, and in addition, we are entitled to receive milestone
	payments potentially totaling $4.5&nbsp;million plus royalties on sales for each antibody humanized under this agreement. We have deferred the $1&nbsp;million upfront payment and are recognizing
	this amount as revenue over the five-year term of the agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	August 2008, sanofi-aventis exercised its option under a 2006 agreement for expanded access to our TAP technology. The exercise of this option enables sanofi-aventis to evaluate, with
	certain restrictions, our maytansinoid TAP technology with antibodies to targets that were not included in the existing research collaboration between the companies and to license the exclusive right
	to use the technology to develop products to specific targets on the terms in the 2006 agreement. We are entitled to earn upfront and milestone payments potentially totaling $32&nbsp;million per
	target for each compound developed under the 2006 agreement, as well as royalties on the commercial sales of any resulting product. We are also entitled to manufacturing payments for any materials
	made on behalf of sanofi-aventis. We received $3.5&nbsp;million with the exercise of this option in August 2008, in addition to the $500,000 we received in December 2006 with the signing of the
	option agreement. The agreement has a three-year term from the date of the exercise of the option and can be renewed by sanofi-aventis for one additional three-year term by
	payment of a $2&nbsp;million fee. We have deferred the $3.5&nbsp;million exercise fee and are recognizing this amount as revenue over the initial three-year option term.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Genentech
</I>
</FONT>
<FONT SIZE=2>
	&#151;In May 2000, we entered into a license agreement with Genentech that granted Genentech exclusive rights to use our maytansinoid TAP
	technology with antibodies, such as trastuzumab, that target HER2. We received a $2&nbsp;million upfront payment from Genentech upon execution of the agreement. We also are entitled to up to
	$44&nbsp;million in milestone payments from
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	42
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=42,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=747058,FOLIO='42',FILE='DISK104:[09ZCX1.09ZCX49301]DI49301A.;14',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DI49301_1_43">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Genentech
	under this agreement, as amended in May 2006, in addition to royalties on the net sales of any resulting product. Through the end of fiscal 2009, we have received $13.5&nbsp;million in
	milestone payments.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	December 2008, Genentech licensed the exclusive right to use our maytansinoid TAP technology with its therapeutic antibodies to an undisclosed target. This license was taken under a
	"right-to-test" agreement entered into by the companies in 2000 that provided Genentech with the right to take exclusive licenses to use our maytansinoid TAP technology to
	develop products for individual targets on agreed-upon terms. While the agreement expired in May 2008, a limited number of options to targets remain in place for a short period of time.
	This license was taken under one of these options. Under the terms of the license, we received a $1&nbsp;million upfront payment and are entitled to receive up to $38&nbsp;million in milestone
	payments plus royalties on the sales of any resulting products. Genentech is responsible for the development, manufacturing, and marketing of any products resulting from this license. We have deferred
	the $1&nbsp;million upfront payment and are recognizing this amount as revenue over the estimated period of substantial involvement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bayer HealthCare
</I>
</FONT>
<FONT SIZE=2>
	&#151;In October 2008, we entered into a development and license agreement with Bayer HealthCare AG. The agreement grants Bayer HealthCare
	exclusive rights to use our maytansinoid TAP technology to develop and commercialize therapeutic compounds to a specific target. We received a $4&nbsp;million upfront payment upon execution of the
	agreement, and&#151;for each compound developed and marketed by Bayer HealthCare under this collaboration&#151;we could potentially receive up to $170.5&nbsp;million in milestone
	payments; additionally, we are entitled to receive royalties on the sales of any resulting products. We will be compensated by Bayer HealthCare at a stipulated rate for work performed on behalf of
	Bayer HealthCare under a mutually agreed-upon research plan and budget which may be amended from time to time during the term of the agreement. We also are entitled to receive payments for
	manufacturing any preclinical and clinical materials made at the request of Bayer HealthCare as well as for any related process development activities. We have deferred the $4&nbsp;million upfront
	payment and are recognizing this amount as revenue over the estimated period of substantial involvement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
	date, we have not generated revenues from commercial product sales and we expect to incur significant operating losses for the foreseeable future. As of June&nbsp;30, 2009, we had
	approximately $71.1&nbsp;million in cash and marketable securities compared to $47.9&nbsp;million in cash and marketable securities as of June&nbsp;30, 2008.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	anticipate that future cash expenditures will be partially offset by collaboration-derived proceeds, including milestone payments and upfront fees. Accordingly,
	period-to-period operational results may fluctuate dramatically based upon the timing of receipt of the proceeds. We believe that our established collaborative agreements,
	while subject to specified milestone achievements, will provide funding to assist us in meeting obligations under our collaborative agreements while also assisting in providing funding for the
	development of internal product candidates and technologies. However, we can give no assurances that such collaborative agreement funding will, in fact, be realized in the time frames we expect, or at
	all. Should we or our partners not meet some or all of the terms and conditions of our various collaboration agreements, we may be required to secure alternative financing arrangements and/or defer or
	limit some or all of our research, development and/or clinical projects. However, we cannot provide assurance that any such opportunities presented by additional strategic partners or alternative
	financing arrangements will be entirely available to us, if at all.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Critical Accounting Policies
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the U.S. The
	preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=43,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=78904,FOLIO='43',FILE='DISK104:[09ZCX1.09ZCX49301]DI49301A.;14',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DI49301_1_44">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	and
	related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to our collaborative agreements and inventory. We base
	our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Revenue Recognition
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We enter into licensing and development agreements with collaborative partners for the development of monoclonal antibody-based
	anticancer therapeutics. We follow the provisions of the Securities and Exchange Commission's Staff Accounting Bulletin No.&nbsp;104,
</FONT>
<FONT SIZE=2>
<I>
	Revenue
	Recognition
</I>
</FONT>
<FONT SIZE=2>
	, or SAB&nbsp;104, and Emerging Issues Task Force Issue No.&nbsp;00-21,
</FONT>
<FONT SIZE=2>
<I>
	Accounting for Revenue Arrangements with Multiple
	Elements
</I>
</FONT>
<FONT SIZE=2>
	, or EITF&nbsp;00-21. In accordance with SAB&nbsp;104 and EITF&nbsp;00-21, we recognize revenue related to research activities as they are
	performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The terms of our agreements contain
	multiple elements which typically include non-refundable license fees, payments based upon the achievement of certain milestones and royalties on product sales. We evaluate such
	arrangements to determine if the deliverables are separable into units of accounting and then apply applicable revenue recognition criteria to each unit of accounting.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	June&nbsp;30, 2009, we had the following three types of collaborative contracts with the parties identified below:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Exclusive license to use our TAP technology and/or certain other intellectual property to develop compounds to a single
	target antigen:
</FONT>
</DD>
</DL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Bayer
	HealthCare (single-target license)
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Biogen
	Idec (single-target license)
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Biotest
	(single-target license)
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Genentech
	(multiple single-target licenses)
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	sanofi-aventis
	(license to multiple individual targets)
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Option agreement for a defined period of time to secure licenses to use our TAP technology to develop anticancer compounds
	to a limited number of targets on established terms (broad option agreement):
</FONT>
</DD>
</DL>
</UL>
<UL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amgen
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Genentech
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Non-exclusive license to our humanization technology:
</FONT>
</DD>
</DL>
</UL>
<UL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</P>
</UL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
	the foregoing collaboration agreements provide that we will (i)&nbsp;at the collaborator's request, manufacture and provide to them preclinical and clinical materials at our
	cost, or, in some cases, cost plus a margin, (ii)&nbsp;earn payments upon the collaborators' achievements of certain milestones and (iii)&nbsp;earn royalty payments, generally until the later of
	the last applicable patent expiration or 10 to 12&nbsp;years after product launch. Royalty rates may vary over the royalty term depending on certain intellectual property rights. We are required to
	provide technical training and to share any process
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	44
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=44,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=364428,FOLIO='44',FILE='DISK104:[09ZCX1.09ZCX49301]DI49301A.;14',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DI49301_1_45">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	improvements
	and know-how with our collaborators during the research term of the collaboration agreements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
	upfront payments on single-target licenses are deferred over the period of our substantial involvement during development. The determination of the length of this period is
	subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. Our employees are available to assist our collaborators during the development of their
	products. We estimate this development phase to begin at the inception of the collaboration agreement and conclude at the end of non-pivotal Phase&nbsp;II testing. We believe this period
	of involvement is, depending on the nature of the license, on average six and one-half years. Quarterly, we reassess our periods of substantial involvement over which we amortize our
	upfront license fees. In the event that a single-target license were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue,
	but was classified as deferred revenue at the date of such termination.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	defer upfront payments received from our broad option agreements over the period during which the collaborator may elect to receive a license. These periods are specific to each
	collaboration
	agreement, but are between three and 12&nbsp;years. If a collaborator selects an option to acquire a license under these agreements, any option fee is deferred and is recorded over the life of the
	option, generally 12 to 18&nbsp;months. If a collaborator exercises an option and we grant a single-target license to the collaborator, we defer the license fee and account for the fee as we would
	an upfront payment on a single-target license, as discussed above. Upon exercise of an option to acquire a license, we would recognize any remaining deferred option fee over the period of our
	substantial involvement under the license acquired. In the event a broad option agreement were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously
	been recorded as revenue, but was classified as deferred revenue at the date of such termination. In the event a collaborator elects to discontinue development of a specific product candidate under a
	single-target license, but retains its right to use our technology to develop an alternative product candidate to the same target or a target substitute, we would cease amortization of any remaining
	portion of the upfront fee until there is substantial preclinical activity on another product candidate and our remaining period of substantial involvement can be estimated.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
	milestone fees are specifically tied to a separate earnings process and are deemed to be substantive and at risk, revenue is recognized when such milestones are achieved. In
	addition, we recognize research and development support revenue from certain collaboration and development agreements based upon the level of research services performed during the period of the
	research agreement. Deferred revenue substantially represents amounts received under collaborative agreements and not yet earned pursuant to these policies. Where we have no continuing involvement, we
	will record non-refundable license fees as revenue upon receipt and will record revenue upon achievement of milestones by our collaborative partners.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	produce preclinical and clinical materials for our collaborators. We are reimbursed for our direct costs and a portion of our overhead costs to produce clinical materials. We
	recognize revenue on preclinical and clinical materials when the materials have passed all quality testing required for collaborator acceptance and title and risk of loss have transferred to the
	collaborator.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also produce research material for potential collaborators under material transfer agreements. Additionally, we perform research activities, including developing antibody-specific
	conjugation processes, on behalf of our collaborators and potential collaborators during the early evaluation and preclinical testing stages of drug development. Generally, we are reimbursed for
	certain of our direct and overhead costs of producing these materials or providing these services. We record the amounts received for the preclinical materials produced or services performed as a
	component of research and development support. We also develop conjugation processes for materials for later stage testing and
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	45
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=45,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=978311,FOLIO='45',FILE='DISK104:[09ZCX1.09ZCX49301]DI49301A.;14',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DI49301_1_46">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	commercialization
	for certain collaborators. We are reimbursed for certain of our direct and overhead costs and may receive milestone payments for developing these processes which are recorded as a
	component of research and development support.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Inventory
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We review our estimates of the net realizable value of our inventory at each reporting period. Our estimate of the net realizable value
	of our inventory is subject to judgment and estimation. The actual net realizable value of our inventory could vary significantly from our estimates. We consider quantities of raw materials in excess
	of twelve-month projected usage that is not supported by firm, fixed collaborator orders and projections at the time of the assessment to be excess. During fiscal 2008, we obtained additional amounts
	of DMx from a new supplier. Due to the need to evaluate the process which was developed to prepare such material from this new supplier across multiple batches, we had committed to a level of
	production which yielded more material than would be required by our collaborators over the next twelve months. As a result, during the year ended June&nbsp;30, 2008, we recorded a
	$2.1&nbsp;million charge to research and development expense related to raw material inventory identified as excess. We also recorded $1.6&nbsp;million to write down the raw material inventory
	purchased during the fiscal year 2008 to its net realizable value, which is also included in research and development expense for the year ended June&nbsp;30, 2008. No similar costs were recorded
	during the years ended June&nbsp;30, 2009 and 2007. Our collaborators' estimates of their clinical material requirements are based upon expectations of their clinical trials, including the timing,
	size, dosing schedule and the maximum tolerated dose likely to be reached for the compound being evaluated. Our collaborators' actual requirements for clinical materials may vary significantly from
	their projections. Significant differences between our collaborators' actual manufacturing orders and their projections could result in our actual twelve-month usage of raw materials varying
	significantly from our estimated usage at an earlier reporting period. Reductions in collaborators' projections could indicate that we have additional excess raw material inventory and we would then
	evaluate the need to record further write-downs, which would be included as charges to research and development expense.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Stock-based Compensation
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2009, the Company is authorized to grant future awards under one share-based compensation plan, which is the
	ImmunoGen,&nbsp;Inc. 2006 Employee, Director and Consultant Equity Incentive Plan. The stock-based awards are accounted for under Statement of Financial Accounting Standards No.&nbsp;123(R),
</FONT>
<FONT SIZE=2>
<I>
	Share-Based Payment,
</I>
</FONT>
<FONT SIZE=2>
	or Statement 123(R), using the modified-prospective-transition method. Under this methodology, the estimated fair value of awards
	is charged to the statement of operations over the requisite service period, which is the vesting period. Such amounts have been reduced by our estimate of forfeitures of all unvested awards.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. Expected volatility is based exclusively on historical volatility data
	of our stock. The expected term of stock options granted is based exclusively on historical data and represents the period of time that stock options granted are expected to be outstanding. The
	expected term is calculated for and applied to one group of stock options as we do not expect substantially different exercise or post-vesting termination behavior amongst our employee
	population. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time
	of grant for the expected term of the stock options. Estimated forfeitures are based on historical data as well as current trends. Stock compensation cost incurred during the years ended
	June&nbsp;30, 2009, 2008 and 2007 was $4.0&nbsp;million, $2.9&nbsp;million and $2.4&nbsp;million, respectively. During fiscal year 2009, we recorded approximately $843,000 of stock
	compensation cost related to the modification of certain outstanding common stock options in accordance with the former Chief Executive Officer's succession plan.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	46
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=46,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=221759,FOLIO='46',FILE='DISK104:[09ZCX1.09ZCX49301]DI49301A.;14',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_47">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Investment in Marketable Securities
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We invest in marketable securities of highly rated financial institutions and investment-grade debt instruments and limit the amount of
	credit exposure with any one entity. We have classified our marketable securities as "available-for-sale" and, accordingly, carry such securities at aggregate fair value. In
	accounting for investments, we evaluate if a decline in the fair value of a marketable security below our cost basis is other-than-temporary, and if so, we record an impairment
	charge related to any credit loss in our consolidated statement of operations. The factors that we consider in our evaluation include the fair market value of the security, the duration and magnitude
	of the security's decline, and our intent to sell or whether it would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. The determination
	of whether a loss is other than temporary is highly judgmental and can have a material impact on our results. During the fiscal years ended June&nbsp;30, 2009 and 2008, we recorded approximately
	$516,000 and $535,000, respectively, in other-than-temporary impairment charges. No similar charges were recorded in the fiscal year ended June&nbsp;30, 2007. In April 2009,
	the FASB issued FSP No. FAS&nbsp;115-2 and FAS&nbsp;124-2,
</FONT>
<FONT SIZE=2>
<I>
	Recognition and Presentation of Other-than-Temporary
	Impairments
</I>
</FONT>
<FONT SIZE=2>
	, or FSP FAS&nbsp;115-2, which amended the other-than-temporary impairment model for debt securities. As a result of the
	adoption of this standard, during fiscal year 2009 we reclassified $54,000 of previously recognized other-than-temporary impairment charges to other comprehensive loss as a
	cumulative effect adjustment.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Fair Value of Financial Instruments
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of July&nbsp;1, 2008, we partially adopted the provisions of FASB Statement No.&nbsp;157,
</FONT>
<FONT SIZE=2>
<I>
	Fair Value
	Measurements
</I>
</FONT>
<FONT SIZE=2>
	, or Statement 157, for financial assets and liabilities recognized at fair value on a recurring basis. Statement 157 defines fair value, establishes a framework
	for measuring fair value in accordance with accounting principles generally accepted in the U.S., and expands disclosures about fair value measurements. The provisions of Statement 157 related to
	other non-financial assets and liabilities will be effective for us on July&nbsp;1, 2009, and will be applied prospectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair
	value is defined under Statement 157 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
	market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under Statement 157 must maximize the
	use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy to measure fair value which is based on three levels of inputs, of which the first
	two are considered observable and the last unobservable. As noted in Note&nbsp;B., Summary of Significant Accounting Policies, the fair value of our investments is generally determined from market
	prices based upon either quoted prices from active markets or other significant observable market transactions at fair value.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective
	this quarter, we implemented FSP FAS&nbsp;157-4,
</FONT>
<FONT SIZE=2>
<I>
	Determining Fair Value When the Volume and Level of Activity for the Asset or Liability
	Have Significantly Decreased and Identifying Transactions That Are Not Orderly
</I>
</FONT>
<FONT SIZE=2>
	, or FSP FAS&nbsp;157-4. FSP FAS&nbsp;157-4 provides additional
	guidelines for making fair value measurements more consistent with the principles presented in SFAS&nbsp;157 and provides authoritative guidance in determining whether a market is active or
	inactive, and whether a transaction is distressed. This FSP is applicable to all assets and liabilities (i.e.&nbsp;financial and non-financial) and requires enhanced disclosures,
	including interim and annual disclosure of the input and valuation techniques (or changes in techniques) used to measure fair value and the defining of the major security types comprising debt and
	equity securities held based upon the nature and risk of the security. The adoption of this FSP did not impact our financial position or results of operations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective
	this quarter, we have also implemented FSP FAS&nbsp;107-1 and APB&nbsp;28-1,
</FONT>
<FONT SIZE=2>
<I>
	Interim Disclosures about Fair Value of
	Financial Instruments
</I>
</FONT>
<FONT SIZE=2>
	, or FSP FAS&nbsp;107-1. FSP FAS&nbsp;107-1 amended Statement of
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	47
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=47,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=36603,FOLIO='47',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_48">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Financial
	Accounting Standards No.&nbsp;107,
</FONT>
<FONT SIZE=2>
<I>
	Disclosures about Fair Value of Financial Instruments
</I>
</FONT>
<FONT SIZE=2>
	, and APB Opinion No.&nbsp;28,
</FONT>
<FONT SIZE=2>
<I>
	Interim Financial Reporting
</I>
</FONT>
<FONT SIZE=2>
	, to
	require disclosures about the fair value of financial
	instruments in interim as well as in annual financial statements. Since this FSP addresses disclosure requirements, the adoption of this FSP did not impact our financial position or results of
	operations.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Derivatives
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative instruments include a portfolio of short duration foreign currency forward contracts intended to mitigate the risk of
	exchange rate fluctuations for existing or anticipated receivable and payable balances denominated in foreign currency. Derivatives are estimated at fair value and classified as other current assets
	or liabilities in the accompanying consolidated balance sheets. The fair value of these instruments represent the present value of estimated future cash flows under the contracts, which are a function
	of underlying interest rates, currency rates, related volatility, counterparty creditworthiness and duration of the contracts. Changes in these factors or a combination thereof may affect the fair
	value of these instruments.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	do not designate foreign currency forward contracts as hedges for accounting purposes, and changes in the fair value of these instruments are recognized in earnings during the period
	of change. Because we enter into forward contracts only as an economic hedge, any gain or loss on the underlying foreign-denominated balance or anticipated receivable or payable balance would be
	offset by the loss or gain on the forward contract. Net (losses) gains recognized on forward contracts for the years ended June&nbsp;30, 2009, 2008 and 2007 were $(234,000), $699,000 and $112,000,
	respectively, and are included in the accompanying Consolidated Statement of Operations as other (expense) income, net. As of June&nbsp;30, 2009, we had outstanding forward contracts with amounts
	equivalent to approximately $517,000 (371,000 in Euros), all maturing on or before July&nbsp;24, 2009. As of June&nbsp;30, 2008, we had outstanding forward contracts with amounts equivalent to
	approximately $1.4&nbsp;million (924,000 in Euros), all maturing on or before August&nbsp;20, 2008. As of June&nbsp;30, 2007, we had outstanding forward contracts with amounts equivalent to
	approximately $6.5&nbsp;million (4.8&nbsp;million in Euros). We do not anticipate using derivative instruments for any purpose other than hedging our exchange rate exposure.
</FONT>
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Results of Operations
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Revenues
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our total revenues for the year ended June&nbsp;30, 2009 were $28.0&nbsp;million compared with $40.2&nbsp;million and
	$38.2&nbsp;million for the years ended June&nbsp;30, 2008 and 2007, respectively. The $12.2&nbsp;million decrease in revenues in fiscal year 2009 from fiscal year 2008 is primarily attributable
	to lower revenues from research and development support and clinical materials reimbursement, partially offset by higher revenues from license and milestone fees, as discussed below. The
	$2.0&nbsp;million increase in revenues in fiscal year 2008 from fiscal year 2007 is primarily attributable to higher revenues from clinical materials reimbursement and license and milestone fees, as
	discussed below.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
	and development support was $7.6&nbsp;million for the year ended June&nbsp;30, 2009, $15.0&nbsp;million for the year ended June&nbsp;30, 2008, and $25.5&nbsp;million
	for the year ended June&nbsp;30, 2007. These amounts primarily represent committed research funding earned based on actual resources utilized under our discovery, development and commercialization
	agreement with sanofi-aventis, as well as amounts earned for resources utilized under our development and license agreements with other various collaborators. Under the terms of the sanofi-aventis
	agreement, we were entitled to receive committed research funding totaling not less than $79.3&nbsp;million over the five years of the research collaboration, which included the initial
	three-year term of the research program ending August&nbsp;31, 2006 plus the two 12-month extensions beginning September&nbsp;1, 2006. The two companies subsequently agreed
	to extend the date of payment through October&nbsp;31, 2008 to enable completion of previously agreed-upon research. Through the end of the research program, we earned
	$81.5&nbsp;million of committed
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=48,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=104060,FOLIO='48',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_49">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	funding.
	Subsequent to October&nbsp;31, 2008, we have performed, and will continue to perform, research on behalf of sanofi-aventis as mutually agreed-upon. Also included in research and
	development support revenue are development fees charged for reimbursement for our direct and overhead costs incurred in producing and delivering research-grade materials to our collaborators and for
	developing antibody-specific conjugation processes on behalf of our collaborators and potential collaborators during the early evaluation and preclinical testing stages of drug development. The amount
	of development fees we earn is directly related to the number of our collaborators and potential collaborators, the stage of development of our collaborators' product candidates and the resources our
	collaborators allocate to the development effort. As such, the amount of development fees may vary widely from quarter to quarter and year to year. Total revenue recognized from research and
	development support from each of our collaborative partners in the years ended June&nbsp;30, 2009, 2008 and 2007 is included in the following table (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="269" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Collaborative Partner:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Bayer HealthCare
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	227
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	88
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Biogen Idec
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	621
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	336
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	447
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Biotest
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,361
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,648
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,653
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Centocor
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	466
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	418
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Genentech
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	238
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	741
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,487
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,861
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,697
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18,916
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	258
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	59
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	565
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,566
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,035
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25,486
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue
	from license and milestone fees for the year ended June&nbsp;30, 2009 increased approximately $1.9&nbsp;million to $15.1&nbsp;million from $13.2&nbsp;million in the year
	ended June&nbsp;30, 2008. Revenue from license and milestone fees for the year ended June&nbsp;30, 2007 was $7.6&nbsp;million. Included in license and milestone fees for the year ended
	June&nbsp;30, 2009 was a $6.5&nbsp;million milestone related to the initiation of Phase&nbsp;III clinical testing of trastuzumab-DM1, or T-DM1, by Genentech, a $4&nbsp;million
	milestone related to the initiation of Phase&nbsp;II clinical testing of AVE1642 by sanofi-aventis and a $500,000 milestone related to the initiation of Phase&nbsp;I clinical testing of
	BT-062 by Biotest. Also during the year ended June&nbsp;30, 2009, Millennium Pharmaceuticals and Boehringer Ingelheim agreed to terminate their licenses with us that were no longer being
	used to develop products and as a result, we recognized as license and milestone fees $361,000 and $486,000, respectively, of upfront fees previously deferred. Included in license and milestone fees
	for the year ended June&nbsp;30, 2008 was $5&nbsp;million related to the achievement of a milestone under the Genentech agreement from the initiation of Phase&nbsp;II clinical testing of
	T-DM1, $1.5&nbsp;million related to the achievement of a milestone under the Biogen Idec agreement from the submission of the IND application for BIIB015, $2&nbsp;million related to
	the achievement of milestones under the sanofi-aventis agreement from the initiation of clinical testing of SAR3419 and certain preclinical milestones. Included in license and milestone fees for the
	year ended June&nbsp;30, 2007 was $2&nbsp;million related to the achievement of a milestone under the sanofi-aventis agreement from the initiation of clinical testing of AVE1642. Total revenue
	recognized from license and milestone fees from
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	49
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=49,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=188163,FOLIO='49',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_50">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	each
	of our collaborative partners in the years ended June&nbsp;30, 2009, 2008 and 2007 is included in the following table (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="269" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Collaborative Partner:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Amgen
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	511
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	433
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	406
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Bayer HealthCare
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	410
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Biogen Idec
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	228
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,684
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	88
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Biotest
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	669
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	169
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	157
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Boehringer Ingelheim
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	486
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Centocor
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	138
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	113
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Genentech
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,651
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,991
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,550
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Millennium
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	361
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	653
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,663
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,810
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,618
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,117
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,156
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,585
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
	revenue of $12.7&nbsp;million at June&nbsp;30, 2009 represents payments received from our collaborators pursuant to our license and supply agreements with them which we have
	yet to earn pursuant to our revenue recognition policy.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
	materials reimbursement decreased by approximately $6.8&nbsp;million to $5.3&nbsp;million in the year ended June&nbsp;30, 2009 compared to $12.1&nbsp;million in the year
	ended June&nbsp;30, 2008. We earned clinical materials reimbursement of $5.1&nbsp;million during the year ended June&nbsp;30, 2007. During the years ended June&nbsp;30, 2009, 2008 and 2007, we
	shipped clinical materials in support of a number of clinical trials including, for certain of these years, those of T-DM1, AVE9633, SAR3419, BIIB015, BT-062, and of Centocor's
	planned clinical testing of their antibody-DMx conjugate now called IMGN388, as well as preclinical materials in support of the development efforts of certain other collaborators and DMx
	shipments to certain collaborators in support of development and manufacturing efforts. The decrease in clinical materials reimbursement in fiscal year 2009 as compared to fiscal year 2008 is
	primarily related to $5.0&nbsp;million in revenue recognized from supplying DMx to a collaborator in fiscal year 2008, along with the transfer of T-DM1 to commercial-scale production at
	a third-party contract manufacturing organization in fiscal year 2009. The increase in clinical materials reimbursement in fiscal year 2008 as compared to fiscal year 2007 is primarily related to
	$5.0&nbsp;million in revenue recognized from supplying DMx to a collaborator in fiscal year 2008, along with the advancement of the clinical trials of AVE9633 and SAR3419. During fiscal year 2009,
	sanofi-aventis discontinued clinical trial activity for AVE9633. We are reimbursed for certain of our direct and overhead costs to produce clinical materials plus, for certain programs, a profit
	margin. The amount of clinical materials reimbursement we earn, and the related cost of clinical materials charged to research and development expense, is directly related to the number of clinical
	trials our collaborators are preparing or have underway, the speed of enrollment in those trials, the dosage schedule of each clinical trial and the time period, if any, during which patients in the
	trial receive clinical benefit from the clinical materials, and the supply of clinical-grade material to our collaborators for process development and analytical purposes. As such, the amount of
	clinical materials reimbursement revenue and the related cost of clinical materials charged to research and development expense may vary significantly from quarter to quarter and year to&nbsp;year.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Research and Development Expenses
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our net research and development expenses relate to (i)&nbsp;research to evaluate new targets and to develop and evaluate new
	antibodies, linkers and cytotoxic agents, (ii)&nbsp;preclinical testing of our own
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	50
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=50,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=1009281,FOLIO='50',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_51">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	and,
	in certain instances, our collaborators' product candidates, and the cost of our own clinical trials, (iii)&nbsp;development related to clinical and commercial manufacturing processes and
	(iv)&nbsp;manufacturing
	operations. Our research and development efforts have been primarily focused in the following areas:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	activities pursuant to our discovery, development and commercialization agreement with sanofi-aventis;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	activities pursuant to our development and license agreements with various other collaborators;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	activities related to the preclinical and clinical development of IMGN901, IMGN242 and IMGN388;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	process development related to production of the huN901 antibody and IMGN901 conjugate for clinical materials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	process development related to production of the huC242 antibody and IMGN242 conjugate for clinical materials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	process development related to production of IMGN388 conjugate for clinical materials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	process improvements related to the production of DM1, DM4 and strain development of their precursor, ansamitocin P3;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	funded development activities with contract manufacturers for the huN901 antibody, the huC242 antibody and DM1, DM4 and
	their precursor, ansamitocin P3;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	production costs for the supply of the huN901 antibody and the huC242 antibody;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	production costs for the supply of DMx for our and our partners' preclinical and clinical activities;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	operation and maintenance of our conjugate manufacturing facility, including production of our own and our collaborators'
	clinical materials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	process improvements to our TAP technology;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	evaluation of potential antigen targets;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	evaluation of internally developed and/or in-licensed product candidates and technologies; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	development and evaluation of additional cytotoxic agents and linkers.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
	and development expense for the year ended June&nbsp;30, 2009 decreased $14.1&nbsp;million to $45.9&nbsp;million from $60.0&nbsp;million for the year ended
	June&nbsp;30, 2008. Research and development expense was $49.4&nbsp;million for the year ended June&nbsp;30, 2007. The average number of our research and development personnel increased to 175
	for the year ended June&nbsp;30, 2009 compared to 172 for the year ended June&nbsp;30, 2008. We had an average of 167 research and development personnel for the year ended June&nbsp;30, 2007.
	Research and development salaries and related expenses increased by $1.4&nbsp;million in the year ended June&nbsp;30, 2009 compared to the year ended June&nbsp;30, 2008 and increased by $336,000
	in the year ended June&nbsp;30, 2008 compared to the year ended June&nbsp;30, 2007. Included in salaries and related expenses for the year ended June&nbsp;30, 2009 is $1.7&nbsp;million of
	stock compensation costs compared to $1.6&nbsp;million and $1.4&nbsp;million of stock compensation costs for fiscal years 2008 and 2007, respectively. Facilities expense, including depreciation,
	increased $680,000 during fiscal year 2009 as compared to fiscal year 2008 and increased $1.2&nbsp;million in fiscal year 2008 compared to fiscal year 2007. The increase in facilities expense in
	fiscal year 2009 was principally due to an increase in depreciation and amortization resulting from the build out of laboratory and office space at our Waltham, MA facility, which is partially offset
	by the amortization of the lease incentive, and significant capital improvements made to our Norwood, MA facility. The increase in facilities expense in fiscal year 2008 was principally due to an
	increase in depreciation and amortization and an increase in rent expense. The increase in
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	51
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=51,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=1014420,FOLIO='51',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_52">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	depreciation
	and amortization was due to the acceleration of amortization of leasehold improvements for our Cambridge, MA facilities resulting from our move to Waltham, MA in fiscal year 2008, as well
	as new capital purchases.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Included
	in research and development expenses for the year ended June&nbsp;30, 2008 is a $2.1&nbsp;million charge related to raw material inventory identified as excess and a
	$1.6&nbsp;million charge to write down raw material purchased during that year to its net realizable value. No similar costs were recorded during fiscal years 2009 and 2007. Reserve requirements for
	excess quantities of DMx are principally determined based on our collaborators' forecasted demand compared to our inventory position. The DMx purchased during fiscal year 2008 was produced by a
	supplier in conjunction with process scale-up, resulting in the purchase of quantities of material exceeding anticipated collaborator demand in the next twelve months. Due to lead times
	required to secure material, process development and the changing requirements of our collaborators, expenses to recognize excess quantities have fluctuated from period to period and we expect that
	these period fluctuations will continue in the future. See "Inventory" within our Critical Accounting Policies above for further discussion of our inventory reserve policy.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are unable to accurately estimate which potential product candidates, if any, will eventually move into our internal preclinical research program. We are unable to reliably estimate
	the costs to develop these products as a result of the uncertainties related to discovery research efforts as well as preclinical and clinical testing. Our decision to move a product candidate into
	the clinical development phase is predicated upon the results of preclinical tests. We cannot accurately predict which, if any, of the discovery stage product candidates will advance from preclinical
	testing and move into our internal clinical development program. The clinical trial and regulatory approval processes for our product candidates that have advanced or that we intend to advance to
	clinical testing are lengthy, expensive and uncertain in both timing and outcome. As a result, the pace and timing of the clinical development of our product candidates is highly uncertain and may not
	ever result in approved products.
	Completion dates and development costs will vary significantly for each product candidate and are difficult to predict. A variety of factors, many of which are outside our control, could cause or
	contribute to the prevention or delay of the successful completion of our clinical trials, or delay or prevent our obtaining necessary regulatory approvals. The costs to take a product through
	clinical trials are dependent upon, among other factors, the clinical indications, the timing, size and design of each clinical trial, the number of patients enrolled in each trial, and the speed at
	which patients are enrolled and treated. Product candidates may be found to be ineffective or to cause unacceptable side effects during clinical trials, may take longer to progress through clinical
	trials than anticipated, may fail to receive necessary regulatory approvals or may prove impractical to manufacture in commercial quantities at reasonable cost or with acceptable quality.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	lengthy process of securing FDA approvals for new drugs requires the expenditure of substantial resources. Any failure by us to obtain, or any delay in obtaining, regulatory
	approvals would materially adversely affect our product development efforts and our business overall. Accordingly, we cannot currently estimate, with any degree of certainty, the amount of time or
	money that we will be required to expend in the future on our product candidates prior to their regulatory approval, if such approval is ever granted. As a result of these uncertainties surrounding
	the timing and outcome of our clinical trials, we are currently unable to estimate when, if ever, our product candidates that have advanced into clinical testing will generate revenues and cash flows.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	do not track our research and development costs by project. Since we use our research and development resources across multiple research and development projects, we manage our
	research and
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	52
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=52,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=322870,FOLIO='52',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_53">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	development
	expenses within each of the categories listed in the following table and described in more detail below (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="284" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:127PT;">
<FONT SIZE=1>
<B>
	Research and Development Expense
<!-- COMMAND=ADD_SCROPPEDRULE,127PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,965
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,265
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,647
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Preclinical and Clinical Testing
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,762
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,280
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,072
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Process and Product Development
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,037
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,731
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,599
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Manufacturing Operations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16,140
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30,737
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	20,091
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total Research and Development Expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	45,904
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,013
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	49,409
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
</I>
</FONT>
<FONT SIZE=2>
	&#151;Research includes expenses associated with activities to evaluate new targets and to develop and evaluate new antibodies, linkers and
	cytotoxic agents for our products and in support of our collaborators. Such expenses primarily include personnel, fees to in-license certain technology, facilities and lab supplies.
	Research expenses decreased $1.3&nbsp;million to $14.0&nbsp;million in fiscal year 2009 from fiscal year 2008 and decreased $382,000 to $15.3&nbsp;million in fiscal year 2008 from fiscal year
	2007. The decrease in research expense in fiscal year 2009 was principally the result of a decrease in salaries and related expenses due to a reorganization of departments in March 2008 and July 2008,
	resulting in lower personnel costs included in research expense for the current period. The decrease in research expenses in fiscal year 2008 was principally the result of a decrease in salaries and
	related expenses, partially offset by an increase in facilities expense. Included in salaries and related expense for the year ended June&nbsp;30, 2007 were severance costs related to the departure
	of an executive, as well as the reorganization of departments mentioned previously, resulting in lower personnel costs included in research expenses for fiscal year 2008.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical and Clinical Testing
</I>
</FONT>
<FONT SIZE=2>
	&#151;Preclinical and clinical testing includes expenses related to preclinical testing of our own and, in certain
	instances, our collaborators' product candidates, and the cost of our own clinical trials, excluding the cost of clinical materials which is included in manufacturing operations expense. Such expenses
	include personnel, patient enrollment at our clinical testing sites, consultant fees, contract services, and facility expenses. Preclinical and clinical testing expenses increased $1.5&nbsp;million
	to $9.8&nbsp;million in fiscal year 2009 from fiscal year 2008 and $208,000 to $8.3&nbsp;million in fiscal year 2008 from fiscal year 2007. The increase in fiscal year 2009 was primarily due to an
	increase in salaries and related expenses due to a reorganization of departments in March 2008 and July 2008, as well as an increase in clinical trials costs. The increase in fiscal year 2008 was
	primarily the result of a $500,000 milestone fee incurred with a third party related to gaining authorization from the FDA to begin clinical testing with IMGN388, as well as increased consulting
	and recruiting fees. These increases were partially offset by a decrease in salaries and related expense resulting from a decrease in personnel due to turnover.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Process and Product Development
</I>
</FONT>
<FONT SIZE=2>
	&#151;Process and product development expenses include costs for development of clinical and commercial manufacturing
	processes for our own and collaborator compounds. Such expenses include the costs of personnel, contract services and facility expenses. Total development expenses increased $306,000 to
	$6.0&nbsp;million in fiscal year 2009 from fiscal year 2008 and increased $132,000 to $5.7&nbsp;million in fiscal year 2008 from fiscal year 2007. The increase in fiscal year 2009 was primarily
	the result of the reorganization of departments in July 2008. The increase in fiscal year 2008 was primarily the result of an increase in facilities expense.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing Operations
</I>
</FONT>
<FONT SIZE=2>
	&#151;Manufacturing operations expense includes costs to manufacture preclinical and clinical materials for our own and our
	collaborators' product candidates, quality control and quality assurance activities and costs to support the operation and maintenance of our conjugate manufacturing facility. Such expenses include
	personnel, raw materials for our and our collaborators'
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	53
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=53,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=71224,FOLIO='53',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_54">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	preclinical
	studies and clinical trials, development costs with contract manufacturing organizations, manufacturing supplies, and facilities expense. Manufacturing operations expense decreased
	$14.6&nbsp;million to $16.1&nbsp;million in fiscal year 2009 from fiscal year 2008 and increased $10.6&nbsp;million to $30.7&nbsp;million in fiscal year 2008 from fiscal year 2007. The
	decrease in fiscal year 2009 was primarily the result of (i)&nbsp;a decrease in supply of DMx and clinical materials to our collaborators; (ii)&nbsp;a decrease in antibody supply and development
	expenses; (iii)&nbsp;a decrease in contract service expenses; and (iv)&nbsp;a significant decrease in charges incurred related to the write down of raw material inventory. Partially offsetting
	these decreases, salaries and related expenses increased, depreciation and amortization increased, and overhead utilization from the manufacture of clinical materials on behalf of our collaborators
	decreased. The increase in fiscal year 2008 was primarily the result of (i)&nbsp;an increase in supply of DMx and clinical materials to our collaborators; (ii)&nbsp;an increase in salaries and
	related expenses due to an increase in personnel, as well as salary increases; (iii)&nbsp;an increase in antibody supply and development expenses; (iv)&nbsp;an increase in facilities expense; and
	(v)&nbsp;an increase in charges incurred related to the write down of raw material inventory purchased during the year to its net realizable value and raw material inventory identified as excess.
	Partially offsetting these increases contract service expense decreased due primarily to lower DMx development costs for the potential production of later-stage materials.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Antibody
	expense in anticipation of potential future clinical trials, as well as our ongoing trials, was $503,000 in fiscal year 2009, $7.4&nbsp;million in fiscal year 2008, and
	$6.8&nbsp;million in fiscal year 2007. The process of antibody production is lengthy as is the lead time to establish a satisfactory production process at a vendor. Accordingly, costs incurred
	related to antibody production and development have fluctuated from period to period and we expect these cost fluctuations to continue in the future.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	General and Administrative Expenses
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses for the year ended June&nbsp;30, 2009 decreased $448,000 to $13.9&nbsp;million from
	$14.3&nbsp;million for the year ended June&nbsp;30, 2008. General and administrative expenses for the year ended June&nbsp;30, 2007 were $11.0&nbsp;million. The decrease in fiscal year 2009 as
	compared to fiscal year 2008 was primarily the result of a decrease in rent expense and move-related expenses, partially offset by greater salaries and related expenses. During fiscal year
	2008, the Company recognized $1.5&nbsp;million of expense related to the rental of laboratory and office space in Waltham prior to occupying the space in late March 2008, as well as $799,000 of
	move-related expenses, classifying such as general and administrative expenses. During fiscal year 2009, the Company recognized a total of $1.6&nbsp;million in stock compensation expense
	and other compensation costs related to the former Chief Executive Officer's succession plan and a termination of an executive. The increase in fiscal year 2008 as compared to fiscal year 2007 was
	primarily the result of (i)&nbsp;an increase in rent expense for the new facility for the period prior to occupancy; (ii)&nbsp;an increase in move-related expenses; (iii)&nbsp;an
	increase in salaries and related expenses due to an increase in personnel, salary increases, and higher stock compensation costs; (iv)&nbsp;an increase in patent costs resulting from expanded
	filings; and (v)&nbsp;an increase in facilities expense.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	54
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=54,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=23675,FOLIO='54',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_55">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Other (Expense) Income, net
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other (expense) income, net for the years ended June&nbsp;30, 2009, 2008, and 2007 is included in the following table (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="302" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="20" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:102PT;">
<FONT SIZE=1>
<B>
	Other (Expense) Income, net
<!-- COMMAND=ADD_SCROPPEDRULE,102PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Interest Income
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	583
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,152
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,265
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net Realized (Losses) Gains on Investments
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(33
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	39
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other-Than-Temporary Impairment
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(516
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(535
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other (Expense) Income
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(255
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	463
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total Other (Expense) Income, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(221
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,119
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,274
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Investment Income, net
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income for the years ended June&nbsp;30, 2009, 2008 and 2007 was $583,000, $2.2&nbsp;million and $3.3&nbsp;million,
	respectively. The decrease in interest income in fiscal year 2009 and fiscal year 2008 from fiscal year 2007 is primarily the result of lower yields on investments tied to market rates and lower
	average investable balances.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Net Realized (Losses) Gains on Investments
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net realized (losses) gains on investments were ($33,000), $39,000 and ($1,000), for the years ended June&nbsp;30, 2009, 2008, and
	2007, respectively.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Other than Temporary Impairment
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the years ended June&nbsp;30, 2009 and 2008, we recognized $516,000 and $535,000, respectively, in charges for the impairment
	of
	available-for-sale securities that were determined to be other-than-temporary following a decline in value. No similar charges were recognized during
	the year ended June&nbsp;30, 2007.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Other (Expense) Income
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other (expense) income for the years ended June&nbsp;30, 2009, 2008 and 2007 was $(255,000), $463,000 and $10,000, respectively.
	During the years ended June&nbsp;30, 2009, 2008 and 2007, we recorded net (losses) gains on forward contracts of $(234,000), $699,000 and $112,000, respectively. We incurred $29,000, $243,000 and
	$105,000 in foreign currency translation expenses related to obligations with non-U.S. dollar-based suppliers during the years ended June&nbsp;30, 2009, 2008 and 2007, respectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Liquidity and Capital Resources
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="321" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(In thousands)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash, cash equivalents and short-term investments
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	71,125
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	47,871
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Working capital
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	65,738
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	45,655
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stockholders' equity
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	66,857
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	55,299
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash used for operating activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,334
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(20,149
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash provided by investing activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,995
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,154
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash provided by financing activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	39,359
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26,009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	55
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=55,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=510291,FOLIO='55',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_56">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Cash Flows
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We require cash to fund our operating expenses, including the advancement of our own clinical programs, and to make capital
	expenditures. Historically, we have funded our cash requirements primarily through equity financings in public markets and payments from our collaborators, including equity investments, license fees,
	milestones and research funding. As of June&nbsp;30, 2009, we had approximately $71.1&nbsp;million in cash and marketable securities. Net cash used in operations was $13.3&nbsp;million,
	$20.1&nbsp;million and $15.8&nbsp;million during the years ended June&nbsp;30, 2009, 2008 and 2007, respectively. The principal use of cash in operating activities for all periods presented was
	to fund our net loss.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
	cash provided by investing activities was $12.0&nbsp;million, $15.2&nbsp;million and $19.4&nbsp;million for the years ended June&nbsp;30, 2009, 2008 and 2007, respectively,
	and substantially represents cash inflows from the sales and maturities of marketable securities partially offset by capital expenditures. Capital expenditures were $1.9&nbsp;million,
	$18.0&nbsp;million and $2.0&nbsp;million for the fiscal years ended June&nbsp;30, 2009, 2008 and 2007, respectively. The significant capital expenditures for fiscal 2008 were primarily leasehold
	improvements made to our Waltham, MA facility related to the construction allowance received from the landlord to build out laboratory and office space to our specifications, as well as expansion and
	improvements of our manufacturing plant in Norwood, MA. The leasehold improvements made to the Waltham, MA facility were paid by the landlord, with such reimbursement recorded as a benefit to cash
	used in operations. Capital expenditures for the years ended June&nbsp;30, 2009 and 2007 consisted primarily of laboratory equipment and computer software applications.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
	cash provided by financing activities was $39.4&nbsp;million, $26.0&nbsp;million and $2.2&nbsp;million for the years ended June&nbsp;30, 2009, 2008 and 2007, respectively,
	which includes the proceeds from the exercise of 416,000, 619,000 and 870,000 stock options, respectively. Also, in June 2009, pursuant to a public offering, we issued and sold 5,750,000 shares of our
	common stock resulting in net proceeds of $38&nbsp;million. In June 2008, pursuant to a securities purchase agreement with a private investor, we issued and sold 7,812,500 shares of our common stock
	resulting in net proceeds of $24.9&nbsp;million. The shares of common stock offered were registered under our existing shelf registration statement on Form&nbsp;S-3 which was filed
	with the Securities and Exchange Commission in July 2007.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	anticipate that our current capital resources and future collaborator payments will enable us to meet our operational expenses and capital expenditures for fiscal year 2010 and at
	least a portion of the following fiscal year. However, we cannot provide assurance that such collaborative agreement funding will, in fact, be received. Should we not meet some or all of the terms and
	conditions of our various collaboration agreements, we may be required to pursue additional strategic partners, secure alternative financing arrangements, and/or defer or limit some or all of our
	research, development and/or clinical projects.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	mentioned above, on July&nbsp;11, 2007, we filed a Registration Statement on Form&nbsp;S-3 (Registration No.&nbsp;333-144488) with the Securities and
	Exchange Commission. The Securities and Exchange Commission declared the Registration Statement effective on August&nbsp;13, 2007. Subject to our ongoing obligations under the Securities Act of
	1933, as amended, and the Securities Exchange Act of 1934, as amended, the Registration Statement permits us to offer and sell up to an aggregate of $75&nbsp;million of our common stock,
	$65.3&nbsp;million of which we sold in the transactions discussed above.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	56
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=56,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=307634,FOLIO='56',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_57">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Contractual Obligations
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below is a table that presents our contractual obligations and commercial commitments as of June&nbsp;30, 2009 (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="193" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="31" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=14 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Payments Due by Period
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Total
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Less than
<BR>
	One Year
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	1-3
<BR>
	Years
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	4-5
<BR>
	Years
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	More than
<BR>
	5 Years
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Waltham lease obligation
<SUP>
	(1)
</SUP>
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	54,142
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,592
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,517
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,784
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30,249
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other operating lease obligations
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,955
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,728
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,227
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Purchase obligations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	924
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	924
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	58,021
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,244
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,744
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,784
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30,249
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
<SUP>
	(1)
</SUP>
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Lease
	agreement was signed on July&nbsp;27, 2007.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
<SUP>
	(2)
</SUP>
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	Company entered into a sub-sublease in May 2008 for the entire space at 148 Sidney Street, Cambridge, MA through
	October&nbsp;2010, the remainder of the sublease. We will receive approximately $1.0&nbsp;million in minimum rental payments over the remaining term of the sub-sublease, which is not
	included in the table above. We intend to sublease approximately 14,000 square feet of laboratory and office space at 830 Winter Street, Waltham, MA. However, we have not included estimated sublease
	income in the table above.
</FONT>
</DD>
</DL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Recent Accounting Pronouncements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2008, the FASB issued Statement No.&nbsp;161,
</FONT>
<FONT SIZE=2>
<I>
	Disclosures about Derivative Instruments and Hedging
	Activities
</I>
</FONT>
<FONT SIZE=2>
	, or Statement 161, which is effective for fiscal years beginning after November&nbsp;15, 2008 (our fiscal year 2010). Statement 161 requires enhanced disclosures
	about an entity's derivative and hedging activities and thereby improves the transparency of financial reporting. We do not believe the adoption of Statement 161 will have a material impact on our
	financial statements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	December 2007, the FASB ratified EITF Issue No.&nbsp;07-1,
</FONT>
<FONT SIZE=2>
<I>
	Accounting for Collaborative Arrangements
</I>
</FONT>
<FONT SIZE=2>
	, or
	EITF&nbsp;07-1, which is effective for fiscal years beginning after December&nbsp;15, 2008 (our fiscal year 2010). EITF&nbsp;07-1 defines collaborative arrangements and
	establishes reporting requirements for transactions between participants in a collaborative arrangement and between participants in the arrangement and third parties. EITF&nbsp;07-1 also
	establishes the appropriate income statement presentation and classification for joint operating activities and payments between participants, as well as the sufficiency of the disclosures related to
	these arrangements. We do not believe the adoption of EITF&nbsp;07-1 will have a material impact on our results of operations or financial position.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Off-Balance Sheet Arrangements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.
</FONT>
</P>
</EFX_RESULTS_OF_OPERATIONS>
</EFX_MANAGEMENTS_DISCUSSION>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_DM49301_ITEM_7A__QUANTITATIVE_AND_QUAL__ITE02619">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_DM49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;7A.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Quantitative and Qualitative Disclosure About Market Risk
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain an investment portfolio in accordance with our investment policy. The primary objectives of our investment policy are to
	preserve principal, maintain proper liquidity to meet operating needs and maximize yields. Although our investments are subject to credit risk, our investment policy specifies credit quality standards
	for our investments and limits the amount of credit exposure from any single issue, issuer or type of investment. Our investments are also subject to interest rate risk and will decrease in value if
	market interest rates increase. However, due to the conservative nature of our investments and relatively short duration, interest rate risk is mitigated. We do not own derivative financial
	instruments in our investment portfolio. Accordingly, we do not believe
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	57
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=57,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=476342,FOLIO='57',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<A NAME="A2194303Z10-K_HTM_PAGE_DM49301_1_58">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	that
	there is any material market risk exposure with respect to derivative or other financial instruments that would require disclosure under this item.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	foreign currency hedging program uses forward contracts to manage the foreign currency exposures that exist as part of our ongoing business operations. The contracts are denominated
	in Euros and have maturities of less than one year. Our foreign currency risk management strategy is principally designed to mitigate the future potential financial impact of changes in the value of
	transactions, anticipated transactions and balances denominated in foreign currency, resulting from changes in foreign currency exchange rates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	market risks associated with changes in foreign currency exchange rates are concentrated primarily in a portfolio of short duration foreign currency forward contracts. Generally,
	these contracts provide that we receive certain foreign currencies and pay U.S. dollars at specified exchange rates at specified future dates. Although we are exposed to credit and market risk in the
	event of future nonperformance by a counterparty, management has no reason to believe that such an event will occur.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	58
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=12,SEQ=58,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=213248,FOLIO='58',FILE='DISK104:[09ZCX1.09ZCX49301]DM49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FA49301_1_59">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_MARKET_RISK>
<A NAME="A2194303Z10-K_HTM_FA49301_FINANCIAL_STATEMENTS_AND_SUPPLEMENTARY_DATA_1ANK">
</A>
<A NAME="A2194303Z10-K_HTM_INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMENTS">
</A>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FA49301_ITEM_8__FINANCIAL_STATEMENTS_AND_SUPPLEMENTARY_DATA">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Financial Statements and Supplementary Data
<BR>
</I>
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FA49301_IMMUNOGEN,_INC__INDEX___FA402275">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	IMMUNOGEN,&nbsp;INC.
<BR>
<BR>
	INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FA49301_TOC">
</A>
</FONT>
</P>
<!-- COMMAND=ADD_START_LINKTABLE -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="409" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="18" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Page
</B>
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FC49301_REPORT_OF_INDEPENDENT___FC402281">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Report of Independent Registered Public Accounting Firm
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FC49301_REPORT_OF_INDEPENDENT___FC402281">
<FONT SIZE=2>
	60
</FONT>
</A>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Financial Statements:
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FE49301_IMMUNOGEN,_INC__CONSOLIDATED_B__IMM03836">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Balance Sheets as of June&nbsp;30, 2009 and 2008
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FE49301_IMMUNOGEN,_INC__CONSOLIDATED_B__IMM03836">
<FONT SIZE=2>
	61
</FONT>
</A>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_OPERATIONS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Statements of Operations for the Years Ended June&nbsp;30, 2009, 2008, and
	2007
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_OPERATIONS">
<FONT SIZE=2>
	62
</FONT>
</A>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_STOCKHOLDERS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Statements of Stockholders' Equity for the Years Ended June&nbsp;30, 2009,
	2008, and 2007
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_STOCKHOLDERS">
<FONT SIZE=2>
	63
</FONT>
</A>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_CASH_FLOWS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Statements of Cash Flows for the Years Ended June&nbsp;30, 2009, 2008, and
	2007
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_CASH_FLOWS">
<FONT SIZE=2>
	64
</FONT>
</A>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FM49301_IMMUNOGEN,_INC__NOTES_TO_CONSO__IMM02641">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Notes to Consolidated Financial Statements
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303Z10-K_HTM_FM49301_IMMUNOGEN,_INC__NOTES_TO_CONSO__IMM02641">
<FONT SIZE=2>
	65
</FONT>
</A>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	59
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=59,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=461420,FOLIO='59',FILE='DISK104:[09ZCX1.09ZCX49301]FA49301A.;9',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FC49301_1_60">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FC49301_REPORT_OF_INDEPENDENT___FC402281">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FC49301_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	Report of Independent Registered Public Accounting Firm
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	Board of Directors and Stockholders of ImmunoGen,&nbsp;Inc.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have audited the accompanying consolidated balance sheets of ImmunoGen,&nbsp;Inc. as of June&nbsp;30, 2009 and 2008, and the related consolidated statements of operations,
	stockholders' equity, and cash flows for each of the three years in the period ended June&nbsp;30, 2009. Our audits also included the financial statement schedule listed in the Index at
	Item&nbsp;15. These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based
	on our audits.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
	obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in
	the
	financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.
	We believe that our audits provide a reasonable basis for our opinion.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of ImmunoGen,&nbsp;Inc. at June&nbsp;30, 2009
	and 2008, and the consolidated results of its operations and its cash flows for each of the three years in the period ended June&nbsp;30, 2009, in conformity with U.S. generally accepted accounting
	principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the
	information set forth therein.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of ImmunoGen,&nbsp;Inc.'s internal control
	over financial reporting as of June&nbsp;30, 2009, based on criteria established in Internal Control&#151;Integrated Framework issued by the Committee of Sponsoring Organizations of the
	Treadway Commission and our report dated August&nbsp;28, 2009 expressed an unqualified opinion thereon.
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="241" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="211" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	/s/ E
</FONT>
<FONT SIZE=2>
	RNST
</FONT>
<FONT SIZE=2>
	&nbsp;&amp; Y
</FONT>
<FONT SIZE=2>
	OUNG&nbsp;LLP
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Boston,
	Massachusetts
<BR>
	August&nbsp;28, 2009
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=60,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=429530,FOLIO='60',FILE='DISK104:[09ZCX1.09ZCX49301]FC49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FE49301_1_61">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_AUDITORS_OPINION>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FE49301_IMMUNOGEN,_INC__CONSOLIDATED_B__IMM03836">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FE49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
<BR>
<BR>
	CONSOLIDATED BALANCE SHEETS
<BR>
<BR>
	AS OF JUNE 30, 2009 AND JUNE 30, 2008
<BR>
<BR>
	In thousands, except per share amounts
<BR>
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="321" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="38" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="38" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=4 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	June&nbsp;30,
<BR>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	June&nbsp;30,
<BR>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	ASSETS
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and cash equivalents
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69,639
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31,619
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,486
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16,252
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accounts receivable
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,746
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	396
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Unbilled revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	561
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,472
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Inventory
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,836
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,116
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Restricted cash
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	366
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	366
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Prepaid and other current assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,232
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,820
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total current assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	76,866
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	56,041
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Property and equipment, net of accumulated depreciation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	19,671
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22,751
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Long-term restricted cash
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,142
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,508
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100,704
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	83,338
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	LIABILITIES AND STOCKHOLDERS' EQUITY
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accounts payable
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,244
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,411
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,140
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,164
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other accrued liabilities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,566
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,304
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Current portion of deferred lease incentive
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	979
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	935
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Current portion of deferred revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,199
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,572
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total current liabilities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,128
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,386
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred lease incentive, net of current portion
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,540
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,052
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred revenue, net of current portion
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,543
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,293
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other long-term liabilities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,636
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,308
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total liabilities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	33,847
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	28,039
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Commitments and contingencies (Note&nbsp;H)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stockholders' equity:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Preferred stock, $.01 par value; authorized 5,000 shares; no shares issued and outstanding
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Common stock, $.01 par value; authorized 75,000 shares; issued and outstanding 56,947 and 50,778 shares as of June&nbsp;30, 2009 and 2008,
	respectively
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	569
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	508
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Additional paid-in capital
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	387,947
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	344,498
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accumulated deficit
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(321,451
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(289,568
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accumulated other comprehensive loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(208
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(139
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total stockholders' equity
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	66,857
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	55,299
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total liabilities and stockholders' equity
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100,704
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	83,338
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BALANCE_SHEET>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	accompanying notes are an integral part of the consolidated financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	61
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=61,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=873593,FOLIO='61',FILE='DISK104:[09ZCX1.09ZCX49301]FE49301A.;5',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FG49301_1_62">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_OPERATIONS">
</A>
</FONT>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FG49301_IMMUNOGEN,_INC__CONSOLIDATED_S__IMM03474">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FG49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
<BR>
<BR>
	CONSOLIDATED STATEMENTS OF OPERATIONS
<BR>
<BR>
	In thousands, except per share data
<BR>
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="292" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Revenues:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development support
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,566
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,035
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25,486
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	License and milestone fees
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,117
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,156
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,585
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Clinical materials reimbursement
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,305
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,058
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,141
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total revenues
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27,988
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	40,249
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38,212
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Operating Expenses:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	45,904
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,013
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	49,409
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,900
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,348
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,029
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total operating expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	59,804
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74,361
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,438
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss from operations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(31,816
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(34,112
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(22,226
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Investment income, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	583
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,191
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,264
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other-than-temporary impairment
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(516
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(535
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other (expense) income, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(288
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	463
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss before provision for income taxes
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(32,037
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(31,993
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(18,952
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	(Benefit) provision for income taxes
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(100
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(31,937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(32,020
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(18,987
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Basic and diluted net loss per common share
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.63
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.75
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.45
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Basic and diluted weighted average common shares outstanding
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	51,068
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	42,969
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	41,759
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_INCOME_STATEMENT>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	accompanying notes are an integral part of the consolidated financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=62,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=823776,FOLIO='62',FILE='DISK104:[09ZCX1.09ZCX49301]FG49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FI49301_1_63">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_STOCKHOLDERS">
</A>
</FONT>
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FI49301_IMMUNOGEN,_INC__CONSOLIDATED_S__IMM03050">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FI49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
<BR>
<BR>
	CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<BR>
<BR>
	In thousands
<BR>
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="182" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="19" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="21" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="28" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="35" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="42" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="36" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="42" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Common Stock
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Accumulated
<BR>
	Other
<BR>
	Comprehensive
<BR>
	(Loss)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Additional
<BR>
	Paid-In
<BR>
	Capital
</B>
</FONT>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Accumulated
<BR>
	Deficit
</B>
</FONT>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Total
<BR>
	Stockholders'
<BR>
	Equity
</B>
</FONT>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Comprehensive
<BR>
	(Loss)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Amount
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Balance at June&nbsp;30, 2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	41,474
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	414
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	310,851
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(238,561
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(354
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	72,350
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Unrealized gains on marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	259
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	259
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	259
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(18,987
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(18,987
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(18,987
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock options exercised
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	870
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	9
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2,141
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2,150
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock-based compensation expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2,348
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2,348
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Directors' stock-based compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	281
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	281
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Shares issued upon resignation of director
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Balance at June&nbsp;30, 2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	42,346
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	423
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	315,621
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(257,548
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(95
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	58,401
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Comprehensive loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(18,728
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Unrealized losses on marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(44
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(44
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(44
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(32,020
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(32,020
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(32,020
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock options exercised
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	619
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	6
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1,087
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1,093
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock-based compensation expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2,861
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2,861
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Directors' stock-based compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	92
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	92
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Issuance of common stock in a private offering, net of financing costs
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	7,813
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	79
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	24,837
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	24,916
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Balance at June&nbsp;30, 2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	50,778
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	508
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	344,498
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(289,568
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(139
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	55,299
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Comprehensive loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(32,064
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Unrealized losses on marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Cumulative effect adjustment relating to the adoption of FSP FAS&nbsp;115-2 and FAS&nbsp;124-2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	54
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(54
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(31,937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(31,937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(31,937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock options exercised
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	416
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1,310
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1,314
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock-based compensation expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	3,956
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	3,956
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Restricted stock issued
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	3
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	20
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	20
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Issuance of common stock in a public offering, net of financing costs
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	5,750
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	57
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	37,988
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	38,045
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Directors' stock-based compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	175
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	175
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Balance at June&nbsp;30, 2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	56,947
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	569
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	387,947
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(321,451
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(208
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	66,857
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Comprehensive loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(31,952
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_STOCKHOLDERS_EQUITY>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The accompanying notes are an integral part of the consolidated financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=63,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=123270,FOLIO='63',FILE='DISK104:[09ZCX1.09ZCX49301]FI49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FK49301_1_64">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_CONSOLIDATED_STATEMENTS_OF_CASH_FLOWS">
</A>
</FONT>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FK49301_IMMUNOGEN,_INC__CONSOLIDATED_S__IMM02601">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FK49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
<BR>
<BR>
	CONSOLIDATED STATEMENTS OF CASH FLOWS
<BR>
<BR>
	In thousands
<BR>
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="277" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="38" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=4 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=4 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash flows from operating activities:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(31,937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(32,020
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(18,987
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Adjustments to reconcile net loss to net cash used for operating activities:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Depreciation and amortization
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,995
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,445
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,153
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss (gain) on sale/disposal of fixed assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	103
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Amortization of deferred lease incentive obligation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(975
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(512
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss (gain) on sale of marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	33
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(39
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other-than-temporary impairment of investments
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	516
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	535
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss (gain) on forward contracts
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	234
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(699
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(112
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock and deferred share unit compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,235
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,915
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,540
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred rent
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,450
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,816
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Change in operating assets and liabilities:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accounts receivable
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,350
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,140
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	33
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Unbilled revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,911
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,508
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(561
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Inventory
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	280
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,151
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2,032
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Prepaid and other current assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	312
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(241
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Restricted cash
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	366
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,511
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(173
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	37
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accounts payable
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(167
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(815
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	880
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,976
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(49
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	288
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other accrued liabilities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2,871
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(44
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,347
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,877
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(5,910
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2,253
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proceeds from landlord for tenant improvements
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	750
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,041
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net cash used for operating activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,334
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(20,149
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(15,781
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash flows from investing activities:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proceeds from maturities or sales of marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,227
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	45,908
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	297,690
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Purchases of marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(25
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(276,318
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Reclassification of cash equivalent balance to marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,605
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Purchases of property and equipment, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,896
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(17,995
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,981
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proceeds from settlement of forward contracts
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(311
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	846
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	32
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net cash provided by investing activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,995
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,154
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	19,423
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash flows from financing activities:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proceeds from stock options exercised
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,314
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,093
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,150
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proceeds from common stock issuance, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38,045
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24,916
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net cash provided by financing activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	39,359
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26,009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,150
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net change in cash and cash equivalents
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38,020
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	21,014
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,792
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and cash equivalents, beginning balance
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31,619
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,605
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,813
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and cash equivalents, ending balance
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69,639
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31,619
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,605
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Supplemental disclosure:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash paid for income taxes
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	34
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=4 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CASH_FLOW>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	accompanying notes are an integral part of the consolidated financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	64
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=64,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=972200,FOLIO='64',FILE='DISK104:[09ZCX1.09ZCX49301]FK49301A.;8',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FM49301_1_65">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FM49301_IMMUNOGEN,_INC__NOTES_TO_CONSO__IMM02641">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FM49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
<BR>
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
<BR>
<BR>
	AS OF JUNE 30, 2009
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	A.&nbsp;&nbsp;&nbsp;&nbsp;Nature of Business and Plan of Operations
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ImmunoGen,&nbsp;Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development of antibody-based anticancer therapeutics. The Company continues to
	research and develop its various product candidates and technologies and does not expect to derive revenue from commercial product sales within the near future. It is anticipated that the Company's
	existing capital resources, enhanced by collaborative agreement funding, will enable current and planned operations to be maintained for fiscal 2010 and at least a portion of fiscal 2011. However, if
	the Company is unable to achieve future milestones under its collaborative agreements (see Note&nbsp;C) or raise additional capital, the Company may be required to defer or limit some or all of its
	research, development and/or clinical projects. Additional funding may not be available on favorable terms, or at all. The Company may raise additional funds through public or private financings,
	collaborative arrangements or other arrangements. Debt financing, if available, may involve covenants that could restrict business activities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations,
	dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, collaboration arrangements, third-party reimbursements and compliance with governmental
	regulations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Principles of Consolidation
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, ImmunoGen Securities Corp.
	(established in December 1989), and ImmunoGen Europe Limited (established in October 2005). All intercompany transactions and balances have been eliminated.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Use of Estimates
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with accounting principles generally accepted in the United States (U.S.)
	requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
	statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Subsequent Events
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective June&nbsp;15, 2009, the Company adopted Statement of Financial Accounting Standards No.&nbsp;165, subsequent Events, or
	SFAS&nbsp;165. This standard establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued. The adoption
	of SFAS&nbsp;165 did not impact the Company's financial position or results of operations. The Company has evaluated all events or transactions that occurred after June&nbsp;30, 2009 up through
	August&nbsp;28, 2009, the date the Company issued these financial statements. During the period the Company did not have any material recognizable or unrecognizable subsequent events.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	65
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=65,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=338190,FOLIO='65',FILE='DISK104:[09ZCX1.09ZCX49301]FM49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FM49301_1_66">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Revenue Recognition
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company enters into licensing and development agreements with collaborative partners for the development of monoclonal
	antibody-based anticancer therapeutics. The Company follows the provisions of the Securities and Exchange Commission's Staff Accounting Bulletin No.&nbsp;104,
</FONT>
<FONT SIZE=2>
<I>
	Revenue
	Recognition
</I>
</FONT>
<FONT SIZE=2>
	, or SAB&nbsp;104, and Emerging Issues Task Force Issue (EITF) Issue No.&nbsp;00-21,
</FONT>
<FONT SIZE=2>
<I>
	Accounting for Revenue Arrangements with
	Multiple Elements
</I>
</FONT>
<FONT SIZE=2>
	, or EITF&nbsp;00-21. In accordance with SAB&nbsp;104 and EITF&nbsp;00-21, the Company recognizes revenue related to research
	activities as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The terms of the
	Company's agreements contain multiple elements which typically include non-refundable license fees, payments based upon the achievement of certain milestones and royalties on product
	sales. The Company evaluates such arrangements to determine if the deliverables are separable into units of accounting and then applies applicable revenue recognition criteria to each unit of
	accounting.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	June&nbsp;30, 2009, the Company had the following three types of collaborative contracts with the parties identified below:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Exclusive license to use the Company's TAP technology and/or certain other intellectual property to develop compounds to a
	single antigen:
</FONT>
</DD>
</DL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Bayer
	HealthCare (single-target license)
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Biogen
	Idec (single-target license)
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Biotest
	(single-target license)
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Genentech
	(multiple single-target licenses)
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	sanofi-aventis
	(license to multiple individual targets)
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Option agreement for a defined period of time to secure licenses to use the Company's TAP technology to develop anticancer
	compounds to a limited number of targets on established terms (broad option agreement):
</FONT>
</DD>
</DL>
</UL>
<UL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amgen
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Genentech
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Non-exclusive license to the Company's humanization technology:
</FONT>
</DD>
</DL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</P>
</UL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
	the foregoing collaboration agreements provide that the Company will (i)&nbsp;at the collaborator's request, manufacture and provide to them preclinical and clinical
	materials at the Company's cost, or, in some cases, cost plus a margin, (ii)&nbsp;earn payments upon the collaborators' achievements of certain milestones and (iii)&nbsp;earn royalty payments,
	generally until the later of the last applicable patent expiration or 10 to 12&nbsp;years after product launch. Royalty rates may vary over the royalty term depending on certain intellectual
	property rights. The Company is required to provide
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	66
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=66,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=786972,FOLIO='66',FILE='DISK104:[09ZCX1.09ZCX49301]FM49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FM49301_1_67">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	technical
	training and to share any process improvements and know-how with its collaborators during the research term of the collaboration agreements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
	upfront payments on single-target licenses are deferred over the period of the Company's substantial involvement during development. The determination of the length of this
	period is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. The Company's employees are available to assist the Company's collaborators
	during the development of their products. The Company estimates this development phase to begin at the inception of the collaboration agreement and conclude at the end of non-pivotal
	Phase&nbsp;II testing. The Company believes this period of involvement is, depending on the nature of the license, on average six and one-half years. Quarterly, the Company reassesses
	its periods of substantial involvement over which the Company amortizes its upfront license fees. In the event that a single-target license were to be terminated, the Company would recognize as
	revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue at the date of such termination.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company defers upfront payments received from its broad option agreements over the period during which the collaborator may elect to receive a license. These periods are specific to
	each collaboration agreement, but are between three and 12&nbsp;years. If a collaborator selects an option to acquire a license under these agreements, any option fee is deferred and recorded over
	the life of the option, generally 12 to 18&nbsp;months. If a collaborator exercises an option and the Company grants a single-target license to the collaborator, the Company defers the license fee
	and accounts for the fee as it would an upfront payment on a single-target license, as discussed above. Upon exercise of an option to acquire a license, the Company would recognize any remaining
	deferred option fee over the period of the Company's substantial involvement under the license acquired. In the event that a broad option agreement were to be terminated, the Company would recognize
	as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue at the date of such termination. In the event a collaborator elects
	to discontinue development of a specific product candidate under a single-target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same
	target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and the
	Company's remaining period of substantial involvement can be estimated.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
	milestone fees are specifically tied to a separate earnings process and are deemed to be substantive and at risk, revenue is recognized when such milestones are achieved. In
	addition, the Company recognizes research and development support revenue from certain collaboration and development agreements based upon the level of research services performed during the period of
	the relevant research agreement. Deferred revenue substantially represents amounts received under collaborative agreements and not yet earned pursuant to these policies. Where the Company has no
	continuing involvement, the Company will record non-refundable license fees as revenue upon receipt and will record revenue upon achievement of milestones by its collaborative partners.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company produces preclinical and clinical materials for its collaborators. The Company is reimbursed for its direct costs and a portion of its overhead costs to produce clinical
	materials. The Company recognizes revenue on preclinical and clinical materials when the materials have passed all
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	67
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=67,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=476898,FOLIO='67',FILE='DISK104:[09ZCX1.09ZCX49301]FM49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FM49301_1_68">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	quality
	testing required for collaborator acceptance and title and risk of loss have transferred to the collaborator.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company also produces research material for potential collaborators under material transfer agreements. Additionally, the Company performs research activities, including developing
	antibody-specific conjugation processes, on behalf of its collaborators and potential collaborators during the early evaluation and preclinical testing stages of drug development. Generally, the
	Company is reimbursed for certain of its direct and overhead costs of producing these materials or providing these services. The Company records the amounts received for the preclinical materials
	produced or services performed as a component of research and development support. The Company also develops conjugation processes for materials for later stage testing and commercialization for
	certain collaborators. The Company is reimbursed for certain of its direct and overhead costs and may receive milestone payments for developing these processes which are recorded as a component of
	research and development support.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Inventory
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory costs primarily relate to clinical trial materials being manufactured for sale to the Company's collaborators. Inventory is
	stated at the lower of cost or market as determined on a first-in, first-out (FIFO) basis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory
	at June&nbsp;30, 2009 and 2008 is summarized below (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="298" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Raw materials
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	952
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	565
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Work in process
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	884
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,551
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,836
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,116
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Raw
	materials inventory consists entirely of DM1 or DM4 , our proprietary cell-killing agents, which are included in all Targeted Antibody Payload, or TAP, product candidates
	currently in preclinical and clinical testing with our collaborators.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory
	cost is stated net of write-downs of $1.8&nbsp;million and $2.5&nbsp;million as of June&nbsp;30, 2009 and June&nbsp;30, 2008, respectively. The write-downs represent
	the cost of raw materials that the Company considers to be in excess of a twelve-month supply based on firm, fixed orders and projections from its collaborators as of the respective balance sheet
	date.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due
	to yield fluctuations, the actual amount of raw materials that will be produced in future periods under supply agreements is highly uncertain. As such, the amount of raw materials
	produced could be more than is required to support the development of the Company's and its collaborators' product candidates. Such excess supply, as determined under the Company's inventory reserve
	policy, is charged to research and development expense.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company produces preclinical and clinical materials for its collaborators either in anticipation of or in support of preclinical studies and clinical trials, or for process
	development and analytical
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	68
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=68,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=160749,FOLIO='68',FILE='DISK104:[09ZCX1.09ZCX49301]FM49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FM49301_1_69">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	purposes.
	Under the terms of supply agreements with its collaborators, the Company generally receives rolling six-month firm, fixed orders for conjugate that the Company is required to
	manufacture, and rolling twelve-month manufacturing projections for the quantity of conjugate the collaborator expects to need in any given twelve-month period. The amount of clinical material
	produced is directly related to the number of Company and collaborator anticipated or on-going clinical trials for which the Company is producing clinical material, the speed of enrollment
	in those trials, the dosage schedule of each clinical trial and the time period, if any, during which patients in the trial receive clinical benefit from the clinical materials. Because these elements
	are difficult to estimate over the course of a trial, substantial differences between collaborators' actual manufacturing orders and their projections could result in usage of raw materials varying
	significantly from estimated usage at an earlier reporting period. To the extent that a collaborator has provided the Company with a firm, fixed order, the collaborator is required by contract to
	reimburse the Company the full cost of the conjugate and any agreed margin thereon, even if the collaborator subsequently cancels the manufacturing run.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company accounts for the raw material inventory as follows:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	a)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	raw
	material is capitalized as inventory upon receipt of the materials. The portion of the raw material the Company uses in the production of its own
	products is recorded as research and development expense as consumed;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	b)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	to
	the extent that the Company has up to twelve months of firm, fixed orders and/or projections from its collaborators, the Company capitalizes the value of
	raw materials that will be used in the production of conjugate subject to these firm, fixed orders and/or projections;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	c)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the
	Company considers more than a twelve month supply of raw materials that is not supported by firm, fixed orders or projections from its collaborators to
	be excess and establishes a reserve to reduce to zero the value of any such excess raw material inventory with a corresponding charge to research and development expense; and
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	d)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the
	Company also considers any other external factors and information of which it becomes aware and assesses the impact of such factors or information on the
	net realizable value of the raw material inventory at each reporting period.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
	the year ended June&nbsp;30, 2008, the Company obtained additional amounts of DM1 and DM4 from a new supplier. Due to the need to evaluate the process which was developed to
	prepare such material from this new supplier across multiple batches, the Company had committed to a level of production which yielded more material than would be required by its collaborators over
	the next twelve months. As a result, the Company recorded a $2.1&nbsp;million charge to research and development expense related to excess inventory during the year ended June&nbsp;30, 2008. The
	Company also recorded $1.6&nbsp;million as research and development expense to write down this material to its net realizable value. No similar costs were recorded during the years ended
	June&nbsp;30, 2009 and 2007. Increases in the Company's on-hand supply of raw materials, or a reduction to the Company's collaborators' projections, could result in significant changes
	in the Company's estimate of the net realizable value of such raw material inventory. Reductions in collaborators' projections could indicate that the Company has additional excess raw material
	inventory and the Company would then evaluate the need to record further write-downs as charges to research and development expense.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=69,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=940687,FOLIO='69',FILE='DISK104:[09ZCX1.09ZCX49301]FM49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_70">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Unbilled Revenue
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The majority of the Company's unbilled revenue at June&nbsp;30, 2009 and 2008 represents research funding earned based on actual
	resources utilized under the Company's various collaborator agreements.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Restricted Cash
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash at June&nbsp;30, 2009 and 2008 are cash balances securing irrevocable letters of credit required for the Company to
	receive value added tax reimbursements related to payments to foreign vendors for activities performed in fiscal 2008 and 2007 and as security deposits for the Company's leased facilities.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Other Accrued Liabilities
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities consisted of the following at June&nbsp;30, 2009 and 2008 (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="298" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued contract payments
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	130
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,335
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other current accrued liabilities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	295
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,004
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued professional services
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	722
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	535
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued employee benefits
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	306
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	305
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued public reporting charges
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	113
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	125
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,566
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,304
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Research and Development Expenses
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's net research and development expenses are charged to expense as incurred and relate to (i)&nbsp;research to evaluate
	new targets and to develop and evaluate new antibodies, linkers and cytotoxic agents, (ii)&nbsp;preclinical testing of its own and, in certain instances, its collaborators' product candidates, and
	the cost of its own clinical trials, (iii)&nbsp;development related to clinical and commercial manufacturing processes and (iv)&nbsp;manufacturing operations.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Income Taxes
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the liability method to account for income taxes. Deferred tax assets and liabilities are determined based on
	differences between the financial reporting and income tax basis of assets and liabilities, as well as net operating loss carry forwards and tax credits and are measured using the enacted tax rates
	and laws that will be in effect when the differences reverse. A valuation allowance against net deferred tax assets is recorded if, based on the available evidence, it is more likely than not that
	some or all of the deferred tax assets will not be realized.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company adopted the provisions of FASB Financial Interpretation No.&nbsp;48,
</FONT>
<FONT SIZE=2>
<I>
	Accounting for Uncertainty in Income Taxes
</I>
</FONT>
<FONT SIZE=2>
	, or
	FIN&nbsp;48, an interpretation of FASB Statement No 109, or Statement 109, on July&nbsp;1, 2007. FIN&nbsp;48 prescribes a recognition threshold and measurement attribute for financial
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=70,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=365256,FOLIO='70',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_71">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	statement
	recognition and measurement of a tax position taken or expected to be taken in a tax return and also provides guidance on various related matters such as derecognition, interest and
	penalties, and disclosure.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Financial Instruments and Concentration of Credit Risk
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents are primarily maintained with two financial institutions in the U.S. Deposits with banks may exceed the
	amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. Financial instruments that potentially subject the Company to
	concentrations of credit risk consist principally of marketable securities. Marketable securities at June&nbsp;30, 2009 generally consist of high-grade corporate bonds and asset-backed
	securities. The Company's investment policy, approved by the Board of Directors, limits the amount it may invest in any one type of investment, thereby reducing credit risk concentrations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative
	instruments include a portfolio of short duration foreign currency forward contracts intended to mitigate the risk of exchange fluctuations for existing or anticipated
	receivable and payable balances denominated in foreign currency. Derivatives are estimated at fair value and classified as other current assets or liabilities. The fair value of these instruments
	represents the present value of estimated future cash flows under the contracts, which are a function of underlying interest rates, currency rates, related volatility, counterparty creditworthiness
	and duration of the contracts. Changes in these factors or a combination thereof may affect the fair value of these instruments.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company does not designate foreign currency forward contracts as hedges for accounting purposes, and changes in the fair value of these instruments are recognized in earnings during
	the period of change. Because the Company enters into forward contracts only as an economic hedge, any gain or loss on the underlying foreign-denominated existing or anticipated receivable or payable
	balance would be offset by the loss or gain on the forward contract. Net (losses) gains on forward contracts for the years ended June&nbsp;30, 2009, 2008 and 2007 were ($234,000), $699,000 and
	$112,000, respectively, and are included in the accompanying Consolidated Statement of Operations as other (expense) income, net. As of June&nbsp;30, 2009, we had outstanding forward contracts with
	amounts equivalent to approximately $517,000 (371,000 in Euros), all maturing on or before July&nbsp;24, 2009. As of June&nbsp;30, 2008, we had outstanding forward contracts with amounts
	equivalent to approximately $1.4&nbsp;million (924,000 in Euros), all maturing on or before August&nbsp;20, 2008. As of June&nbsp;30, 2007, the Company had outstanding forward contracts with
	amounts equivalent to approximately $6.5&nbsp;million (4.8&nbsp;million in Euros). The Company
	does not anticipate using derivative instruments for any purpose other than hedging exchange rate exposure.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Cash Equivalents
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash equivalents consist principally of money market funds and other investments with original maturities of three months or less at
	the date of purchase.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Marketable Securities
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company invests in marketable securities of highly rated financial institutions and investment-grade debt instruments and limits
	the amount of credit exposure with any one entity. The Company has
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	71
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=71,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=256767,FOLIO='71',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_72">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	classified
	its marketable securities as "available-for-sale" and, accordingly, carries such securities at aggregate fair value. Unrealized gains and losses, if any, are
	reported as other comprehensive income (loss) in shareholders' equity. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to
	maturity. Such amortization and accretions are included in other income, net, as well as interest and dividends. Realized gains and losses on available-for-sale securities are
	also included in other income, net, as well as charges for the impairment of available-for-sale securities that were determined to be
	other-than-temporary and related to a credit loss. The cost of securities sold is based on the specific identification method.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Other-than-Temporary Impairments
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2009, the FASB issued FSP No. FAS&nbsp;115-2 and FAS&nbsp;124-2,
</FONT>
<FONT SIZE=2>
<I>
	Recognition and Presentation of Other-than-Temporary Impairments
</I>
</FONT>
<FONT SIZE=2>
	,
	or FSP FAS&nbsp;115-2, which amended the
	other-than-temporary impairment model for debt securities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	this FSP, an other-than-temporary impairment must be recognized through earnings if an investor has the intent to sell the debt security or if it is more
	likely than not that the investor will be required to sell the debt security before recovery of its amortized cost basis. In the event of a credit loss, only the amount associated with the credit loss
	is recognized in net income (loss). The amount of loss relating to other factors is recorded in accumulated other comprehensive income (loss).
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company adopted the provisions of FSP FAS&nbsp;115-2 on April&nbsp;1, 2009. As a result of the adoption, $54,000 of previously recognized
	other-than-temporary impairment charges was reclassified to other comprehensive loss as a cumulative effect adjustment.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company conducts periodic reviews to identify and evaluate each investment that has an unrealized loss, which exists when the current fair value of an individual security is less
	than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in
	accumulated other comprehensive loss.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
	available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether it intends to sell or whether it would more
	likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where the Company intends to sell a security, or may be required to do so, the security's
	decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is recorded in the statement of operations as an
	other-than-temporary impairment charge. When this is not the case, the Company performs additional analysis on all securities with unrealized losses to evaluate losses
	associated with the creditworthiness of the security. Credit losses are identified where the Company does not expect to receive cash flows, based on using a single best estimate, sufficient to recover
	the amortized cost basis of a security and these are recognized in other income (expense), net.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Fair Value of Financial Instruments
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of July&nbsp;1, 2008, the Company partially adopted the provisions of FASB Statement No.&nbsp;157,
</FONT>
<FONT SIZE=2>
<I>
	Fair
	Value Measurements
</I>
</FONT>
<FONT SIZE=2>
	, or Statement 157, for financial assets and liabilities recognized at fair value on a recurring basis. Statement 157 defines fair value, establishes a
	framework for measuring fair value in accordance with accounting principles generally accepted in the U.S., and expands disclosures about fair
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	72
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=72,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=244979,FOLIO='72',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_73">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	value
	measurements. The provisions of Statement 157 related to other non-financial assets and liabilities will be effective on July&nbsp;1, 2009, and will be applied prospectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair
	value is defined under Statement 157 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
	market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under Statement 157 must maximize the
	use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy to measure fair value which is based on three levels of inputs, of which the first
	two are considered observable and the last unobservable, as follows:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Level&nbsp;2&#151;Inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as
	quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially
	the full term of the assets or liabilities.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market activity and that are significant
	to the fair value of the assets or liabilities.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective
	this quarter, the Company implemented FSP FAS&nbsp;157-4,
</FONT>
<FONT SIZE=2>
<I>
	Determining Fair Value When the Volume and Level of Activity for the Asset or
	Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly
</I>
</FONT>
<FONT SIZE=2>
	, or FSP FAS&nbsp;157-4. FSP FAS&nbsp;157-4 provides
	additional guidelines for making fair value measurements more consistent with the principles presented in SFAS&nbsp;157 and provides authoritative guidance in determining whether a market is active
	or inactive, and whether a transaction is distressed. This FSP is applicable to all assets and liabilities (i.e.&nbsp;financial and nonfinancial) and requires enhanced disclosures, including interim
	and annual disclosure of the input and valuation techniques (or changes in techniques) used to measure fair value and the defining of the major security types comprising debt and equity securities
	held based upon the nature and risk of the security. The adoption of this FSP did not impact the Company's financial position or results of operations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of June&nbsp;30, 2009, the Company held certain assets that are required to be measured at fair value on a recurring basis, including our cash equivalents and marketable securities.
	The following table represents the fair value hierarchy for the Company's financial assets measured at fair value on a recurring basis as of June&nbsp;30, 2009 (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="200" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="62" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="43" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=11 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Fair Value Measurements at June&nbsp;30, 2009 Using
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Quoted Prices in
<BR>
	Active Markets for
<BR>
	Identical Assets
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Significant Other
<BR>
	Observable Inputs
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Significant
<BR>
	Unobservable
<BR>
	Inputs
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Total
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	(Level&nbsp;1)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	(Level&nbsp;2)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	(Level&nbsp;3)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash, cash equivalents and restricted cash
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74,147
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74,147
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Available-for-sale marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,486
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,486
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	75,633
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74,147
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,486
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	73
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=73,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=61682,FOLIO='73',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_74">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	fair value of the Company's investments is generally determined from market prices based upon either quoted prices from active markets or other significant observable market
	transactions at fair value.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the fourth quarter of fiscal 2009, the Company has also implemented FSP FAS&nbsp;107-1 and APB&nbsp;28-1,
</FONT>
<FONT SIZE=2>
<I>
	Interim Disclosures about
	Fair Value of Financial Instruments
</I>
</FONT>
<FONT SIZE=2>
	, or FSP FAS&nbsp;107-1. FSP FAS&nbsp;107-1 amended Statement of Financial Accounting Standards No.&nbsp;107,
</FONT>
<FONT SIZE=2>
<I>
	Disclosures about Fair Value of Financial
	Instruments
</I>
</FONT>
<FONT SIZE=2>
	, and APB Opinion No.&nbsp;28,
</FONT>
<FONT SIZE=2>
<I>
	Interim Financial
	Reporting
</I>
</FONT>
<FONT SIZE=2>
	, to require disclosures about the fair value of financial instruments in interim as well as in annual financial statements. Since this FSP addresses disclosure
	requirements, the adoption of this FSP did not impact the Company's financial position or results of operations.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Property and Equipment
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are stated at cost. The Company provides for depreciation based upon expected useful lives using the
	straight-line method over the following estimated useful lives:
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="179" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="188" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Machinery and equipment
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3-5&nbsp;years
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Computer hardware and software
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3-5&nbsp;years
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Furniture and fixtures
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5&nbsp;years
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Leasehold improvements
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Shorter of remaining lease term or 7&nbsp;years
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintenance
	and repairs are charged to expense as incurred. Upon retirement or sale, the cost of disposed assets and the related accumulated depreciation are removed from the accounts
	and any resulting gain or loss is included in the statement of operations. The Company recorded $18,000 and $103,000 of losses on the sale/disposal of certain furniture and equipment during the years
	ended June&nbsp;30, 2009 and 2008, respectively. The Company recorded a $1,000 gain on the sale of certain equipment during the year ended June&nbsp;30, 2007.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Impairment of Long-Lived Assets
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the Financial Accounting Standards Board (FASB) SFAS No.&nbsp;144,
</FONT>
<FONT SIZE=2>
<I>
	Accounting for the
	Impairment or Disposal of Long-Lived Assets
</I>
</FONT>
<FONT SIZE=2>
	, the Company continually evaluates whether events or circumstances have occurred that indicate that the estimated
	remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company evaluates the realizability of its
	long-lived assets based on cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. Based on this evaluation,
	the Company believes that, as of each of the balance sheet dates presented, none of the Company's long-lived assets were impaired.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Computation of Net Loss Per Common Share
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted net loss per common share is calculated based upon the weighted average number of common shares outstanding during
	the period. The Company's common stock equivalents,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=74,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=771661,FOLIO='74',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_75">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	as
	calculated in accordance with the treasury-stock accounting method, are shown in the following table (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="274" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="19" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="19" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="19" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Options to purchase common stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,529
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,678
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,763
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Common stock equivalents under treasury stock method
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	848
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	483
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	771
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company's common stock equivalents have not been included in the net loss per share calculation because their effect is anti-dilutive due to the Company's net loss
	position.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Stock-Based Compensation
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2009, the Company is authorized to grant future awards under one employee share-based compensation plan, which is
	the ImmunoGen,&nbsp;Inc. 2006 Employee, Director and Consultant Equity Incentive Plan, or the 2006 Plan. The 2006 Plan was approved by the Company's Board of Directors and the shareholders of the
	Company on November&nbsp;14, 2006 and replaced the previous stock option plan, the ImmunoGen,&nbsp;Inc. Restated Stock Option Plan, as amended, or the Former Plan. At the annual meeting of
	shareholders on November&nbsp;12, 2008, an amendment to the 2006 Plan was approved and an additional 2,000,000 shares were authorized for issuance under this plan. As amended, the 2006 Plan provides
	for the issuance of Stock Grants, the grant of Options and the grant of Stock-Based Awards for up to 4,500,000 shares of the Company's common stock, as well as any shares of common stock that are
	represented by awards granted under the Former Plan that are forfeited, expire or are cancelled without delivery of shares of common stock or which result in the forfeiture of shares of common stock
	back to the Company on or after November&nbsp;13, 2006, or the equivalent of such number of shares after the Administrator, in its sole discretion, has interpreted the effect of any stock split,
	stock dividend, combination, recapitalization or similar transaction in accordance with the 2006 Plan; provided, however, that no more than 5,900,000 shares shall be added to the Plan from the Former
	Plan, pursuant to this provision. Option awards are granted with an exercise price equal to the market price of the Company's stock at the date of grant. Options vest at various periods of up to four
	years and may be exercised within ten years of the date of grant.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model with the assumptions noted in the following table. As the Company has
	not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. Expected volatility is based exclusively on
	historical volatility data of the Company's stock. The expected term of stock options granted is based exclusively on historical data and represents the period of time that stock options granted are
	expected to be outstanding. The expected term is calculated for and applied to one group of stock options as the Company does not expect substantially different exercise or post-vesting
	termination behavior amongst
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	75
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=75,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=838602,FOLIO='75',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_76">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	its
	employee population. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options.
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="253" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="18" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="20" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="18" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="20" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="18" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="20" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Dividend
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	None
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	None
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	None
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Volatility
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63.11
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	66.60
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	73.42
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Risk-free interest rate
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.40
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.72
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expected life (years)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.9
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Using
	the Black-Scholes option-pricing model, the weighted average grant date fair values of options granted during fiscal 2009, 2008 and 2007 were $2.73, $2.38, and $3.99 per share,
	respectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	summary of option activity under the Plan as of June&nbsp;30, 2009, and changes during the twelve month period then ended is presented below (in thousands, except weighted-average
	data):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="185" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="31" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="31" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number of
<BR>
	Stock
<BR>
	Options
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Weighted-
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Weighted-
<BR>
	Average
<BR>
	Remaining
<BR>
	Life in Yrs
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Aggregate
<BR>
	Intrinsic
<BR>
	Value
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Outstanding at June&nbsp;30, 2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,678
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.28
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Granted
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	505
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.31
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Exercised
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(416
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.16
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Forfeited/Canceled
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(238
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.74
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Outstanding at June&nbsp;30, 2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,529
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.36
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	19,246
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Outstanding at June&nbsp;30, 2009&#151;vested or unvested and expected to vest
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.59
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.85
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17,040
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Exercisable at June&nbsp;30, 2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,906
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9.00
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.05
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,075
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of June&nbsp;30, 2009, the estimated fair value of unvested employee awards was $3.2&nbsp;million, net of estimated forfeitures. The weighted-average remaining vesting period for
	these awards is approximately two and one-half years.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	summary of option activity for shares vested during the fiscal years ended June&nbsp;30, 2009, 2008 and 2007 is presented below (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="259" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total fair value of shares vested
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,838
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,817
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,406
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total intrinsic value of options exercised
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	920
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,749
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,053
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash received for exercise of stock options
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,314
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,093
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,150
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
	the years ended June&nbsp;30, 2009 and 2007, the Company recorded approximately $843,000 and $80,000, respectively of stock-based compensation expense related to the
	modification of certain outstanding common stock options. During the year ended June&nbsp;30, 2009, certain options previously
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	76
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=76,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=474804,FOLIO='76',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_77">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	B.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	granted
	to the former Chief Executive Officer of the Company were modified in accordance with the succession plan approved by the Company's Board of Directors in September 2008. No similar charges
	were recorded during the year ended June&nbsp;30, 2008.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Comprehensive Loss
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company presents comprehensive loss in accordance with FASB Statement No.&nbsp;130,
</FONT>
<FONT SIZE=2>
<I>
	Reporting
	Comprehensive Income.
</I>
</FONT>
<FONT SIZE=2>
	Comprehensive loss is comprised of the Company's net loss for the period and unrealized gains and losses recognized on
	available-for-sale marketable securities.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Segment Information
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the three fiscal years ended June&nbsp;30, 2009, the Company continued to operate in one reportable business segment under the
	management approach of FASB Statement No.&nbsp;131,
</FONT>
<FONT SIZE=2>
<I>
	Disclosures about Segments of an Enterprise and Related Information
</I>
</FONT>
<FONT SIZE=2>
	, which is the business of
	discovery of monoclonal antibody-based anticancer therapeutics.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	percentages of revenues recognized from significant customers of the Company in the years ended June&nbsp;30, 2009, 2008 and 2007 are included in the following table:
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="283" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="16" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="16" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="16" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:78PT;">
<FONT SIZE=1>
<B>
	Collaborative Partner:
<!-- COMMAND=ADD_SCROPPEDRULE,78PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	sanofi-aventis
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	45%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	64%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Genentech
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	34%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Biotest
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	were no other customers of the Company with significant revenues in the years ended June&nbsp;30, 2009, 2008 and 2007.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Recent Accounting Pronouncements
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2008, the FASB issued Statement No.&nbsp;161,
</FONT>
<FONT SIZE=2>
<I>
	Disclosures about Derivative Instruments and Hedging
	Activities
</I>
</FONT>
<FONT SIZE=2>
	, or Statement 161, which is effective for fiscal years beginning after November&nbsp;15, 2008 (our fiscal year 2010). Statement 161 requires enhanced disclosures
	about an entity's derivative and hedging activities and thereby improves the transparency of financial reporting. The Company does not believe the adoption of Statement 161 will have a material impact
	on its financial statements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	December 2007, the FASB ratified EITF Issue No.&nbsp;07-1,
</FONT>
<FONT SIZE=2>
<I>
	Accounting for Collaborative Arrangements
</I>
</FONT>
<FONT SIZE=2>
	, or
	EITF&nbsp;07-1, which is effective for fiscal years beginning after December&nbsp;15, 2008 (the Company's fiscal year 2010). EITF&nbsp;07-1 defines collaborative
	arrangements and establishes reporting requirements for transactions between participants in a collaborative arrangement and between participants in the arrangement and third parties.
	EITF&nbsp;07-1 also establishes the appropriate income statement presentation and classification for joint operating activities and payments between participants, as well as the
	sufficiency of the disclosures related to these arrangements. The Company does not believe the adoption of EITF&nbsp;07-1 will have a material impact on its results of operations or
	financial position.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	77
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=77,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=960092,FOLIO='77',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_78">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	C.&nbsp;&nbsp;&nbsp;&nbsp;Agreements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Significant Collaborative Agreements
</I>
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	sanofi-aventis
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2003, the Company entered into a broad collaboration agreement with sanofi-aventis to discover, develop and commercialize
	antibody-based anticancer therapeutics.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	agreement provides sanofi-aventis with worldwide commercialization rights to new anticancer therapeutics developed to targets that were included in the collaboration, including the
	right to use the Company's TAP technology and humanization technology in the creation of therapeutics to these targets. The product candidates (targets) as of June&nbsp;30, 2009 in the collaboration
	include SAR3419 (CD19), SAR566658 (CA6), SAR650984 (CD38) and additional compounds at earlier stages of development that have yet to be disclosed. During fiscal 2009, sanofi-aventis discontinued
	clinical trial activity for two product candidates previously included in the collaboration, AVE9633 (CD33) and AVE1642 (IGF-1R).
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	collaboration agreement entitles the Company to receive milestone payments potentially totaling $21.5&nbsp;million, per antigen target for each therapeutic developed under the
	collaboration agreement. The Company has earned a $500,000 payment in September 2004 for a preclinical milestone related to SAR3419, a $1&nbsp;million milestone payment in October 2007 with the
	start of clinical testing of SAR3419, a $500,000 payment in December 2007 for a preclinical milestone related to SAR650984 and a $500,000 payment in March 2008 for a preclinical milestone related to
	SAR566658. The Company also earned an aggregate of $8&nbsp;million of milestone payments related to two product candidates that previously had been in the collaboration, AVE9633 and AVE1642. Rights
	to these two product candidates and their respective targets have been returned to us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	agreement also entitles the Company to royalties on the commercial sales of any resulting products if and when such sales commence. Sanofi-aventis is responsible for the cost of the
	development, manufacturing and marketing of any products created through the collaboration. The Company is reimbursed for any preclinical and clinical materials that it makes under the agreement. The
	collaboration agreement also provides the Company an option to certain co-promotion rights in the U.S. on a product-by-product basis. The terms of the collaboration
	agreement allow sanofi-aventis to terminate the Company's co-promotion rights if there is a change of control of the company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	overall term of the agreement extends to the later of the latest patent to expire or twelve years after the latest launch of any product discovered, developed and/or commercialized
	under the agreement. Sanofi-aventis paid the Company an upfront fee of $12&nbsp;million in August 2003. Inclusive of its extensions, the agreement entitled the Company to receive committed research
	funding totaling $79.3&nbsp;million over the five years of the research collaboration. The two companies subsequently agreed to extend the date of research funding through October&nbsp;31, 2008 to
	enable completion of previously agreed-upon research. The Company recorded the research funding as it was earned based upon its actual resources utilized in the collaboration. The Company
	earned $81.5&nbsp;million of committed funding over the duration of the research program, of which $2.7&nbsp;million, $10.8&nbsp;million and $18.9&nbsp;million was recognized during fiscal
	years 2009, 2008 and 2007, respectively. The Company is now compensated for research performed for sanofi-aventis on a mutually agreed-upon basis.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	78
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=78,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=73634,FOLIO='78',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_79">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	C.&nbsp;&nbsp;&nbsp;&nbsp;Agreements (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	October 2006, sanofi-aventis licensed non-exclusive rights to use the Company's proprietary resurfacing technology to humanize antibodies to targets not included in the
	collaboration, including antibodies for non-cancer applications. This license provides sanofi-aventis with the non-exclusive right to use the Company's proprietary humanization
	technology through August&nbsp;31, 2011 with the right to extend for one or more additional periods of three years each by providing the Company with written notice prior to expiration of the
	then-current license term. Under the terms of the license, the Company is entitled to a $1&nbsp;million license fee, half of which was paid upon contract signing and the second half was
	paid in August 2008, and in addition, the Company is entitled to receive milestone payments potentially totaling $4.5&nbsp;million for each antibody humanized under this agreement and also royalties
	on commercial sales, if any.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	August 2008, sanofi-aventis exercised its option under a 2006 agreement for expanded access to ImmunoGen's TAP technology. The exercise of this option enables sanofi-aventis to
	evaluate, with certain restrictions, the Company's maytansinoid TAP technology with antibodies to targets that were not included in the existing research collaboration between the companies and to
	license the exclusive right to use the technology to develop products to specific targets on the terms in the 2006 agreement. ImmunoGen is entitled to earn upfront and milestone payments potentially
	totaling $32&nbsp;million per target for each compound developed under the 2006 agreement, as well as royalties on the commercial sales of any resulting products. ImmunoGen also is entitled to
	manufacturing payments for any materials made on behalf of sanofi-aventis. The Company received $3.5&nbsp;million with the exercise of this option in August 2008, in addition to the $500,000
	ImmunoGen received in December 2006 with the signing of the option agreement. The agreement has a three-year term from the date of the exercise of the option and can be renewed by
	sanofi-aventis for one additional three-year term by payment of a $2&nbsp;million fee.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Genentech
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2000, the Company entered into two separate agreements with Genentech. The first agreement grants Genentech an exclusive license
	to the Company's maytansinoid TAP technology for use with antibodies, such as trastuzumab, that target HER2. Under the terms of this agreement, Genentech has exclusive worldwide rights to develop and
	commercialize maytansinoid TAP compounds with antibodies that target HER2. Genentech is responsible for the manufacturing, product development and marketing of any products resulting from the
	agreement. The Company received a $2&nbsp;million non-refundable payment from Genentech upon execution of the agreement. The Company is also entitled to up to $44&nbsp;million in
	milestone payments from Genentech under this agreement, as amended in May 2006, in addition to royalties on the net sales of any resulting products. Genentech began Phase&nbsp;II evaluation of
	T-DM1 in July 2007 and the Company earned a $5&nbsp;million milestone payment with this event, which is included in license and milestone fees for the fiscal year ended June&nbsp;30,
	2008. Genentech and Roche began Phase&nbsp;III evaluation of T-DM1 in February 2009 and the company earned a $6.5&nbsp;million milestone payment with this event. This milestone is
	included in license and milestone fees for the fiscal year ended June&nbsp;30, 2009. Through June&nbsp;30, 2009, the Company has received $13.5&nbsp;million in milestone payments.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	May 2000 the Company also entered into a "right-to-test" agreement with Genentech. This agreement provided Genentech with the right to test the Company's
	maytansinoid TAP technology with
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	79
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=79,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=757321,FOLIO='79',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_80">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	C.&nbsp;&nbsp;&nbsp;&nbsp;Agreements (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Genentech
	antibodies to a defined number of targets on an exclusive basis for specified option periods and to take exclusive licenses for individual targets on agreed-upon terms to use the
	Company's maytansinoid TAP technology to develop products. The Company received a non-refundable technology access fee of $3&nbsp;million when the Company entered into this
	five-year agreement in May 2000, and an additional technology access fee of $2&nbsp;million when Genentech renewed this agreement in April 2005 for the one additional
	three-year period allowed. The upfront fees were deferred and recognized ratably over the period during which Genentech could elect to obtain product licenses. Genentech no longer has the
	right to designate new targets under this "right-to-test" agreement, although there are options with respect to previously designated targets that remain in effect for the
	remainder of the respective option periods, which will expire during 2009.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	this agreement, in December 2008, December 2005, July 2005 and April 2005, Genentech licensed exclusive rights to use the Company's maytansinoid TAP technology with antibodies to
	four undisclosed targets. Under the terms defined in the 2000 "right-to-test" agreement, for each license the Company received a $1&nbsp;million license fee and may receive
	up to $38&nbsp;million in milestone payments. The Company is also entitled to receive royalties on the sales of any resulting products. Genentech is responsible for the development, manufacturing,
	and marketing of any products resulting from these licenses.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Biotest
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2006, the Company entered into a development and license agreement with Biotest AG. The agreement grants Biotest exclusive
	rights to use our maytansinoid TAP technology to develop and commercialize therapeutic compounds to the target CD138. The Company received a $1&nbsp;million upfront payment upon execution of the
	agreement and could potentially receive up to $35.5&nbsp;million in milestone payments, as well as royalties on the sales of any resulting products. The Company receives payments for manufacturing
	any preclinical and clinical materials made at the request of Biotest. In September 2008, Biotest began Phase&nbsp;I evaluation of BT062 which triggered a $500,000 milestone payment to the Company.
	This milestone is included in license and milestone fees for the fiscal year ended June&nbsp;30, 2009.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	agreement also provides the Company with the right to elect at specific stages during the clinical evaluation of any compound created under this agreement, to participate in the U.S.
	development and commercialization of that compound in lieu of receiving royalties on U.S. sales of that product and the milestone payments not yet earned. The Company can exercise this right by making
	a payment to
	Biotest of an agreed-upon fee of $5&nbsp;million or $15&nbsp;million, depending on the stage of development. Upon exercise of this right, the Company would share equally with Biotest
	the associated costs of product development and commercialization in the U.S. along with the profit, if any, from U.S. product sales.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Bayer HealthCare
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2008, the Company entered into a development and license agreement with Bayer HealthCare AG. The agreement grants Bayer
	HealthCare exclusive rights to use the Company's maytansinoid TAP technology to develop and commercialize therapeutic compounds to a specific target. Bayer HealthCare is responsible for the research,
	development, manufacturing and marketing of any
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	80
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=80,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=865564,FOLIO='80',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_81">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	C.&nbsp;&nbsp;&nbsp;&nbsp;Agreements (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	products
	resulting from the license. The Company received a $4&nbsp;million upfront payment upon execution of the agreement, and&#151;for each compound developed and marketed by Bayer
	HealthCare under this collaboration&#151;the Company could potentially receive up to $170.5&nbsp;million in milestone payments; additionally, the Company is entitled to receive royalties on
	the sales of any resulting products. The Company will be compensated by Bayer HealthCare at a stipulated rate for work performed on behalf of Bayer HealthCare under a mutually agreed-upon
	research plan and budget which may be amended from time to time during the term of the agreement. The Company also is entitled to receive payments for manufacturing any preclinical and clinical
	materials at the request of Bayer HealthCare as well as for any related process development activities. The Company has deferred the $4&nbsp;million upfront payment and is recognizing this amount as
	revenue ratably over the estimated period of substantial involvement.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Other Collaborative Agreements
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2008, the Company received notice of Millennium Pharmaceuticals&nbsp;Inc.'s election to terminate its exclusive license to
	the Company's TAP technology to develop and commercialize antibody-based cytotoxic products directed to the prostate specific membrane antigen (PSMA) target. This license was granted pursuant to the
	Access, Option and License Agreement between the Company and Millennium dated March&nbsp;30, 2001. As a result of the termination, the Company recognized the remaining $361,000 of the
	$1&nbsp;million upfront fee received from Millennium upon execution of the license which had been previously deferred, and is included in license and milestone fees for the fiscal year ended
	June&nbsp;30, 2009.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	August 2008, the Company received notice of Boehringer Ingelheim's election to terminate its exclusive license to use the Company's technology to develop and commercialize TAP
	compounds to CD44 or the alternative target selected. This license was granted pursuant to the Development and License Agreement between the Company and Boehringer Ingelheim dated November&nbsp;27,
	2001. As a result of the termination, the Company recognized the remaining $486,000 of the $1&nbsp;million upfront fee received from Boehringer Ingelheim upon execution of the license agreement
	which had been previously deferred, and is included in license and milestone fees for the fiscal year ended June&nbsp;30, 2009.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Other Agreements
</I>
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Cytovance Biologics
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2007, the Company entered into an agreement with Cytovance Biologics&nbsp;LLC., or Cytovance, to develop a process for
	production of our huN901 antibody in accordance with current Good Manufacturing Practices, or cGMP, for potential use in IMGN901 clinical materials for pivotal trials and commercial applications.
	Under the terms of the agreement, the Company pays Cytovance incremental amounts for each step in the development process. During the fiscal years ended June&nbsp;30, 2009 and 2008, the Company
	incurred $13,000 and $1.7&nbsp;million in antibody-related expenses under the supply agreement.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	81
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=12,SEQ=81,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=837434,FOLIO='81',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_82">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	C.&nbsp;&nbsp;&nbsp;&nbsp;Agreements (Continued)
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Laureate Pharma
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2005, the Company entered into an antibody supply agreement with Laureate Pharma,&nbsp;Inc., or Laureate. Under the terms
	of the agreement, Laureate agreed to perform process qualification and manufacture one of the Company's antibodies pursuant to cGMP regulations. Under the terms of the agreement, the Company agreed to
	pay a stated price per manufactured batch of antibody, subject to adjustment as set forth in the agreement. In January 2007,
	the agreement was amended to provide additional quantities of the monoclonal antibody at a stated price per manufactured batch of antibody. In October 2007, the Company entered into an additional
	agreement with Laureate to develop a process for cGMP production of the Company's huC242 antibody for potential use in IMGN242 clinical materials for pivotal trials and commercial applications. Under
	the terms of the agreements, the Company pays Laureate incremental amounts for each step in the development process. During the fiscal years ended June&nbsp;30, 2009, 2008 and 2007, the Company
	recorded $395,000, $5.5&nbsp;million and $1.5&nbsp;million, respectively, in antibody-related expenses under these agreements.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	BioInvent International
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2006, the Company entered into a supply agreement with BioInvent International AB to produce quantities of a monoclonal
	antibody that is a component of one of the Company's internal products pursuant to cGMP regulations. Under the terms of the agreement, the Company agreed to pay a stated price per manufactured batch
	of antibody, subject to adjustment as set forth in the agreement. During the fiscal year ended June&nbsp;30, 2007, the Company recorded $1.3&nbsp;million in antibody-related expenses under the
	supply agreement. No expenses were incurred in the fiscal years ended June&nbsp;30, 2009 and 2008.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Diosynth RTP
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2005, the Company entered into a bioprocessing services agreement with Diosynth RTP,&nbsp;Inc., or Diosynth. Under the
	terms of the agreement, Diosynth agreed to perform technology transfer, process development and scale-up of the antibody component of one of the Company's product candidates pursuant to
	cGMP regulations. Under the terms of the agreement, the Company agreed to pay Diosynth a stated price for the technology transfer and process development. During the fiscal year ended June&nbsp;30,
	2007, the Company recorded $3.3&nbsp;million in antibody-related expenses under the agreement. No expenses were incurred in the fiscal years ended June&nbsp;30, 2009 and 2008.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Societ&agrave; Italiana Corticosteroidi S.r.l (SICOR)
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective November 2004, the Company entered into a technology transfer and development agreement with SICOR. Under the terms of the
	agreement, SICOR agreed to perform a feasibility study and full process development work to produce DM1, a component of the Company's TAP products. Under the terms of the agreement, the Company agreed
	to pay SICOR a stated price for work performed based on achievement of certain milestone events. In June 2006, the Company amended the 2004 technology transfer and development agreement with SICOR.
	Under the terms of the amendment, SICOR also provides preparatory activities in order to scale-up the production of ansamitocin P3, a precursor to DM1 and DM4, collectively DMx, in
	anticipation of large-scale
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	82
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=13,SEQ=82,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=883818,FOLIO='82',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_83">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	C.&nbsp;&nbsp;&nbsp;&nbsp;Agreements (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	production
	of ansamitocin P3 to be used in TAP compounds for later-stage clinical trials and commercialization. During the fiscal years ended June&nbsp;30, 2009, 2008 and 2007, the Company recorded
	$611,000, $1&nbsp;million and $2.4&nbsp;million, respectively, in expenses under the agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	April 2007, the Company entered into a manufacturing agreement with SICOR. Under the terms of the agreement, SICOR agreed to produce a certain number of cGMP-compliant
	batches of DMx for use in the production of TAP compounds. Under the terms of the agreement, the Company agreed to pay SICOR five million Euros for these cGMP-compliant batches of DMx
	through completion of the contract in early calendar 2008. Pursuant to a letter agreement, the Company received additional quantities of DM4 from Sicor during fiscal 2009. The Company and Sicor are
	currently negotiating terms and conditions of a Clinical Supply Agreement, pursuant to which Sicor will manufacture and supply DMx based on purchase orders placed by the Company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	D.&nbsp;&nbsp;&nbsp;&nbsp;Marketable Securities
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2009, $71.1&nbsp;million in cash and money market funds were classified as cash and cash equivalents. The Company's cash, cash equivalents and marketable
	securities as of June&nbsp;30, 2009 are as follows (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="161" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Amortized
<BR>
	Cost
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Gross
<BR>
	Unrealized
<BR>
	Gains
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Gross
<BR>
	Unrealized
<BR>
	Losses
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Estimated
<BR>
	Fair Value
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and money market funds
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69,639
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69,639
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Asset-backed securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Current
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	395
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(25
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	395
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Non-current
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,024
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	201
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(410
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	815
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Corporate notes
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Current
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	250
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	250
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Non-current
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	71,333
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	227
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(435
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	71,125
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Less amounts classified as cash and cash equivalents
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(69,639
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(69,639
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,694
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	227
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(435
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,486
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	83
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=14,SEQ=83,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=715031,FOLIO='83',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FO49301_1_84">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	D.&nbsp;&nbsp;&nbsp;&nbsp;Marketable Securities (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of June&nbsp;30, 2008, $31.6&nbsp;million in cash and money market funds were classified as cash and cash equivalents. The Company's cash, cash equivalents and marketable
	securities as of June&nbsp;30, 2008 are as follows (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="201" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="34" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Amortized
<BR>
	Cost
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Gross
<BR>
	Unrealized
<BR>
	Gains
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Gross
<BR>
	Unrealized
<BR>
	Losses
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Estimated
<BR>
	Fair Value
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and money market funds
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31,619
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31,619
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Money market fund reclassified to marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,193
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,193
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Asset-backed securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Current
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,070
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(147
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,930
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Non-current
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,558
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,563
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Corporate notes
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Current
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,570
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,566
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48,010
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(169
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	47,871
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Less amounts classified as cash and cash equivalents
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(31,619
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(31,619
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total marketable securities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16,391
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(169
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16,252
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	2009, the Company realized losses of $33,000 and realized zero gains. In 2008, the Company realized losses of $42,000 and realized gains of $3,000. In 2007, the Company realized
	losses of $19,000 and realized gains of $18,000.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of June&nbsp;30, 2009, the Company had 19 individual securities in its investment portfolio, of which seven were in an unrealized loss position. The aggregate fair value of
	investments with unrealized losses was approximately $705,000 as of June&nbsp;30, 2009, of which $332,000 had been in an unrealized loss position for more than a year, as of June&nbsp;30, 2009.
	All such other investments as of June&nbsp;30, 2009 have been or were in an unrealized loss position for less than a year. As of June&nbsp;30, 2008, the Company had 47 individual securities in its
	investment portfolio, of which 19 were in an unrealized loss position. The aggregate fair value of investments with unrealized losses was approximately $4.4&nbsp;million, of which
	$3.5&nbsp;million had been in an unrealized loss position for more than one year, as of June&nbsp;30, 2008. See Note&nbsp;B
</FONT>
<FONT SIZE=2>
<I>
	Other-than-Temporary
	Impairments.
</I>
</FONT>
<FONT SIZE=2>
	The Company reviewed its investments with unrealized losses and as a result recorded $516,000 and $535,000, respectively, as an
	other-than-temporary impairment charge during the years ended June&nbsp;30, 2009 and 2008. No similar charges were incurred during the fiscal year ended June&nbsp;30, 2007.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	84
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=15,SEQ=84,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=629551,FOLIO='84',FILE='DISK104:[09ZCX1.09ZCX49301]FO49301A.;9',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FQ49301_1_85">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	E.&nbsp;&nbsp;&nbsp;&nbsp;Property and Equipment
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment consisted of the following at June&nbsp;30, 2009 and 2008 (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="321" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Leasehold improvements
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25,189
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	23,760
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Machinery and equipment
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,910
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,418
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Computer hardware and software
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,635
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	949
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Furniture and fixtures
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,361
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,297
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Assets under construction
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	766
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,882
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	40,861
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	39,306
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Less accumulated depreciation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(21,190
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(16,555
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Property and equipment, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	19,671
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22,751
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
	the fiscal year ended June&nbsp;30, 2008, the Company added $3.7&nbsp;million in improvements to its capabilities at its manufacturing plant in Norwood, MA and
	$12.0&nbsp;million to build out the laboratory and office space at the Waltham, MA facility occupied by ImmunoGen in late March 2008. The $12.0&nbsp;million of leasehold improvements was paid by
	the landlord of the Waltham, MA facility. Depreciation expense was approximately $5.0&nbsp;million, $4.4&nbsp;million and $3.2&nbsp;million for the years ended June&nbsp;30, 2009, 2008 and
	2007, respectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The difference between the Company's expected tax benefit, as computed by applying the U.S. federal corporate tax rate of 34% to loss before the provision for income taxes, and actual
	tax is reconciled in the following chart (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="272" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss before income tax expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(32,037
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(31,993
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(18,952
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expected tax benefit at 34%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,893
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,888
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(6,444
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	State tax benefit net of federal benefit
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(677
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(394
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(718
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Increase in valuation allowance, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,531
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,538
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,518
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expired loss and credit carryforwards
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,924
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,235
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,703
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	536
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(24
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Provision for income taxes
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(100
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	June&nbsp;30, 2009, the Company has net operating loss carryforwards of approximately $205.3&nbsp;million available to reduce federal taxable income, if any, that expire in 2010
	through 2029 and $113.4&nbsp;million available to reduce state taxable Income, if any, that expire in fiscal 2010 through fiscal 2014. A portion of such carryforwards related to the exercise of
	stock options and the related tax benefit will result in an increase in additional paid-in capital if and when realized. The Company also has federal and state research tax credits of
	approximately $9.4&nbsp;million available to offset federal and state income taxes, which expire beginning in fiscal 2010. Due to the degree of uncertainty related to
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	85
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=85,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=234604,FOLIO='85',FILE='DISK104:[09ZCX1.09ZCX49301]FQ49301A.;8',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FQ49301_1_86">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the
	ultimate use of the loss carryforwards and tax credits, the Company has established a valuation allowance to fully reserve these tax benefits.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
	income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used
	for income tax
	purposes. Significant components of the Company's deferred tax assets as of June&nbsp;30, 2009 and 2008 are as follows (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="321" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="33" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	June&nbsp;30,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net operating loss carryforwards
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74,626
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	75,504
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development tax credit carryforwards
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,081
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,625
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Property and other intangible assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(745
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2,067
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,005
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,167
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock-based compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	879
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	590
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred lease incentive
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,132
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,424
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other liabilities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,148
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,318
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total deferred tax assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	94,126
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	92,561
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Valuation allowance
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(94,126
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(92,561
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net deferred tax assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	valuation allowance increased by $1.6&nbsp;million during 2009 due primarily to deferred revenue and depreciation timing differences, partially offset by the expiration of research
	and development credits.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company adopted the provisions of FASB Financial Interpretation No.&nbsp;48,
</FONT>
<FONT SIZE=2>
<I>
	Accounting for Uncertainty in Income Taxes
</I>
</FONT>
<FONT SIZE=2>
	, or
	FIN&nbsp;48, an interpretation of FASB Statement No.&nbsp;109, or Statement 109, on July&nbsp;1, 2007. The adoption of FIN&nbsp;48 did not impact the Company's financial condition, results of
	operations or cash flows for the years ended June&nbsp;30, 2009 and 2008. Utilization of the NOL and R&amp;D credit carryforwards may be subject to a substantial annual limitation due to ownership
	change limitations that have occurred previously or that could occur in the future as provided by Section&nbsp;382 of the Internal Revenue Code of 1986, as well as similar state and foreign
	provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carry forwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an
	ownership change, as defined by Section&nbsp;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than
	50&nbsp;percentage points over a three-year period. Since the Company's formation, it has raised capital through the issuance of capital stock on several occasions (both pre and post
	initial public offering) which, combined with the purchasing shareholders' subsequent disposition of those shares, may have resulted in a change of control, as defined by Section&nbsp;382, or could
	result in a change of control in the future upon subsequent disposition. The Company has not currently completed a study to assess whether a change of control has occurred or whether there have been
	multiple changes of control since its formation due to the significant complexity and cost associated with such study and the possibility that there could be additional changes in control in the
	future. If the Company has experienced a change of control at any time since
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	86
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=86,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=252692,FOLIO='86',FILE='DISK104:[09ZCX1.09ZCX49301]FQ49301A.;8',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FQ49301_1_87">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	its
	formation, utilization of its NOL or R&amp;D credit carry forwards would be subject to an annual limitation under Section&nbsp;382 which is determined by first multiplying the value of the Company's
	stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may
	result in expiration of a portion of the NOL or R&amp;D credit carry forwards before utilization. Further, until a study is completed and any limitation known, no amounts are being presented as an
	uncertain tax position under FIN&nbsp;48. The Company does not expect to have any taxable income for at least the next several years.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company did not recognize any interest and penalties associated with unrecognized tax benefits in the accompanying consolidated financial statements. The Company does not expect any
	material changes to the unrecognized benefits within 12&nbsp;months of the reporting date. Due to existence of the valuation allowance, future changes in our unrecognized tax benefits will not
	impact our effective tax rate. The Company's loss carry forwards are subject to adjustment by state and federal taxing authorities, commencing when those losses are utilized to reduce taxable income.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	G.&nbsp;&nbsp;&nbsp;&nbsp;Capital Stock
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Sale of Common Stock
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;11, 2007, the Company filed a Registration Statement on Form&nbsp;S-3 with the Securities and Exchange
	Commission. The Securities and Exchange Commission declared the Registration Statement effective on August&nbsp;13, 2007. Subject to our ongoing obligations under the Securities Act of 1933, as
	amended, and the Securities Exchange Act of 1934, as amended, the Registration Statement permits the Company to offer and sell up to an aggregate of $75&nbsp;million of our common stock. Pursuant to
	the shelf registration statement, in June 2009, the Company issued and sold 5,750,000 shares of our common stock at $7.00 per share through a public offering resulting in gross proceeds of
	$40.3&nbsp;million, and in June 2008, a private investor purchased 7,812,500 shares of our common stock at $3.20 per share resulting in gross proceeds of $25&nbsp;million.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Common Stock Reserved
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At June&nbsp;30, 2009, the Company has reserved 8.263&nbsp;million shares of authorized common stock for the future issuance of
	shares under the 2006 Plan. See "Stock-Based Compensation" in Note&nbsp;B for a description of the 2006 Plan and the Former Plan.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Stock Options
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2009, the 2006 Plan was the only employee share-based compensation plan of the Company. During the year ended
	June&nbsp;30, 2009, holders of options issued under the 2006 Plan and the Former Plan exercised their rights to acquire an aggregate of 415,891 shares of common stock at prices ranging from $1.38 to
	$6.78 per share. The total proceeds to the Company from these option exercises were approximately $1.3&nbsp;million.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	87
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=87,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=841611,FOLIO='87',FILE='DISK104:[09ZCX1.09ZCX49301]FQ49301A.;8',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FQ49301_1_88">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	G.&nbsp;&nbsp;&nbsp;&nbsp;Capital Stock (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company has granted options at the fair market value of the common stock on the date of such grant. The following options and their respective weighted-average exercise prices per
	share were exercisable at June&nbsp;30, 2009, 2008 and 2007:
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="252" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="48" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="46" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exercisable
<BR>
	(in thousands)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Weighted-
<BR>
	Average
<BR>
	Exercise Price
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	June&nbsp;30, 2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,906
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9.00
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	June&nbsp;30, 2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,430
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.57
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	June&nbsp;30, 2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,623
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.33
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	2001 Non-Employee Director Stock Plan
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2001, the Company's shareholders approved the establishment of the 2001 Non-Employee Director Stock Plan, or
	the 2001 Director Plan, and 50,000 shares of common stock to be reserved for grant thereunder. The 2001 Director Plan provided for the granting of awards to Non-Employee Directors and, at
	the election of Non-Employee Directors, to have all or a portion of their awards in the form of cash, stock, or stock units. All stock or stock units are immediately vested. The number of
	stock or stock units to be issued is determined by the market value of the Company's common stock on the last date of the Company's fiscal quarter for which the services are rendered. The 2001
	Director Plan was administered by the Board of Directors which was authorized to interpret the provisions of the 2001 Director Plan, determine which Non-Employee Directors would be granted
	awards, and determine the number of shares of stock for which a stock right will be granted. The 2001 Director Plan was replaced in 2004 by the 2004 Non-Employee Director Compensation and
	Deferred Share Unit Plan.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
	the years ended June&nbsp;30, 2009, 2008 and 2007, the Company recorded approximately $84,000, (38,000), and $49,000 in compensation expense or (expense reduction),
	respectively, related to stock units outstanding under the 2001 Director Plan. The value of the stock units is adjusted to market value at each reporting period. No stock units have been issued under
	the 2001 Plan subsequent to June&nbsp;30, 2004.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to the 2001 Director Plan, during the year ended June&nbsp;30, 2007, the Company paid a retiring director approximately $40,000 to settle outstanding stock units.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	2004 Non-Employee Director Compensation and Deferred Share Unit Plan
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2004, the Board of Directors approved the establishment of the 2004 Non-Employee Director Compensation and Deferred
	Share Unit Plan, or the 2004 Director Plan. The 2004 Director Plan provided for the compensation to Non-Employee Directors, awarding their annual retainers in the form of deferred share
	units, and, at their discretion, to have all or a portion of their other compensation such as meeting fees in the form of cash or deferred share units. The deferred share units for annual retainers
	vested one-twelfth monthly over the next year after the award; other deferred share units vested immediately upon issuance. The number of deferred share units issued was determined by the
	market value of the Company's common stock on the last date of the Company's fiscal year prior to the fiscal year for which services were rendered. The deferred share units were to be
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	88
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=88,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=276661,FOLIO='88',FILE='DISK104:[09ZCX1.09ZCX49301]FQ49301A.;8',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FQ49301_1_89">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	G.&nbsp;&nbsp;&nbsp;&nbsp;Capital Stock (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	paid
	out in cash to each non-employee director based upon the market value of the Company's common stock on the date of such director's retirement from the Board of Directors of the
	Company. The 2004 Director Plan was administered by the Board of Directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to the 2004 Director Plan, during the year ended June&nbsp;30, 2007, the Company paid a retiring director approximately $41,000 to settle outstanding deferred share units.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	2004 Director Plan was amended on September&nbsp;5, 2006. Under the terms of the amended 2004 Director Plan, the redemption amount of deferred share units will be paid in shares of
	common stock of the Company under the 2006 Plan in lieu of cash. As a result of the change in payout structure, the value of the vested awards was transferred to additional paid-in capital
	as of the modification date and the total value of the awards, as calculated on the modification date, was expensed over the remainder of the vesting period. Accordingly, the value of the share units
	is fixed and will no longer be adjusted to market value at each reporting period. In addition, the amended 2004 Director Plan changed the vesting for annual retainers to take place quarterly over the
	three years after the award and the number of deferred share units awarded for all compensation is now based on the market value of the Company's common stock on the date of the award.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to the 2004 Director Plan, as amended, the Company recorded approximately $175,000 in compensation expense during the year ended June&nbsp;30, 2009 related to the issuance of
	54,000 deferred share units and 183,000 deferred share units previously issued under the 2004 Director Plan. The Company recorded approximately $92,000 in compensation expense during the year ended
	June&nbsp;30, 2008 related to the issuance of 49,000 deferred share units and 108,000 deferred share units previously issued under the 2004 Director Plan. The Company recorded approximately $210,000
	in compensation expense during the year ended June&nbsp;30, 2007 related to the issuance of 76,000 deferred share units and 32,000 deferred share units previously issued under the 2004 Director
	Plan.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	H.&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Leases
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective July&nbsp;27, 2007, the Company entered into a lease agreement with Intercontinental Fund&nbsp;III for the rental of
	approximately 89,000 square feet of laboratory and office space at 830 Winter Street, Waltham, MA. The Company uses this space for its corporate headquarters and other operations. The initial term of
	the lease is for twelve years with an option for the Company to extend the lease for two additional terms of five years. The Company is required to pay certain operating expenses for the leased
	premises subject to escalation charges for certain expense increases over a base amount.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	part of the lease agreement, the Company received a construction allowance of up to approximately $13.3&nbsp;million to build out laboratory and office space to the Company's
	specifications. The construction allowance is accounted for as a lease incentive pursuant to FASB Statement No.&nbsp;13,
</FONT>
<FONT SIZE=2>
<I>
	Accounting for Leases,
</I>
</FONT>
<FONT SIZE=2>
	and
	FASB Technical Bulletin 88-1,
</FONT>
<FONT SIZE=2>
<I>
	Issues Relating to Accounting for Leases
</I>
</FONT>
<FONT SIZE=2>
	. After completion, the Company had recorded $12.0&nbsp;million of
	leasehold improvements under the construction allowance. The Company received $10.8&nbsp;million from the landlord and paid out the same amount towards these leasehold improvements. The remaining
	balance of the improvements was paid
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	89
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=89,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=179353,FOLIO='89',FILE='DISK104:[09ZCX1.09ZCX49301]FQ49301A.;8',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FQ49301_1_90">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	H.&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	directly
	by the landlord. The lease term began on October&nbsp;1, 2007, when the Company obtained physical control of the space in order to begin construction.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	the terms of the agreement, any remaining construction allowance was to be applied evenly as a credit to rent for the first year. The final balance of the construction allowance
	was determined in August 2008, resulting in a credit of $1.3&nbsp;million to the Company from the landlord during the current fiscal year relating to the first year of occupancy.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	June&nbsp;30, 2009, the Company also leases facilities in Norwood and Cambridge, MA under agreements through 2011. The Company is required to pay certain operating expenses for the
	leased premises subject to escalation charges for certain expense increases over a base amount. The Company entered into a sub-sublease in May 2008 for the entire space in Cambridge, MA
	through October 2010, the remainder of the sublease.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Facilities
	rent expense, net of sublease income, was approximately $5.0&nbsp;million, $5.3&nbsp;million and $3.2&nbsp;million during fiscal years 2009, 2008 and 2007, respectively.
	During fiscal 2008, the Company recorded $1.8&nbsp;million of rent expense related to the Waltham, MA facility for the period prior to occupancy, which has been classified as general and
	administrative expense in the accompanying Consolidated Statement of Operations for the year ended June&nbsp;30, 2008.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	minimum rental commitments, including real estate taxes and other expenses, for the next five fiscal years under the non-cancelable operating lease agreements discussed
	above are as follows (in thousands):
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="333" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="29" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2010
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,320
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2011
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,885
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2012
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,859
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2013
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,859
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2014
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,925
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total minimum lease payments
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26,848
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total minimum rental income from sub-sublease
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,046
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total minimum lease payments, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25,802
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Purchase Obligations
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At June&nbsp;30, 2009, the Company is obligated to a number of vendors for certain contractual services to be performed totaling
	$924,000 in fiscal 2010 and fiscal 2011.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Litigation
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not party to any material litigation.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee Benefit Plans
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has a deferred compensation plan under Section&nbsp;401(k) of the Internal Revenue Code (the 401(k) Plan). Under the 401(k) Plan, eligible employees are permitted to
	contribute, subject
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	90
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=90,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=87974,FOLIO='90',FILE='DISK104:[09ZCX1.09ZCX49301]FQ49301A.;8',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FQ49301_1_91">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee Benefit Plans (Continued)
</B>
</FONT>
</P>
<BR>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	to
	certain limitations, up to 100% of their gross salary. Effective February&nbsp;1, 2008, the Company increased its matching contribution to 50% of the first 6% of the eligible employees'
	contributions, compared to 20% of the first 7% of the eligible employees' contributions previously. In fiscal years 2009, 2008 and 2007, the Company's contributions to the 401(k) Plan totaled
	approximately $429,000, $268,000, and $170,000, respectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	J.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quarterly Financial Information (Unaudited)
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="146" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="65" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="62" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=11 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Fiscal Year 2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	First Quarter
<BR>
	Ended
<BR>
	September&nbsp;30, 2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Second Quarter
<BR>
	Ended
<BR>
	December&nbsp;31, 2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Third Quarter
<BR>
	Ended
<BR>
	March&nbsp;31, 2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Fourth Quarter
<BR>
	Ended
<BR>
	June&nbsp;30, 2009
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=11 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(In thousands, except per share data)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Revenues:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development support
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,207
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,283
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	908
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,168
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	License and milestone fees
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,223
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,766
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,314
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	814
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Clinical materials reimbursement
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	696
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,285
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,320
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total revenues
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,126
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,334
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,226
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,302
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expenses:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,860
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,888
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,493
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,663
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,678
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,521
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,243
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,458
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,538
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16,409
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,736
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,121
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss from operations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(9,412
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(7,075
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,510
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,819
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other income (expense), net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(129
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(100
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss before income tax expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(9,396
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(7,204
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,610
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,827
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Income tax expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(101
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(9,397
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(7,103
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,610
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,827
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Basic and diluted net loss per common share
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.19
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.09
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.21
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	91
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=91,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=248137,FOLIO='91',FILE='DISK104:[09ZCX1.09ZCX49301]FQ49301A.;8',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FQ49301_1_92">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	AS OF JUNE 30, 2009
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	J.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quarterly Financial Information (Unaudited) (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="10" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="146" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="65" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="62" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=11 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Fiscal Year 2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	First Quarter
<BR>
	Ended
<BR>
	September&nbsp;30, 2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Second Quarter
<BR>
	Ended
<BR>
	December&nbsp;31, 2007
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Third Quarter
<BR>
	Ended
<BR>
	March&nbsp;31, 2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Fourth Quarter
<BR>
	Ended
<BR>
	June&nbsp;30, 2008
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=11 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(In thousands except per share data)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Revenues:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development support
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,473
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,672
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,516
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,374
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	License and milestone fees
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,188
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,680
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,228
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,060
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Clinical materials reimbursement
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,764
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,399
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,846
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	49
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total revenues
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,425
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,751
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,590
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,483
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expenses:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,834
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,158
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	23,282
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,739
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,424
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,527
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,675
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,722
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,258
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16,685
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27,957
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16,461
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss from operations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,833
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(6,934
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,367
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(11,978
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other income (expense), net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	813
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	727
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	524
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	55
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss before income tax expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,020
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(6,207
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(12,843
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(11,923
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Income tax expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,032
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(6,212
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(12,848
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(11,928
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=0>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Basic and diluted net loss per common share
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.02
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.30
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.27
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
<TD COLSPAN=2 ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	92
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=92,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=186651,FOLIO='92',FILE='DISK104:[09ZCX1.09ZCX49301]FQ49301A.;8',USER='CDESORM',CD='26-AUG-2009;10:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FS49301_1_93">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
</EFX_FINANCIAL_STATEMENTS>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FS49301_ITEM_9__CHANGES_IN_AND_DISAGRE__ITE03576">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FS49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FS49301_ITEM_9A__CONTROLS_AND_PROCEDURES">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FS49301_2">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;9A.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Controls and Procedures
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosure Controls and Procedures
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's management, with the participation of its principal executive officer and principal financial officer, has evaluated the effectiveness of the
	Company's disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as
	of the end of the period covered by this Annual Report on Form&nbsp;10-K. Based on such evaluation, the Company's principal executive officer and principal financial officer have
	concluded that, as of the end of such period, the Company's disclosure controls and procedures were adequate and effective.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Internal Control Over Financial Reporting
</I>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	(a)&nbsp;&nbsp;&nbsp;Management's Annual Report on Internal Control Over Financial Reporting
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial
	reporting is defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, the Company's principal executive and
	principal financial officers and effected by the Company's board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the
	preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the U.S. and includes those policies and procedures
	that:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and
	dispositions of the assets of the Company;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
	accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the
	Company; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of
	the Company's assets that could have a material effect on the financial statements.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
	of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods
	are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management
	assessed the effectiveness of the Company's internal control over financial reporting as of June&nbsp;30, 2009. In making this assessment, management used the criteria
	established in
</FONT>
<FONT SIZE=2>
<I>
	Internal Control&#151;Integrated Framework
</I>
</FONT>
<FONT SIZE=2>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission, or
	COSO.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
	on this assessment, management has concluded that, as of June&nbsp;30, 2009 the Company's internal control over financial reporting is effective.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp;
	Young&nbsp;LLP, the Company's independent registered public accounting firm, has issued a report on the effectiveness of the Company's internal control over financial
	reporting, as of June&nbsp;30, 2009. This report appears immediately below.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	93
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=93,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=836669,FOLIO='93',FILE='DISK104:[09ZCX1.09ZCX49301]FS49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FS49301_1_94">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	(b)&nbsp;&nbsp;&nbsp;Attestation Report of the Independent Registered Public Accounting Firm
</I>
</FONT>
</P>
</UL>
</EFX_CONTROL_AND_PROCEDURES>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Report of Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	Board of Directors and Shareholders of ImmunoGen,&nbsp;Inc.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have audited ImmunoGen,&nbsp;Inc.'s internal control over financial reporting as of June&nbsp;30, 2009, based on criteria established in Internal Control&#151;Integrated
	Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). ImmunoGen,&nbsp;Inc.'s management is responsible for maintaining effective internal
	control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on the company's internal control
	over financial reporting based on our audit.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
	obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control
	over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and
	performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
	financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures
	that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide
	reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
	expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely
	detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
	of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future
	periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	our opinion, ImmunoGen,&nbsp;Inc. maintained, in all material respects, effective internal control over financial reporting as of June&nbsp;30, 2009 based on the COSO criteria.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of ImmunoGen,&nbsp;Inc. as of
	June&nbsp;30, 2009 and 2008, and the related consolidated statements of operations, stockholders' equity, and cash flows for each of the three years in the period ended June&nbsp;30, 2009 and our
	report dated August&nbsp;28, 2009 expressed an unqualified opinion thereon.
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="241" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="211" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	/s/ E
</FONT>
<FONT SIZE=2>
	RNST
</FONT>
<FONT SIZE=2>
	&nbsp;&amp; Y
</FONT>
<FONT SIZE=2>
	OUNG&nbsp;LLP
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Boston,
	Massachusetts
<BR>
	August&nbsp;28, 2009
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	94
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=94,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=252148,FOLIO='94',FILE='DISK104:[09ZCX1.09ZCX49301]FS49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<A NAME="A2194303Z10-K_HTM_PAGE_FS49301_1_95">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	(c)&nbsp;&nbsp;&nbsp;Changes in Internal Control Over Financial Reporting
</I>
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rules&nbsp;13a-15(f) and
	15d-15(f) under the Exchange Act) during the quarter ended June&nbsp;30, 2009 that have materially affected, or are reasonably likely to materially affect, the Company's internal control
	over financial reporting.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations on the Effectiveness of Controls
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's management, including its principal executive officer and principal financial officer, does not expect that the Company's disclosure controls and
	procedures or its internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not
	absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls
	must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances
	of fraud, if any, within an organization have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of
	simple error or mistake.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
	controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system
	of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all
	potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the
	inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
</FONT>
</P>
</EFX_AUDITORS_OPINION>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FS49301_ITEM_9B__OTHER_INFORMATION">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FS49301_3">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;9B.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Other Information
<BR>
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	95
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=95,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=191015,FOLIO='95',FILE='DISK104:[09ZCX1.09ZCX49301]FS49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FU49301_1_96">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FU49301_PART_III">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FU49301_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
<A NAME="A2194303Z10-K_HTM_PART3">
</A>
	PART III
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information called for by Part&nbsp;III of Form&nbsp;10-K (Item&nbsp;10&#151;Directors, Executive Officers
	and Corporate Governance of the Registrant, Item&nbsp;11&#151;Executive Compensation, Item&nbsp;12&#151;Security Ownership of Certain Beneficial Owners and Management and Related
	Stockholder Matters, Item&nbsp;13&#151;Certain Relationships and Related Transactions, and Director Independence, and Item&nbsp;14&#151;Principal Accounting Fees and Services) is
	incorporated by reference from our proxy statement related to our 2009 annual meeting of shareholders, which will be filed with the Securities and Exchange Commission not later than October&nbsp;28,
	2009 (120&nbsp;days after the end of the fiscal year covered by this Annual Report on Form&nbsp;10-K), except that information required by Item&nbsp;10 concerning our executive
	officers appears in Part&nbsp;I, Item&nbsp;4.1 of this Annual Report on Form&nbsp;10-K.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	96
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=96,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=215821,FOLIO='96',FILE='DISK104:[09ZCX1.09ZCX49301]FU49301A.;10',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_FW49301_1_97">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_PART_III>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	PART IV
</B>
</FONT>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_FW49301_ITEM_15__EXHIBITS,_FINANCIAL_STATEMENT_SCHEDULES">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_FW49301_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Exhibits, Financial Statement Schedules
<BR>
</I>
</B>
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	(a)&nbsp;&nbsp;&nbsp;
</I>
</FONT>
<FONT SIZE=2>
	Financial Statements:
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;See
	"Index to Consolidated Financial Statements" at Item&nbsp;8 of this Annual Report on Form&nbsp;10-K. Schedules not included herein are omitted
	because they are not applicable or the required information appears in the accompanying Consolidated Financial Statements or Notes thereto.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;The
	following schedule is filed as part of this Annual Report on Form&nbsp;10-K:
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule&nbsp;II&#151;Valuation
	and Qualifying Accounts for the years ended June&nbsp;30, 2009, 2008 and 2007.
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;See
	Exhibit Index following the signature page to this Annual Report on Form&nbsp;10-K.
</FONT>
</P>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	97
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=97,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=293476,FOLIO='97',FILE='DISK104:[09ZCX1.09ZCX49301]FW49301A.;6',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_JC49301_1_98">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_EXHIBITS>
</EFX_PART_IV>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_JC49301_SIGNATURES">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_JC49301_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
<A NAME="A2194303Z10-K_HTM_SIGS">
</A>
	SIGNATURES
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this
	report to be signed on its behalf by the undersigned, thereunto duly authorized.
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="217" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="209" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	IMMUNOGEN,&nbsp;INC.
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	By:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	/s/&nbsp;DANIEL M. JUNIUS
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
<B>
	Daniel M. Junius
<BR>
</B>
</FONT>
<FONT SIZE=2>
<B>
<I>
	President and
<BR>
	Chief Executive Officer
<BR>
	(Principal Executive Officer)
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Dated:
	August&nbsp;28, 2009
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the
	dates indicated.
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="133" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="220" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="82" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:34PT;">
<FONT SIZE=1>
<B>
	Signature
<!-- COMMAND=ADD_SCROPPEDRULE,34PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:17PT;">
<FONT SIZE=1>
<B>
	Title
<!-- COMMAND=ADD_SCROPPEDRULE,17PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:17PT;">
<FONT SIZE=1>
<B>
	Date
<!-- COMMAND=ADD_SCROPPEDRULE,17PT -->
</B>
</FONT>
</DIV>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;DANIEL M. JUNIUS
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Daniel M. Junius
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	President, Chief Executive Officer and Director
<BR>
	(Principal Executive Officer)
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;GREGORY D. PERRY
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Gregory D. Perry
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Senior Vice President and
<BR>
	Chief Financial Officer
<BR>
	(Principal Financial and Accounting Officer)
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;MITCHEL SAYARE
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Mitchel Sayare
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Chairman of the Board of Directors
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;DAVID W. CARTER
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	David W. Carter
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;STEPHEN MCCLUSKI
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Stephen McCluski
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;NICOLE ONETTO, M.D.
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Nicole Onetto
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;MARK SKALETSKY
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Mark Skaletsky
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;JOSEPH VILLAFRANCA
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Joseph Villafranca
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;RICHARD WALLACE
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Richard Wallace
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	August&nbsp;28, 2009
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	98
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=98,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=458600,FOLIO='98',FILE='DISK104:[09ZCX1.09ZCX49301]JC49301A.;10',USER='DPERRY',CD='24-AUG-2009;16:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_JE49301_1_99">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_SIGNATURES>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_JE49301_EXHIBIT_INDEX">
</A>
<A NAME="A2194303Z10-K_HTM_TOC_JE49301_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	EXHIBIT INDEX
<BR>
</B>
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"60%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<DIV ALIGN="CENTER">
<TABLE WIDTH="60%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="35" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="75" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="26" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Incorporated&nbsp;by&nbsp;Reference
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:29PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
<!-- COMMAND=ADD_SCROPPEDRULE,29PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit Description
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Filed
<BR>
	with&nbsp;this
<BR>
	Form&nbsp;10-K
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Form
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Filing&nbsp;Date
<BR>
	with SEC
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;3.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Restated Articles of Organization
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;8,&nbsp;1996
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;3.1(a)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Articles of Amendment to Restated Articles of Organization
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;14,&nbsp;2002
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;3.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amended and Restated By-Laws
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	April&nbsp;6,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;4.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Article&nbsp;4 of Restated Articles of Organization, as amended (see Exhibits&nbsp;3.1 and 3.1(a))
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;4.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Common Stock certificate
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;15,&nbsp;1989
<BR>
	(File No.&nbsp;33-31219)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Leases dated as of December&nbsp;1, 1986 and June&nbsp;21, 1988 by and between James H. Mitchell, Trustee of New Providence Realty Trust, lessor, and Charles River Biotechnical Services,&nbsp;Inc. ("Lessee"), together
	with Assignment of Leases dated June&nbsp;29, 1989 between Lessee and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;22,&nbsp;1989
<BR>
	(File No.&nbsp;33-31219)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.10
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(a)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	First Amendment to Lease dated May&nbsp;9, 1991 by and between James H. Mitchell, Trustee of New Providence Realty Trust, lessor, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;6,&nbsp;1991
<BR>
	(File No.&nbsp;33-43725)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.10a
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(b)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Confirmatory Second Amendment to Lease dated September&nbsp;17, 1997 by and between James H. Mitchell, Trustee of New Providence Realty Trust, lessor, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;26,&nbsp;1997
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.10
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(c)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Third Amendment and Partial Termination of Lease dated as of August&nbsp;8, 2000 by and between James&nbsp;H. Mitchell, Trustee of New Providence Realty Trust, lessor, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;2,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(c
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(d)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Fourth Amendment to Lease dated as of October&nbsp;3, 2000 by and between James H. Mitchell, Trustee of New Providence Realty Trust, lessor, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;2,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(d
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(e)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Fifth Amendment to Lease dated as of June&nbsp;7, 2001 by and between James H. Mitchell, Trustee of New Providence Realty Trust, lessor, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;2,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(e
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(f)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Sixth Amendment to Lease dated as of April&nbsp;30, 2002 by and between Bobson 333 L.L.C., lessor, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;2,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(f
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(g)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Seventh Amendment to Lease dated as of October&nbsp;20, 2005 by and between Bobson 333&nbsp;L.L.C., lessor, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;2,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(g
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(h)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Eighth Amendment to Lease dated as of February&nbsp;21, 2007 by and between Bobson 333&nbsp;L.L.C., lessor, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;2,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1(h
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Lease Agreement, dated as of July&nbsp;27, 2007, by and between Intercontinental Fund III 830 Winter Street&nbsp;LLC, landlord, and the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;7,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	99
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=99,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=1002043,FOLIO='99',FILE='DISK104:[09ZCX1.09ZCX49301]JE49301A.;14',USER='DPERRY',CD='24-AUG-2009;16:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_JE49301_1_100">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"60%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<DIV ALIGN="CENTER">
<TABLE WIDTH="60%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="35" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="75" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="26" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Incorporated&nbsp;by&nbsp;Reference
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:29PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
<!-- COMMAND=ADD_SCROPPEDRULE,29PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit Description
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Filed
<BR>
	with&nbsp;this
<BR>
	Form&nbsp;10-K
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Form
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Filing&nbsp;Date
<BR>
	with SEC
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.3
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Research and License Agreement dated as of May&nbsp;22, 1981 by and between the Registrant and Sidney Farber Cancer Institute,&nbsp;Inc. (now Dana-Farber Cancer Institute,&nbsp;Inc.), with addenda dated as of
	August&nbsp;13, 1987 and August&nbsp;22, 1989
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;22,&nbsp;1989
<BR>
	(File No.&nbsp;33-31219)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.4*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	License Agreement dated as of June&nbsp;1, 1998 by and&nbsp;between the Registrant and Pharmacia&nbsp;&amp; Upjohn&nbsp;AB
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;29,&nbsp;1998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.48
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.4(a)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amendment to License Agreement dated as of October&nbsp;23, 1998 by and between the Registrant and Pharmacia&nbsp;&amp; Upjohn AB
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;2,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.4(a
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.5*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Heads of Agreement dated effective May&nbsp;2, 2000 by and between the Registrant and Genentech,&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;27,&nbsp;2000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.52
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.6*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	License Agreement dated effective May&nbsp;2, 2000 by and between the Registrant and Genentech,&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	September&nbsp;27,&nbsp;2000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.51
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.6(a)*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amendment to License Agreement for Anti-HER2 Antibodies, dated as of May&nbsp;3, 2006, between the Registrant and Genentech,&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	August&nbsp;28,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.32
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.7*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Process Agreement, dated as of May&nbsp;3, 2006, between the Registrant and Genentech,&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	August&nbsp;28,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.31
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.8*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	License Agreement executed November&nbsp;13, 2006, effective as of July&nbsp;22, 2005, between the Registrant and Genentech,&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;8,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.3
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.9*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	License Agreement executed February&nbsp;21, 2007, effective as of April&nbsp;27, 2005, between the Registrant and Genentech,&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	May&nbsp;9,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.10*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	License Agreement executed February&nbsp;21, 2007, effective as of December&nbsp;12, 2005, between the Registrant and Genentech,&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	May&nbsp;9,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.11*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amendment to License Agreements made effective as of March&nbsp;11, 2009, between the Registrant and Genentech,&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	May&nbsp;7,&nbsp;2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.12*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Option and License Agreement dated September&nbsp;5, 2000 by and between the Registrant and Amgen&nbsp;Inc. (as successor-in-interest to Abgenix,&nbsp;Inc.)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8-K/A
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	October&nbsp;10,&nbsp;2000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.13*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Collaboration and License Agreement dated as of July&nbsp;30, 2003 by and between the Registrant and Aventis Pharmaceuticals&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;14,&nbsp;2003
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.13(a)*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amendment No.&nbsp;1, dated as of August&nbsp;31, 2006, to the Collaboration and License Agreement between the Registrant and sanofi-aventis U.S.&nbsp;LLC
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;3,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.13(b)*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amendment No.&nbsp;2, dated as of October&nbsp;11, 2007, to the Collaboration and License Agreement between the Registrant and sanofi-aventis U.S.&nbsp;LLC
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;7,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.13(c)*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amendment No.&nbsp;3, dated as of August&nbsp;31, 2008, to the Collaboration and License Agreement between the Registrant and sanofi-aventis U.S.&nbsp;LLC
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;6,&nbsp;2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.7
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=100,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=118336,FOLIO='100',FILE='DISK104:[09ZCX1.09ZCX49301]JE49301A.;14',USER='DPERRY',CD='24-AUG-2009;16:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_JE49301_1_101">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"60%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<DIV ALIGN="CENTER">
<TABLE WIDTH="60%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="35" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="75" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="26" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Incorporated&nbsp;by&nbsp;Reference
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:29PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
<!-- COMMAND=ADD_SCROPPEDRULE,29PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit Description
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Filed
<BR>
	with&nbsp;this
<BR>
	Form&nbsp;10-K
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Form
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Filing&nbsp;Date
<BR>
	with SEC
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.14*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	License Agreement dated as of October&nbsp;5, 2006 by and between the Registrant and sanofi-aventis U.S.&nbsp;LLC
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;8,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.15*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Option and License Agreement dated as of December&nbsp;21, 2006 by and between the Registrant and sanofi-aventis U.S.&nbsp;LLC
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;8,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.16*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Development and License Agreement dated as of October&nbsp;1, 2004 by and between the Registrant and Biogen Idec MA&nbsp;Inc.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;9,&nbsp;2005
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.17*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Collaborative Development and License Agreement dated as of July&nbsp;7, 2006 by and between the Registrant and Biotest AG
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;3,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.17(a)*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amendment No.&nbsp;1, dated August&nbsp;23, 2006, to Collaborative Development and License Agreement by and between the Registrant and Biotest AG
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;3,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.3
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Securities Purchase Agreement dated as of June&nbsp;20, 2008 by and between the Registrant and Ziff Asset Management,&nbsp;L.P.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	June&nbsp;23,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.18(a)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Registration Rights Agreement dated as of June&nbsp;20, 2008 by and between the Registrant and Ziff Asset Management,&nbsp;L.P.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	June&nbsp;23,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.19&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Restated Stock Option Plan
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;7,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.19(a)&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Incentive Stock Option Agreement
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;7,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.19(b)&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Non-Qualified Stock Option Agreement
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;7,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.3
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.20&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2006 Employee, Director and Consultant Equity Incentive Plan, as amended and restated through November&nbsp;12, 2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;14,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.20(a)&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Incentive Stock Option Agreement for Executives
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;15,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	99.4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.20(b)&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Non-Qualified Stock Option Agreement for Executives
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;15,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	99.5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.20(c)&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Non-Qualified Stock Option Agreement for Directors
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;15,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	99.6
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.20(d)&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Restricted Stock Agreement for Executives
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;15,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	99.9
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.20(e)&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Restricted Stock Agreement for Directors
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;15,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	99.8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.21&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2001 Non-Employee Director Stock Plan
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	S-8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	December&nbsp;18,&nbsp;2001
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	99
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.22&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2004 Non-Employee Director Compensation and Deferred Stock Unit Plan, as amended on September&nbsp;5, 2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;3,&nbsp;2006
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.23&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Proprietary Information, Inventions and Competition Agreement between the Registrant and each of its executive officers
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;8,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.24&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amendment to Stock Option Agreements dated as of September&nbsp;24, 2008 between the Registrant and Mitchel Sayare
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	October&nbsp;31,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.25&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Severance Agreement dated as of December&nbsp;1, 2008 between the Registrant and Mitchel Sayare
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;6,&nbsp;2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	101
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=101,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=806455,FOLIO='101',FILE='DISK104:[09ZCX1.09ZCX49301]JE49301A.;14',USER='DPERRY',CD='24-AUG-2009;16:11' -->
<A NAME="A2194303Z10-K_HTM_PAGE_JE49301_1_102">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"60%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<DIV ALIGN="CENTER">
<TABLE WIDTH="60%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="6" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="35" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="75" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="14" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="26" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Incorporated&nbsp;by&nbsp;Reference
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:29PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
<!-- COMMAND=ADD_SCROPPEDRULE,29PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit Description
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Filed
<BR>
	with&nbsp;this
<BR>
	Form&nbsp;10-K
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Form
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Filing&nbsp;Date
<BR>
	with SEC
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.26&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Severance Agreement dated as of December&nbsp;1, 2008 between the Registrant and Daniel M. Junius
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;6,&nbsp;2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.27&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Severance Agreement dated as of December&nbsp;1, 2008 between the Registrant and John M. Lambert
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;6,&nbsp;2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.3
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.28&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Severance Agreement dated as of December&nbsp;1, 2008 between the Registrant and James J. O'Leary
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;6,&nbsp;2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.29&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Severance Agreement dated as of December&nbsp;1, 2008 between the Registrant and Gregory D. Perry
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;6,&nbsp;2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.30&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Severance Agreement dated as of August&nbsp;17, 2009 between the Registrant and Peter Williams
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	X
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.31&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Employment offer letter between the Registrant and Gregory D. Perry
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;6,&nbsp;2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.6
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.32&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Employment offer letter between the Registrant and James J. O'Leary
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	X
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.33&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Employment Agreement dated as of November&nbsp;27, 2007 between the Registrant and John A. Tagliamonte
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	February&nbsp;7,&nbsp;2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.34&#134;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Summary of Annual Executive Bonus Program
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-Q
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	November&nbsp;7,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	21
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Subsidiaries of the Registrant
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10-K
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	August&nbsp;30,&nbsp;2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	21
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	23
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consent of Ernst&nbsp;&amp; Young&nbsp;LLP
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	X
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Certification of the Chief Executive Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	X
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Certification of the Chief Financial Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	X
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	32
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Certifications of Chief Executive Officer and Chief Financial Officer pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	X
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</EFX_UNIDENTIFIED_TABLE>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	*
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Portions
	of this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission
	pursuant to the Registrant's application requesting confidential treatment.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#134;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Exhibit
	is a management contract or compensatory plan, contract or arrangement required to be filed as an exhibit to the annual report on
	Form&nbsp;10-K.
</FONT>
</DD>
</DL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	102
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=102,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=521818,FOLIO='102',FILE='DISK104:[09ZCX1.09ZCX49301]JE49301A.;14',USER='DPERRY',CD='24-AUG-2009;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303Z10-K_HTM_PAGE_JG49301_1_103">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2194303Z10-K_HTM_BG49301A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_EXHIBIT_INDEX>
<EFX_VALUATION_AND_QUALIFYING_ACCOUNTS>
<A NAME="FIS_VALUATION_AND_QUALIFYING_ACCOUNTS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	IMMUNOGEN,&nbsp;INC.
<BR>
	SCHEDULE II&#151;VALUATION AND QUALIFYING ACCOUNTS
<BR>
	(In thousands)
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="222" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="41" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="5" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="3" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:154PT;">
<FONT SIZE=1>
<B>
	COLUMN&nbsp;A&#151;DESCRIPTION
<!-- COMMAND=ADD_SCROPPEDRULE,154PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	COLUMN&nbsp;B
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	COLUMN&nbsp;C&#151;
<BR>
	ADDITIONS
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	COLUMN&nbsp;D
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	COLUMN&nbsp;E
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:77PT;">
<FONT SIZE=1>
<B>
	Inventory&nbsp;Write-downs
<!-- COMMAND=ADD_SCROPPEDRULE,77PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Balance At
<BR>
	Beginning
<BR>
	of Period
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Charged
<BR>
	to Costs
<BR>
	and
<BR>
	Expenses
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Use of
<BR>
	Zero
<BR>
	Value
<BR>
	Inventory
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Balance at
<BR>
	End of
<BR>
	Period
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Year End June&nbsp;30, 2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,534
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(750
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,784
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Year End June&nbsp;30, 2008
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,430
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,732
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2,628
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,534
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Year End June&nbsp;30, 2007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,922
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,492
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,430
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_VALUATION_AND_QUALIFYING_ACCOUNTS>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	103
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=103,EFW="2194303",CP="IMMUNOGEN, INC.",DN="1",CHK=621936,FOLIO='103',FILE='DISK104:[09ZCX1.09ZCX49301]JG49301A.;11',USER='DPERRY',CD='24-AUG-2009;16:26' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage2"></A>
<A NAME="A2194303ZEX-10_30_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<BR>
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit
	10.30
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SEVERANCE
</FONT>
</B>
<B>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	AGREEMENT
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	This Agreement is entered into as of the 17th day of August, 2009 (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Effective Date
</I>
</B>
	&#148;) by and between
	ImmunoGen,&nbsp;Inc., a Massachusetts corporation (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Company
</I>
</B>
	&#148;)
	and Peter Williams (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Executive
</I>
</B>
	&#148;).
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	WHEREAS, the Company recognizes that the Executive&#146;s service to the
	Company is very important to the future success of the Company;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	WHEREAS, the Executive desires to enter into this Agreement to provide
	the Executive with certain financial protection in the event that his
	employment terminates under certain conditions following a change in control of
	the Company; and
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	WHEREAS the Board of Directors of the Company (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Board
</I>
</B>
	&#148;) has determined that it is in
	the best interests of the Company to enter into this Agreement.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	NOW, THEREFORE, for good and valuable consideration, the receipt and
	sufficiency of which are hereby acknowledged, the Company and the Executive
	hereby agree as follows:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN .5IN .0001PT 0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Definitions
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN .5IN .0001PT 0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Cause
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; For purposes of this Agreement, &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Cause
</I>
</B>
	&#148; shall mean that the Executive
	has (i)&nbsp;intentionally committed an act or omission that materially harms
	the Company; (ii)&nbsp;been grossly negligent in the performance of the Executive&#146;s
	duties to the Company; (iii)&nbsp;willfully failed or refused to follow the
	lawful and proper directives of the Board or the CEO; (iv)&nbsp;been convicted
	of, or pleaded guilty or
<I>
	nolo contendre
</I>
	,
	to a felony; (v)&nbsp;committed an act involving moral turpitude; (vi)&nbsp;committed
	an act relating to the Executive&#146;s employment or the Company involving, in the
	good faith judgment of the Board, material fraud or theft; (vii)&nbsp;breached
	any material provision of this Agreement or any nondisclosure or
	non-competition agreement between the Executive and the Company, as all of the
	foregoing may be amended prospectively from time to time; or (viii)&nbsp;breached
	a material provision of any code of conduct or ethics policy in effect at the
	Company, as all of the foregoing may be amended prospectively from time to
	time.
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H2>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Change in
	Control
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; For purposes of this
	Agreement, a &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Change in Control
</I>
</B>
	&#148; shall mean
	the occurrence of any of the following events;
<U>
	provided
</U>
	&nbsp;
<U>
	that
</U>
	&#147;Change in Control&#148; shall be interpreted in a manner, and limited to the extent
	necessary, so that it will not cause adverse tax consequences for either party
	with respect to Section&nbsp;409A of the Internal Revenue Code of 1986, as
	amended (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Code
</I>
</B>
	&#148;), and Treasury
	Regulations&nbsp;1.409A-3(i)(5), and any successor statute, regulation and
	guidance thereto:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Ownership.&#160; Any &#147;Person&#148; (as such term is used in
	Sections&nbsp;13(d)&nbsp;and 14(d)&nbsp;of the Securities Exchange Act of 1934,
	as amended) becomes the &#147;Beneficial Owner&#148; (as defined in Rule&nbsp;13d-3 under
	said Act), directly or indirectly, of securities of the Company representing
	50% or more of the total voting power represented by the Company&#146;s then
	outstanding voting securities (excluding for this purpose any such voting
	securities held by the Company or its Affiliates (as defined in the Company&#146;s
	2006 Employer, Director and
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Consultant Equity Incentive Plan) or by any employee benefit plan of
	the Company) pursuant to a transaction or a series of related transactions
	which the Board does not approve; or
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<I>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-STYLE:ITALIC;">
	Executive Severance Agreement (18)
</FONT>
</I>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=1,EFW="2194303",CP="IMMUNOGEN, INC.",DN="2",CHK=326586,FOLIO='',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KI_ZCX49302.CHC",USER="CDESORM",CD='AUG 26 16:02 2009' -->
<A NAME="eolPage3"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="LINE-HEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT .5IN;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Merger/Sale of Assets.&#160; (A)&nbsp;A merger or consolidation of the
	Company whether or not approved by the Board, other than a merger or
	consolidation which would result in the voting securities of the Company
	outstanding immediately prior thereto continuing to represent (either by
	remaining outstanding or by being converted into voting securities of the
	surviving entity or the parent of such corporation) at least 50% of the total
	voting power represented by the voting securities of the Company or such
	surviving entity&nbsp;or parent of such corporation, as the case may be,
	outstanding immediately after such merger or consolidation; or (B)&nbsp;the
	stockholders of the Company approve an agreement for the sale or disposition by
	the Company of all or substantially all of the Company&#146;s assets; or
</FONT>
</P>
<P STYLE="LINE-HEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Change in Board
	Composition.&#160; A change in the composition
	of the Board, as a result of which fewer than a majority of the directors are
	Incumbent Directors.&#160; &#147;Incumbent
	Directors&#148; shall mean directors who either (A)&nbsp;are directors of the
	Company as of November&nbsp;11, 2006, or (B)&nbsp;are elected, or nominated for
	election, to the Board with the affirmative votes of at least a majority of the
	Incumbent Directors at the time of such election or nomination (but shall not
	include an individual whose election or nomination is in connection with an
	actual or threatened proxy contest relating to the election of directors to the
	Company).
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Disability
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; For purposes of this Agreement, &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Disability
</I>
</B>
	&#148; shall
	mean that the Executive (i)&nbsp;is unable to engage in any substantial gainful
	activity by reason of any medically determinable physical or mental impairment
	which can be expected to result in death or can be expected to last for a
	continuous period of not less than twelve&nbsp;(12) months, or (ii)&nbsp;is, by
	reason of any medically determinable physical or mental impairment which can be
	expected to result in death or can be expected to last for a continuous period
	of not less than twelve&nbsp;(12) months, receiving income replacement benefits
	for a period of not less than three&nbsp;(3)&nbsp;months under a Company-sponsored
	group disability plan.&#160; Whether the Executive has a Disability will
	be determined by a majority of the Board based on evidence provided by one or
	more physicians selected by the Board and approved by the Executive, which
	approval shall not be unreasonably withheld.
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Good Reason
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; For purposes of this Agreement, &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Good Reason
</I>
</B>
	&#148; shall mean the
	occurrence of one or more of the following without the Executive&#146;s consent: (i)&nbsp;a
	change in the principal location at which the Executive performs his duties for
	the Company to a new location that is at least forty&nbsp;(40) miles from the
	prior location; (ii)&nbsp;a material change in the Executive&#146;s authority,
	functions, duties or responsibilities as an executive of the Company, which would cause his position with
	the Company to become of less responsibility, importance or scope than his highest
	position with the Company at any time from the date of this Agreement to
	immediately prior to the Change in Control,
<U>
	provided
</U>
	,
<U>
	however
</U>
	,
	that such material change is not in connection with the termination of the
	Executive&#146;s employment by the Company for Cause or death or Disability and
	further provided that it shall not be considered a material change if the
	Company becomes a subsidiary of another entity and the Executive continues to
	hold a position in the subsidiary that is at least as high as the highest
	position he held with the Company at any time from the date of this Agreement
	to immediately prior to the Change in Control; (iii)&nbsp;a material reduction
	in the Executive&#146;s annual base
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	salary or (iv)&nbsp;a material reduction in
	the Executive&#146;s target annual bonus as compared to the target annual bonus set
	for the previous fiscal year.
</FONT>
</H2>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=2,EFW="2194303",CP="IMMUNOGEN, INC.",DN="2",CHK=626883,FOLIO='2',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KI_ZCX49302.CHC",USER="CDESORM",CD='AUG 26 16:02 2009' -->
<A NAME="eolPage4"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Term of
	Agreement
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The term of
	this Agreement (the &#147;Term&#148;) shall commence on the Effective Date and shall
	continue in effect for two&nbsp;(2)&nbsp;years;
<U>
	provided
</U>
	,&nbsp;
<U>
	however
</U>
	,
	that commencing on second anniversary of the Effective Date and continuing each
	anniversary thereafter, the Term shall automatically be extended for one&nbsp;(1)&nbsp;additional
	year unless, not later than nine&nbsp;(9)&nbsp;months before the conclusion of
	the Term, the Company or the Executive shall have given notice not to extend
	the Term; and
<U>
	further
</U>
	&nbsp;
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that if a
	Change in Control shall have occurred during the Term, the Term shall expire on
	the last day of the twenty-fourth&nbsp;(24
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	th
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	) month following the month in which such Change in
	Control occurred.&#160; Notice of termination
	or termination of this Agreement shall not constitute Cause or Good Reason
	(both terms as defined above).
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Termination;
	Notice; Severance Compensation
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	In the event that within a
	period of two&nbsp;(2)&nbsp;months before or two&nbsp;(2)&nbsp;years following
	the consummation of a Change in Control the Company elects to terminate the
	Executive&#146;s employment other than for Cause (but not including termination due
	to the Executive&#146;s Disability), then the Company shall give the Executive no
	less than sixty&nbsp;(60) days advance notice of such termination (the &#147;Company&#146;s
	Notice Period&#148;);
<U>
	provided
</U>
	&nbsp;
<U>
	that
</U>
	the Company may elect to
	require the Executive to cease performing work for the Company so long as the
	Company continues the Executive&#146;s full salary and benefits during the Company&#146;s
	Notice Period.
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	In the event that within a
	period of two&nbsp;(2)&nbsp;months before or two&nbsp;(2)&nbsp;years following
	the consummation of a Change in Control the Executive elects to terminate his
	employment for Good Reason, then the Executive shall give the Company no less
	than thirty&nbsp;(30) days and no more than sixty&nbsp;(60) days advance notice
	of such termination (the &#147;Executive&#146;s Notice Period&#148;);
<U>
	provided
</U>
	&nbsp;
<U>
	that
</U>
	the Company may elect to require the Executive to cease performing work for the
	Company so long as the Company continues the Executive&#146;s full salary and
	benefits during the Executive&#146;s Notice Period.&#160;
	In order to effect a termination for Good Reason pursuant to this
	Agreement, the Executive must notice his intent to terminate for Good Reason
	not later than ninety&nbsp;(90) days following the occurrence of the Good
	Reason.
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	In the event that within a
	period of two&nbsp;(2)&nbsp;months before or two&nbsp;(2)&nbsp;years following
	the consummation of a Change in Control the Executive&#146;s employment with the
	Company is terminated by the Company other than for Cause (but not including
	termination due to the Executive&#146;s death or Disability), or by the Executive
	for Good Reason, then, contingent upon the Executive&#146;s execution of a release
	of claims against the Company in a form reasonably acceptable to the Company
	(the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Release
</I>
</B>
	&#148;) the Executive shall
	be entitled to, in addition to any amounts due to the Executive for services
	rendered prior to the termination date:
</FONT>
</H2>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=3,EFW="2194303",CP="IMMUNOGEN, INC.",DN="2",CHK=701383,FOLIO='3',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KI_ZCX49302.CHC",USER="CDESORM",CD='AUG 26 16:02 2009' -->
<A NAME="eolPage5"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<H3 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT 1.0IN;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H3>
<H3 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT 1.0IN;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)&nbsp;
	the Executive&#146;s target annual bonus for the fiscal year in which such
	termination occurs at one hundred percent&nbsp;(100%) of such target annual
	bonus, pro-rated by the number of calendar days in which the Executive is
	employed by the Company during the applicable year, including any applicable
	Notice Period, and less any amount of the target annual bonus for the
	applicable year previously paid to the Executive, which shall be paid no later
	than sixty&nbsp;(60) days after the Executive&#146;s termination of employment,
<U>
	provided
</U>
<U>
	that
</U>
	the Release is executed and effective by then; and
</FONT>
</H3>
<H3 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT 1.0IN;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H3>
<H3 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT 1.0IN;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)&nbsp; a lump sum
	payment from the Company in an amount equal to one and one-half&nbsp;(1.5)
	times the Executive&#146;s Annual Salary, which shall be paid no later than sixty&nbsp;(60)
	days after the Executive&#146;s termination of employment,
<U>
	provided
</U>
	&nbsp;
<U>
	that
</U>
	the Release is executed and effective by then;
</FONT>
</H3>
<H3 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT 1.0IN;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H3>
<H3 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT 1.0IN;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iii)&nbsp; all outstanding
	options, restricted stock and other similar rights held by the Executive, which
	shall become one hundred percent&nbsp;(100%) vested; and
</FONT>
</H3>
<H3 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT 1.0IN;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H3>
<P STYLE="MARGIN:0IN 0IN .0001PT 1.0IN;TEXT-INDENT:0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iv)&nbsp; continuation of medical insurance coverage for the Executive
	and the Executive&#146;s family, subject to COBRA and subject to the Executive&#146;s
	payment of a premium co-pay related to the coverage that is no less favorable
	than the premium co-pay charged to active employees of the Company electing the
	same coverage, for eighteen (18) months from the Separation Date;
<U>
	provided
</U>
	&nbsp;
<U>
	that
</U>
	the Company shall have no obligation to provide such coverage if the Executive
	fails to elect COBRA benefits in a timely fashion or if the Executive becomes
	eligible for medical coverage with another employer.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 1.0IN;TEXT-INDENT:0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	For
	purposes of this Agreement, &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Annual Salary
</I>
</B>
	&#148; shall mean the Executive&#146;s annual base
	salary then in effect or, if higher, in effect at the time of the Change in
	Control, excluding reimbursements and amounts attributable to stock options and
	other non-cash compensation; and the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Severance Compensation
</I>
</B>
	&#148;
	shall mean the compensation set forth in (ii), (iii), and (iv)&nbsp;above.
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Notwithstanding any other
	provision with respect to the timing of payments, if, at the time of the Executive&#146;s
	termination, the Executive is deemed to be a &#147;specified employee&#148; (within the
	meaning of Code Section&nbsp;409A, and any successor statute, regulation and
	guidance thereto) of the Company, then limited only to the extent necessary to
	comply with the requirements of Code Section&nbsp;409A, any payments to which the
	Executive may become entitled under this Agreement which are subject to Code Section&nbsp;409A
	(and not otherwise exempt from its application) will be withheld until the
	first&nbsp;(1
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	st
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	) business day
	of the seventh&nbsp;(7
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	th
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	) month
	following the termination of the Executive&#146;s employment, at which time the Executive
	shall be paid an aggregate amount equal to the accumulated, but unpaid,
	payments otherwise due to the Executive under the terms of this Agreement.
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(e)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	I
</FONT>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	f any payment
	or benefit the Executive would receive under this Agreement, when combined with
	any other payment or benefit the Executive receives pursuant to a Change in
	Control (&#147;Payment&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the
	meaning of Code Section&nbsp;280G, and (ii)&nbsp;but for this sentence, be
	subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;Excise
	Tax&#148;), then such Payment shall be either (x)&nbsp;the full amount of such
	Payment or (y)&nbsp;such less amount as would result in no portion of the
	Payment being subject to the Excise Tax, whichever of the foregoing amounts,
	taking into account the applicable federal, state, and local employments taxes,
	income taxes, and the Excise Tax results in the Executive&#146;s receipt, on an
	after-tax basis, of the
</FONT>
</H2>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=4,EFW="2194303",CP="IMMUNOGEN, INC.",DN="2",CHK=235517,FOLIO='4',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KI_ZCX49302.CHC",USER="CDESORM",CD='AUG 26 16:02 2009' -->
<A NAME="eolPage6"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	greater
	amount of the Payment, notwithstanding that all or some portion of the Payment
	may be subject to the Excise Tax.&#160; The Company
	shall determine in good faith which payment(s)&nbsp;or benefit(s)&nbsp;to
	reduce based on what provides the best economic result for the Executive.&#160; The Company shall provide the Executive with
	sufficient information to make such determination and to file and pay any
	required taxes.
</FONT>
</H2>
<H2 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H2>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	No Duplication
	of Compensation
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The
	Severance Compensation shall replace, and be provided in lieu of, any severance
	or similar compensation that may be provided to the Executive under any other
	agreement or arrangement in relation to termination of employment;
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that this prohibition against duplication shall not be
	construed to otherwise limit the Executive&#146;s rights to payments or benefits
	provided under any pension plan (as defined in Section&nbsp;3(2)&nbsp;of the
	Employee Retirement Income Security Act of 1974, as amended), deferred
	compensation, stock, stock option or similar plan sponsored by the Company.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	5.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	No Mitigation
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; If the Executive&#146;s employment with the
	Company terminates following a Change in Control, the Executive is not required
	to seek other employment or to attempt in any way to reduce any amounts payable
	to the Executive by the Company pursuant to Section&nbsp;3 or Section&nbsp;15.&#160; Except as set forth in Section&nbsp;4, the
	amount of any payment or benefit provided for in this Agreement shall not be
	reduced by any compensation earned by the Executive as the result of employment
	by another employer, by retirement benefits, by offset against any amount
	claimed to be owed by the Executive to the Company, or otherwise.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	6.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Confidentiality,
	Non-Competition, and Assignment of Inventions.
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	&#160; The Company&#146;s obligations under this
	Agreement are contingent upon the Executive&#146;s execution of the Company&#146;s
	Proprietary Information, Inventions, and Competition Agreement (the &#147;Proprietary
	Information Agreement&#148;).&#160; The parties
	agree that the obligations set forth in the Proprietary Information Agreement
	shall survive termination of this Agreement and termination of the Executive&#146;s
	employment, regardless of the reason for such termination.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	7.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Enforceability
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; If any provision of this Agreement shall be
	deemed invalid or unenforceable as written, this Agreement shall be construed,
	to the greatest extent possible, or modified, to the extent allowable by law,
	in a manner which shall render it valid and enforceable.&#160; No invalidity or unenforceability of any
	provision contained herein shall affect any other portion of this Agreement.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	8.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Notices
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; Except as otherwise specifically provided
	herein, any notice required or permitted by this Agreement shall be in writing
	and shall be delivered as follows with notice deemed given as indicated: (i)&nbsp;
	by personal delivery when delivered personally; (ii)&nbsp;by overnight courier
	upon written verification of receipt; (iii)&nbsp;by telecopy or facsimile
	transmission upon acknowledgment of receipt of electronic transmission; or (iv)&nbsp;by
	certified or registered mail, return receipt requested, upon verification of
	receipt.&#160; Notices to the Executive shall
	be sent to the last known address in the Company&#146;s records or such other
	address as the Executive may specify in writing.&#160; Notices to the Company shall be sent to the
	Company&#146;s CEO and Lead Director, or to such other Company representative as the
	Company may specify in writing.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	9.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Claims for
	Benefits.
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	&#160; All claims
	by the Executive for benefits under this Agreement shall be directed to and
	determined by the Board and shall be in writing.&#160; Any denial by the Board of a claim for benefits
	under this Agreement shall be delivered to the Executive in writing and shall
	set forth the specific reasons for the denial and the specific provisions of
	this Agreement relied upon.&#160; The
</FONT>
</H1>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	5
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=5,EFW="2194303",CP="IMMUNOGEN, INC.",DN="2",CHK=345278,FOLIO='5',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KI_ZCX49302.CHC",USER="CDESORM",CD='AUG 26 16:02 2009' -->
<A NAME="eolPage7"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Board
	shall afford a reasonable opportunity to the Executive for a review of the
	decision denying a claim and shall further allow the Executive to appeal to the
	Board a decision of the Board within sixty&nbsp;(60) days after notification by
	the Board that the Executive&#146;s claim has been denied.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	10.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Modifications
	and Amendments
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The terms
	and provisions of this Agreement may be modified or amended only by written
	agreement executed by the Company and the Executive.&#160; The Company and the Executive agree that they
	will jointly execute an amendment to modify this Agreement to the extent
	necessary to comply with the requirements of Code Section&nbsp;409A, or any
	successor statute, regulation and guidance thereto;
<U>
	provided
</U>
	&nbsp;
<U>
	that
</U>
	no such amendment shall increase the total financial obligation of the Company
	under this Agreement.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	11.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Waivers and
	Consents
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The terms
	and provisions of this Agreement may be waived, or consent for the departure
	therefrom granted, only by a written document executed by the party entitled to
	the benefits of such terms or provisions.&#160;
	No such waiver or consent shall be deemed to be or shall constitute a
	waiver or consent with respect to any other terms or provisions of this
	Agreement, whether or not similar.&#160; Each
	such waiver or consent shall be effective only in the specific instance and for
	the purpose for which it was given, and shall not constitute a continuing
	waiver or consent.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	12.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Binding Effect;
	Assignment
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The
	Agreement will be binding upon and inure to the benefit of (a)&nbsp;the heirs,
	executors and legal representatives of the Executive upon the Executive&#146;s death
	and (b)&nbsp;any successor of the Company.&#160;
	Any such successor of the Company will be deemed substituted for the
	Company under the terms of the Agreement for all purposes.&#160; For this purpose, &#147;successor&#148; means any
	person, firm, corporation or other business entity which at any time, whether
	by purchase, merger or otherwise, directly or indirectly acquires all or
	substantially all of the assets or business of the Company.&#160; None of the rights of the Executive to
	receive any form of compensation payable pursuant to the Agreement may be
	assigned or transferred except by will or the laws of descent and
	distribution.&#160; Any other attempted
	assignment, transfer, conveyance or other disposition of the Executive&#146;s right
	to compensation or other benefits will be null and void.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	13.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Governing Law
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; This Agreement and the rights and obligations
	of the parties hereunder shall be construed in accordance with and governed by
	the law of the Commonwealth of Massachusetts, without giving effect to the
	conflict of law principles thereof.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	14.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Jurisdiction
	and Service of Process
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; Any
	legal action or proceeding with respect to this Agreement shall be brought in
	the courts of the Commonwealth of Massachusetts or of the United States of
	America for the District of Massachusetts.&#160;
	By execution and delivery of this Agreement, each of the parties hereto
	accepts for itself and in respect of its property, generally and
	unconditionally, the jurisdiction of the aforesaid courts.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	15.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Attorneys&#146; Fees
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The Company shall pay to the Executive all
	legal fees and expenses incurred by the Executive in disputing in good faith
	any issue hereunder relating to the termination of the Executive&#146;s employment,
	in seeking in good faith to obtain or enforce any benefit or right provided by
	this Agreement.&#160; Such payments shall be
	made within five (5) business days after delivery of the Executive&#146;s written
	requests for payment accompanied with such evidence of fees and expenses
	incurred as the Company reasonably may require.
</FONT>
</H1>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	6
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=6,EFW="2194303",CP="IMMUNOGEN, INC.",DN="2",CHK=662213,FOLIO='6',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KI_ZCX49302.CHC",USER="CDESORM",CD='AUG 26 16:02 2009' -->
<A NAME="eolPage8"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	16.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Withholding
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The Company is authorized to withhold, or to
	cause to be withheld, from any payment or benefit under the Agreement the full
	amount of any applicable withholding taxes.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	17.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Tax
	Consequences
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The Company
	does not guarantee the tax treatment or tax consequences associated with any
	payment or benefit arising under this Agreement.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	18.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Acknowledgment
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; The Executive acknowledges that he has had
	the opportunity to discuss this matter with and obtain advice from his private
	attorney, has had sufficient time to, and has carefully read and fully
	understands all the provisions of the Agreement, and is knowingly and
	voluntarily entering into the Agreement.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	19.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Counterparts
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160; This Agreement may be executed in two or more
	counterparts, each of which shall be deemed an original, but all of which
	together shall constitute one and the same instrument.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	20.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	Section&nbsp;409A
</FONT>
</U>
<FONT SIZE="2" STYLE="FONT-SIZE:10.0PT;">
	.&#160;
	The parties hereto intend that this Agreement comply with the requirements
	of Code Section&nbsp;409A and related regulations and Treasury
	pronouncements.&#160; If any provision
	provided herein results in the imposition of an additional tax under the
	provisions of Code Section&nbsp;409A, the Executive and the Company agree that
	such provision will be reformed to avoid imposition of any such additional tax
	in the manner that the Executive and the Company mutually agree is appropriate
	to comply with Code Section&nbsp;409A.
</FONT>
</H1>
<H1 STYLE="FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="3" FACE="TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	IN WITNESS WHEREOF, the parties have executed and delivered this Severance
	Agreement as of the day and year first above written.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.0%;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	COMPANY:
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	IMMUNOGEN, INC.
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/
	Daniel Junius
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="BORDER:NONE;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Name:
	Daniel Junius
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Title:
	President&nbsp;&amp; Chief Executive Officer
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	EXECUTIVE:
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/
	Peter Williams
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="BORDER:NONE;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Name: Peter Williams
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	7
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=7,EFW="2194303",CP="IMMUNOGEN, INC.",DN="2",CHK=177109,FOLIO='7',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KI_ZCX49302.CHC",USER="CDESORM",CD='AUG 26 16:02 2009' -->
<BR>
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage9"></A>
<A NAME="A2194303ZEX-10_32_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<BR>
<DIV>
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit 10.32
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:5.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	September&nbsp;8, 2008
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	James J. O&#146;Leary, M.D.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	7 Wilmer Street
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Apt. J
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Madison, NJ 07940
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Dear Dr.&nbsp;O&#146;Leary:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	I am delighted to offer you the full-time position of Vice President
	and Chief Medical Officer at ImmunoGen,&nbsp;Inc. (&#147;ImmunoGen&#148; or the &#147;Company&#148;).&#160; Upon commencement of your employment, which
	shall be no later than November&nbsp;1, 2008, you will initially be paid at a
	bi-weekly rate of $12,692.31, which annualized equals $330,000.00 per year,
	less applicable federal, state and/or local payroll and withholding taxes.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	In addition to your annual salary, subject to the
	terms of this letter, ImmunoGen hereby grants to you a sign-on bonus in the
	amount of $70,000.&#160; The sign-on bonus
	will vest quarterly over the first year and will be paid to you in conjunction
	with the Company&#146;s last payroll of each quarter following your hire date.&#160; The Company will also reimburse you for
	reasonable and customary expenses actually incurred and properly documented up
	to $30,000 in connection with your relocation to the Boston area as described
	in the accompanying letter.&#160; Any amount
	above $30,000 will need to be pre-approved.&#160;
	In addition, any relocation expenses paid by Bayer in connection with
	your move to New Jersey that you are required to pay back to Bayer due to your
	acceptance of employment with ImmunoGen will be reimbursed by ImmunoGen.&#160; To the extent this reimbursement is taxable
	to you, ImmunoGen will make an additional payment to you to keep you whole on
	an after-tax basis.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Also in consideration of your employment by the Company, we will
	recommend to the Compensation Committee, for their approval, the grant of a
	stock option award covering 150,000 shares of the Company&#146;s common stock under
	the Company&#146;s Stock Option Plan.&#160; This
	award will vest at a rate of 25 percent (25%) per year over four years,
	beginning on the first anniversary of your first date of employment with
	ImmunoGen.&#160; The exercise price for these
	options will be the closing sale price of the Company&#146;s Common Stock as listed
	on the NASDAQ on your first day of employment.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	In addition, you will be eligible for a
	discretionary annual bonus of up to thirty percent (30%) of your annual
	salary.&#160; Your bonus for this fiscal year
	ending June&nbsp;2009 will be prorated from the date of hire.&#160; Each year following, bonuses are at the
	discretion of the Board of Directors, and are based on Company and individual
	performance.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR:BLACK;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" COLOR="BLACK" FACE="TIMES NEW ROMAN" STYLE="COLOR:WINDOWTEXT;FONT-SIZE:10.0PT;">
	As
	a member of the executive management, you will be eligible for a severance
	arrangement, under certain circumstances, that would provide you with certain
	benefits in the event of a change of control of the Company.&#160; Attached please see an agreement that is
	similar to that which you would receive.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=1,EFW="2194303",CP="IMMUNOGEN, INC.",DN="3",CHK=801424,FOLIO='',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KK_ZCX49302.CHC",USER="CDESORM",CD='AUG 25 21:51 2009' -->
<A NAME="eolPage10"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	You will also be entitled to participate in the
	Company&#146;s benefit plans to the same extent as, and subject to the same terms,
	conditions and limitations as a generally applicable to, full-time employees of
	ImmunoGen of similar rank and tenure.&#160;
	These benefits currently include at this time paid vacation time, life,
	health, dental and disability insurance.&#160;
	With respect to your annual vacation allotment, you are eligible for up
	to four (4)&nbsp;weeks of paid vacation per year, accrued monthly, of which
	five (5)&nbsp;days can be rolled over from year to year.&#160; For a more detailed understanding of the
	benefits and the eligibility requirements, please consult the summary plan
	descriptions for the programs that will be made available to you.&#160; Please note that your compensation and or
	benefits may be modified in any way, at any time, by ImmunoGen at its sole
	discretion, with or without prior notice, to the extent any such modification
	affects similarly situated ImmunoGen executives in the same manner.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Your duties as an employee of the Company shall
	be as determined by me in consultation with you.&#160; You agree to devote your best efforts all
	business time to the performance of such responsibilities and you will not
	perform any professional work outside your work for the Company without
	pre-approval from the Company.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	ImmunoGen is required by the Immigration and
	Naturalization Service to verify that each employee is eligible to work in the
	United States.&#160; To that end, a list of
	acceptable forms of identification is attached.&#160;
	Please bring with you one item on List A,
<U>
	or
</U>
	a combination of one
	item on List B
<U>
	and
</U>
	List C.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	In
	addition, your offer of employment is contingent upon the successful completion
	of a general background and reference check and drug test.&#160; As such, please complete the enclosed
	authorizations and other required forms.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	While we anticipate that our relationship will be
	a long and mutually rewarding one, your employment, of course, will be at will,
	terminable by either you or the Company at any time.&#160; On your first day of employment, you will be
	required to sign our Proprietary Information, Inventions and Competition
	Agreement and the Company&#146;s Insider Trading Policy, acknowledging that you
	understand and agree to be bound by these agreements.&#160; Copies of each are enclosed. You are also
	asked to acknowledge and agree that your employment by the Company will not violate
	any agreement, which you may have with any third party.&#160; Please acknowledge your understanding and
	agreement with the terms of your employment as set forth in this letter by
	signing below.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	I look forward to a long and productive
	relationship with you.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.0%;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Sincerely,
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/ Daniel Junius
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="BORDER:NONE;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Daniel
	Junius
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	President
	and Chief Operating Officer
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Acknowledged
	and Agreed to:
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/ James J. O&#146;Leary
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="BORDER:NONE;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<H1 ALIGN="RIGHT" STYLE="COLOR:BLACK;FONT-WEIGHT:NORMAL;MARGIN:0IN .75IN .0001PT 0IN;PAGE-BREAK-AFTER:AVOID;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" COLOR="BLACK" FACE="TIMES NEW ROMAN" STYLE="COLOR:WINDOWTEXT;FONT-SIZE:10.0PT;">
	Date
</FONT>
</H1>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<H1 STYLE="COLOR:BLACK;FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" COLOR="BLACK" FACE="TIMES NEW ROMAN" STYLE="COLOR:WINDOWTEXT;FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</H1>
</TD>
</TR>
</TABLE>
<H1 STYLE="COLOR:BLACK;FONT-WEIGHT:NORMAL;MARGIN:0IN 0IN .0001PT;PAGE-BREAK-AFTER:AVOID;">
<FONT SIZE="2" COLOR="BLACK" FACE="TIMES NEW ROMAN" STYLE="COLOR:WINDOWTEXT;FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</H1>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Enclosures
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE COLOR="#010101" ALIGN="LEFT">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=2,EFW="2194303",CP="IMMUNOGEN, INC.",DN="3",CHK=833230,FOLIO='',FILE="DISK105:[09ZCX2.09ZCX49302]23693-2-KK_ZCX49302.CHC",USER="CDESORM",CD='AUG 25 21:51 2009' -->
<BR>
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage11"></A>
<A NAME="A2194303ZEX-23_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<BR>
<FONT SIZE=3>
<A HREF="#A2194303ZEX-23_HTM_09ZCX49301_4">
	QuickLinks
</A>
</FONT>
<FONT SIZE=3>
	-- Click here to rapidly navigate through this document
</FONT>
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303ZEX-23_HTM_KM49301_EXHIBIT_23">
</A>
<A NAME="A2194303ZEX-23_HTM_TOC_KM49301_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	EXHIBIT 23
<BR>
</B>
</FONT>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Consent of Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the incorporation by reference in the Registration Statements (Form&nbsp;S-3
	Nos.&nbsp;333-144488 and 333-152502 and Form&nbsp;S-8 Nos.&nbsp;333-47543, 333-53292, 333-75372, 333-75374,
	333-138713, 333-147738 and 333-155540) of ImmunoGen,&nbsp;Inc. and in the related Prospectuses of our reports dated August&nbsp;28, 2009, with respect to the
	consolidated financial statements and schedule of ImmunoGen,&nbsp;Inc. and the effectiveness of internal control over financial reporting of ImmunoGen,&nbsp;Inc., included in the Annual Report
	(Form&nbsp;10-K) for the year ended June&nbsp;30, 2009.
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="229" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="229" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	/s/
</FONT>
<FONT SIZE=2>
	ERNST
</FONT>
<FONT SIZE=2>
	&nbsp;&amp;
</FONT>
<FONT SIZE=2>
	YOUNG
</FONT>
<FONT SIZE=2>
	&nbsp;LLP
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Boston,
	Massachusetts
<BR>
<BR>
	August&nbsp;28, 2009
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=1,EFW="2194303",CP="IMMUNOGEN, INC.",DN="4",CHK=500971,FOLIO='BLANK',FILE='DISK104:[09ZCX1.09ZCX49301]KM49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P>
<BR>
<A NAME="A2194303ZEX-23_HTM_09ZCX49301_4">
	QuickLinks
</A>
<BR>
</P>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303ZEX-23_HTM_TOC_KM49301_1">
	EXHIBIT 23
</A>
</FONT>
<BR>
</UL>
</EFX_EXPERTS_CONSENT>
<!-- SEQ=,FILE='QUICKLINK',USER=CDESORM,SEQ=,EFW="2194303",CP="IMMUNOGEN, INC.",DN="4" -->
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage12"></A>
<A NAME="A2194303ZEX-31_1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<BR>
<FONT SIZE=3>
<A HREF="#A2194303ZEX-31_1_HTM_09ZCX49301_5">
	QuickLinks
</A>
</FONT>
<FONT SIZE=3>
	-- Click here to rapidly navigate through this document
</FONT>
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303ZEX-31_1_HTM_KO49301_EXHIBIT_31_1">
</A>
<A NAME="A2194303ZEX-31_1_HTM_TOC_KO49301_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	EXHIBIT 31.1
<BR>
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	CERTIFICATIONS UNDER SECTION&nbsp;302
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	I,
	Daniel M. Junius, certify that:
</FONT>
</P>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	1.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	I
	have reviewed this Annual Report on Form&nbsp;10-K of ImmunoGen,&nbsp;Inc.;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	2.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Based
	on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
	made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	3.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Based
	on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
	financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	4.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
	Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and
	15d-15(f)) for the registrant and have:
<BR>
<BR>
</FONT>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	a)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	designed
	such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
	material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
	being prepared;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	b)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	designed
	such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
	provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
	principles;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	c)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	evaluated
	the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
	the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	d)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	disclosed
	in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal
	quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over
	financial reporting; and
<BR>
<BR>
</FONT>
</DD>
</DL>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	5.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
	registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
<BR>
<BR>
</FONT>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	a)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	all
	significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
	adversely affect the registrant's ability to record, process, summarize and report financial information; and
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	b)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	any
	fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over
	financial reporting.
</FONT>
</DD>
</DL>
</DD>
</DL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Date:
	August&nbsp;28, 2009
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="217" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="229" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	/s/&nbsp;DANIEL M. JUNIUS
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Daniel M. Junius
<BR>
</FONT>
<FONT SIZE=2>
<I>
	President and Chief Executive Officer
<BR>
	(Principal Executive Officer)
</I>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=1,EFW="2194303",CP="IMMUNOGEN, INC.",DN="5",CHK=918592,FOLIO='BLANK',FILE='DISK104:[09ZCX1.09ZCX49301]KO49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P>
<BR>
<A NAME="A2194303ZEX-31_1_HTM_09ZCX49301_5">
	QuickLinks
</A>
<BR>
</P>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303ZEX-31_1_HTM_TOC_KO49301_1">
	EXHIBIT 31.1
</A>
</FONT>
<BR>
</UL>
</EFX_CERTIFICATION>
<!-- SEQ=,FILE='QUICKLINK',USER=CDESORM,SEQ=,EFW="2194303",CP="IMMUNOGEN, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage13"></A>
<A NAME="A2194303ZEX-31_2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<BR>
<FONT SIZE=3>
<A HREF="#A2194303ZEX-31_2_HTM_09ZCX49301_6">
	QuickLinks
</A>
</FONT>
<FONT SIZE=3>
	-- Click here to rapidly navigate through this document
</FONT>
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303ZEX-31_2_HTM_KR49301_EXHIBIT_31_2">
</A>
<A NAME="A2194303ZEX-31_2_HTM_TOC_KR49301_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	EXHIBIT 31.2
<BR>
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	CERTIFICATIONS UNDER SECTION&nbsp;302
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	I,
	Gregory D. Perry, certify that:
</FONT>
</P>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	1.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	I
	have reviewed this Annual Report on Form&nbsp;10-K of ImmunoGen,&nbsp;Inc.;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	2.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Based
	on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
	made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	3.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Based
	on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
	financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	4.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
	Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and
	15d-15(f)) for the registrant and have:
<BR>
<BR>
</FONT>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	a)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	designed
	such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
	material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
	being prepared;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	b)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	designed
	such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
	provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
	principles;
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	c)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	evaluated
	the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
	the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	d)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	disclosed
	in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal
	quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over
	financial reporting; and
<BR>
<BR>
</FONT>
</DD>
</DL>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	5.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
	registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
<BR>
<BR>
</FONT>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	a)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	all
	significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
	adversely affect the registrant's ability to record, process, summarize and report financial information; and
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	b)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	any
	fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over
	financial reporting.
</FONT>
</DD>
</DL>
</DD>
</DL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Date:
	August&nbsp;28, 2009
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="217" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="229" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	/s/&nbsp;GREGORY D. PERRY
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Gregory D. Perry
<BR>
</FONT>
<FONT SIZE=2>
<I>
	Senior Vice President and Chief Financial Officer
<BR>
	(Principal Financial and Accounting Officer)
</I>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=1,EFW="2194303",CP="IMMUNOGEN, INC.",DN="6",CHK=1028990,FOLIO='BLANK',FILE='DISK104:[09ZCX1.09ZCX49301]KR49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P>
<BR>
<A NAME="A2194303ZEX-31_2_HTM_09ZCX49301_6">
	QuickLinks
</A>
<BR>
</P>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303ZEX-31_2_HTM_TOC_KR49301_1">
	EXHIBIT 31.2
</A>
</FONT>
<BR>
</UL>
</EFX_CERTIFICATION>
<!-- SEQ=,FILE='QUICKLINK',USER=CDESORM,SEQ=,EFW="2194303",CP="IMMUNOGEN, INC.",DN="6" -->
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage14"></A>
<A NAME="A2194303ZEX-32_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<BR>
<FONT SIZE=3>
<A HREF="#A2194303ZEX-32_HTM_09ZCX49301_7">
	QuickLinks
</A>
</FONT>
<FONT SIZE=3>
	-- Click here to rapidly navigate through this document
</FONT>
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2194303ZEX-32_HTM_KT49301_EXHIBIT_32">
</A>
<A NAME="A2194303ZEX-32_HTM_TOC_KT49301_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	EXHIBIT 32
<BR>
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	CERTIFICATIONS UNDER SECTION&nbsp;906
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (subsections&nbsp;(a) and (b)&nbsp;of section&nbsp;1350,
	chapter&nbsp;63 of title 18, United States Code), each of the undersigned officers of ImmunoGen,&nbsp;Inc., a Massachusetts corporation (the "Company"), does hereby certify, to such officer's
	knowledge, that:
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Annual Report for the year ended June&nbsp;30, 2009 (the "Form&nbsp;10-K") of the Company fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the
	Securities Exchange Act of 1934, and the information contained in the Form&nbsp;10-K fairly presents, in all material respects, the financial condition and results of operations of the
	Company.
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="217" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="229" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Dated: August&nbsp;28, 2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	/s/&nbsp;DANIEL M. JUNIUS
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Daniel M. Junius
<BR>
</FONT>
<FONT SIZE=2>
<I>
	President and Chief Executive Officer
<BR>
	(Principal Executive Officer)
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Dated: August&nbsp;28, 2009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	/s/&nbsp;GREGORY D. PERRY
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Gregory D. Perry
<BR>
</FONT>
<FONT SIZE=2>
<I>
	Senior Vice President and Chief Financial Officer
<BR>
	(Principal Financial and Accounting Officer)
</I>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	signed original of this written statement required by Section&nbsp;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and
	Exchange Commission or its staff upon request.
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=1,EFW="2194303",CP="IMMUNOGEN, INC.",DN="7",CHK=213474,FOLIO='BLANK',FILE='DISK104:[09ZCX1.09ZCX49301]KT49301A.;7',USER='DPERRY',CD='24-AUG-2009;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P>
<BR>
<A NAME="A2194303ZEX-32_HTM_09ZCX49301_7">
	QuickLinks
</A>
<BR>
</P>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2194303ZEX-32_HTM_TOC_KT49301_1">
	EXHIBIT 32
</A>
</FONT>
<BR>
</UL>
</EFX_CERTIFICATION>
<!-- SEQ=,FILE='QUICKLINK',USER=CDESORM,SEQ=,EFW="2194303",CP="IMMUNOGEN, INC.",DN="7" -->
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
